var title_f18_35_18992="ER Transcription";
var content_f18_35_18992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Mechanisms of transcription mediated by estrogen receptors (ER)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estrogen receptor-mediated transcription is initiated following estrogen binding to the receptor or ligand-independent activation resulting from growth factor receptor pathway signaling and cross-talk with the estrogen receptor. Once activated, estrogen receptor dimers recruit co-activators and mediate transcription of genes via direct binding to estrogen response elements (EREs) in target genes (\"classical\" mechanism). Alternatively,&nbsp;non-classical indirect mechanisms can either&nbsp;bind to existing transcription factors bound to the DNA and recruit co-activators to an AP-1 complex or remove repressors from the AP-1 complex (AP-1 mediated mechanism). Finally, estrogen receptors can&nbsp;regulate promoters containing Sp1 binding sequences and estrogen-receptor element half sites (Sp1(N)x ERE(1/2) mediated) in a combinatorial&nbsp;direct/indirect DNA binding mechanism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified and updated from: Hewitt SC, Korach KS. Estrogen receptors: structure, mechanisms, and function. Rev Endocr Metab Disord 2002; 3:193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18992=[""].join("\n");
var outline_f18_35_18992=null;
var title_f18_35_18993="GnRH vs GnRH with addback";
var content_f18_35_18993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Effects of gnRH agonist alone (solid lines) versus gnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on surgical staging scores as determined by pre-treatment and post- treatment laparoscopic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both the GnRH-agonist alone, and the GnRH agonist plus low dose estrogen-progestin add-back produced similar reductions in implant scores. RAFS- Revised American Fertility Society scoring system. ADI-additive diameter of implants score.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howell, R, Edmonds, D, Dowsett, M. Gonadotropin releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized clinical trial. Fertil Steril 1995; 64:474. Copyright &copy; 1995 American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18993=[""].join("\n");
var outline_f18_35_18993=null;
var title_f18_35_18994="Pancoast tumor on CT";
var content_f18_35_18994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55842%7EPULM%2F81147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55842%7EPULM%2F81147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of a 60-year-old woman presenting with a four month history of right shoulder pain and numbness and tingling in the right arm. The cavitary mass involved the rib and was squamous histology on biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancoast tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 444px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG8AOUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAyKKKKACiiigAoBzRSHigBaMimO3HAqnLcsmSQAKAL25fUUnmJ/eH51zd7qmwEZwaz4tVcv1oA7XevqKNw9a5y21AyEAda1Unbbz1oAv5oqosxJHBNWUOaAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYpMDNLRQAmKWiigAooooAKKKKACkJwKWobliiEigCvcz7M84xXLa5r0NnGzSyKAPU1D4r1n+z7aSRm4Ar5j+I3j6e7nlhhfCgkcGgD2a78cabLceW0yZzjrV221mzlUGOVSD718a3PiC6SYNvbOfWui0fxlcpCMyMCB60AfYmmXqsw2OPzrrrGfcozzXyh4H+IT/AGpI53JUsBnNfSHhjUVvLeN1PysMigDsYiO1WFNUrfkjmriigB9FA6UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQ3QzEamqOb7hyM0AeO/FneNKuNufunGK+QNdik+2SMwbOa+8vEmm299A6TJkEV4X4x8HaRBK8hUDvQB8vSpNNNtCE/hW1ZaU/k7pARXrFjoGj/AGgLtQEniumTwnpjRdUANAHjOgWvl3ibGOdwr6x+GMkn9mQCQknaBXA6R4J0cTq5YEg5616x4bsIrVEWA/KKAO5svmwa0FHvWfYLwua0VoAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqOVgF5NSEZFRvHuoAwtU+ZGAry3xdor35YKDzXsF1aZBNYV1ZKWOQKAPn4+C7tJ9y5wDWk2hXQhCfMCK9kbT48fdFQNpkbH7o/KgDzbw/oF0sys5bFeo6JYSRIuQeBVrTtOVcfL0roLe2CqMcCgBlsrJjmr8Z4HNRiEVKi4FAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCGdcqaxrlAG61ty4wc1j3ZUZyaAKhXpjpTgoHbmkWRW6UpYDHNAF61HA4rRjBAFZlo/A5rTjORQBKvSlpvPanUAFFFFABRRRmgAopNwoJoAWigUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMlcKpJ6UAQ3cgRDXO3tyuSBU2qXe5iqk1hyOQ2c5oAtxSHdT3m96pC6UDjrQZSw5xQBrWM5LDPSugt5NwFcZBKVce9dDp84+XJoA2waWo0YEAipBQAUhOKCcVVmmIPHSgCV5QoNQNOT04qCR9w4PNRbyKALiy5604SgNiqAfB5o8w7sg8UAa6Nmn1WtmLKKsigAooooAKKKKACiiigAooooAKKMikLAd6AFoqNpkUfeFU573bkJ1oAuySKi5JrF1S/wCqUkzyy9zg1RuY9ikuM0AZrylySRyaryHnBqaZ41BOQKos+9uHBP1oAnZVccdaVECjqah3si+5qSGRipL0AWIiNwrTtpCMEHpXMz3qRSgbsZrXsLjzEBNAHR212Vxu6VopOpXOea5zJ2ZBOaRbl0GDmgDemuRjjpWfJc9eeKom6OOTmqN3LI/KmgDajuFY4HNOaQdjXOQTOHADEGtCORyPmJoAtO3PJoSbJ2qapyvngmi3OJABzQB0dk5xg1fU5FZloc7R9K0k6UAOooooAKKKKACijvQaAA1WnuUjB5qO/uDGnFc9Pcs2SaANZtSXJGRUM2ofL1/WsB52PaonLcEnigDbN3uHLnJ7UQuS+TzWOrZAxz+NaNkCepoA0mm+T5Qc1zfirWYtM06a5upVjjjXcSTW1M4jQ5r5j/AGpfE0saWmkW0pCzBmlAPYEUAcp40+NWp3OqSx6MQlqjEBj/ABCp/BnxluVukh1jhWIG8HivEaKAPunStet9Ss45oHEgYdq0GuCYSQQoAySTwK+dfgh4tuILG5sUsptQuYlzFDHIiFs/7TkAD/ODS+PLX4o+K5Xt5tL+w6c/As7e8hCsP9s78t+PHsKAPa/D3iHQ9f1m80/Tb6O8urRVebyuUGSRw3Q4xzjPUVoat4+8I+HI2Go6/YxyIOYo5PNkH/AEyf0rwb4W/BXxLL4ptl8VaJOnh+dXW5aK/jXjaSuQj7iNwAwPWvpbRPAHhrw4qnRtDsLaVOkoiDSf99nLfrQBl+CfiFbeKdSe20/R9ahsliMg1C6tTFBIQQNqknJOCT07V18wLDK81nXHmRsTzin296F4OTQATzGIfMMmoPteepAFTzqLnkVUkt9injJoAtQKrncDzVoOi8DrWbaEI2SSKsNKHPy9BQBYyGboOau2sBMgOOKz4FEjAA/NXSafbqiDOSaALdmgK54q4KZGgUcDFPoAKKKKACiiigAprHinU2ThaAMHV5TuIz0rILq30FXdWf8AfEZrJbI+XcKAEmGclelQs+AozyaJWdVO3p7VWhZpJcOMbec0AasCDGCOa0ICIxzVFJQEGKr3lzKoVY16mgC9qUpeBgp5xXyR8afCutap4uM8UbSxMSqn+6K+s7OB5YsyDORVXUNDhm+cxqT9KAPm3wN8KLYaY0mpqHndec9q8v8AiT4UbwzrDJGD9mkJK+3NfWfiaddCtJJmjxGgycCvn7xnqMXji9+y2qHeDgEdqAM34Axh/E9wzEjbFx+Yr6TQRtdou7LZrzn4TfDiXQGlu7o/vJFA5r1CysGW83478UAdvoyslsmPSr8nIORVGwZkiAFXC7lckUAQSQK4OazLq0wTtFa2SeMUvl5680Ac3F5kEmG6Grm7eOe9XLm0ydwHArOmJQ4UYFACmFScjNN2bM46GnQuR3zTp/uHggmgDT0m3QuGJ5rpbdVAGK5rSWxj5q6W2+4KAJ6KKKACiiigAooooAKrXsgWI+tWT0rL1OQbSPQUAczqUzPKdvrUEah1w3WnXBBlJp6EbQQKAIynGB0qBodrZA61bYr+NSwp5nSgCCDPQCrCwguCfWnkLDyetSWrrKwPegDRtlwnSpWUEYIpE+VeaGcGgDmfGmiRavo91aED96hXNeQeA/hWuha5PdTneCQV4r32YblIxWcVRX5FAFBrVUiwoxiqccDNOME4Brbk2lfWsu5fyn3AYoA3bEBYxmrOQT1rnLbUGP4Vp2tyJTyeaANHHcCjtRF1HcVMPTFAEbrlB6Vg6gpDEAGukIyOlZWqIME4xQBjxAqQRUzEuM1DyDwc1YhUnrQBd01R5g4rqLUERjNc7ZLhhXTW4xGv0oAkooooAKKKKACiiigAPQ1i6ueDitljgVgauck4oA5yWJjMWFSIflxjmpBy5znNKygg7SN1AEMY3SAGtGMonA61HaQttJZealWEqxY9KAIbuMyDg1NptuYx3pCcygA961LdCFGaAF524pu0jtUxFIelAFSTvWVeHY2a2yOuRWLqrBTigCCGZX471T1SEshIJFSQjYC1RzuJQVDUAZ0EgjjIJGRVrTbkibvjNU5rfaSc1Y01QG5oA7OxYOmatYrJ0+YDgGtZGyM0AAz3qpqce+E4HNXAKSVMoelAHJbGRyD+tWIMg9aL3Kz4z3pyZ28UAa+mgs4yK6FBhRWHpCFmBNbwFABRRRQAUUUUAFFFFADHPBrA1Nic4Fb8n3TWNfDrQBgqjFjkYpDGAwxV5YiCTSRxb5RmgC7p8ZEOW5ouVx24xV63i2QiqGoNtGKAKUMTGfPatiJcKKzdPRt2TWsoO32oAYetNLjOM09h1zUbAd6AILiULn0rDuwJZCx6da1rxQVIrNFuSDg0AZtw2BhelRLwM55q5JbhST1qEx8cUAV3O7O41PawADK9aglAUgsKu2j5AAwKALNgzebgjHNdBFuCisW1i/e7vetyIfIKAJUz+FEgyKVM5wBxSuOKAOe1GJfMz0NQxg8Kan1s7ASAc1V09i+N3SgDp9JjwoNatUtOTEWfWrtABRRRQAUUUUAFFFFAEcv3azrlcjmtKSs+4BZ+KAKaJt4xmpoIRvFTKnAyOamhT5vagCZgBH+FYl/1HFbso/dmuevCTNgdM0AWLMDbkcVdzheDVe1XKDFTPxxQAwk5pG6Gg57VC7EcGgCpcszPjFQSrhD61cYBjkVFKuFJxQBiyPlmDcVCWKmp7pTuJCms+Wco3zAgCgBLpy+QfwqfTcKwyc1RedSSQDVrT2BkB9aAOhh7YrUgI2AZzWXAuVBFaFqeMYoAuqMDIpTyOajD4qQnjrQBlatGrREkVkaax80rgDmtnUuYmrE05WFyT2zQB21iMQirFVrE5hFWaACiiigAooooAKKKDQBFIcAmqigs3NWZMnOKaiYoAiYjpUsNRSDD8VNBQA+cfuzz2rm7uT/ScAd66WYZQ/SuausC5+brmgDTtuEGKlbHU1Fb/cH0p7UANaonxUhowKAIFUE0kicGpyo7VHL0oAy7lBg8Vz9/HmTmuknzzxmuf1QkZIHIoAzDE27A6VdtUCuo71SgllZ+BgVq2cZLhmoA6CyA8sVcT5TxVa0UbBVzZx1oAkU5xUi5xzUSjAp4PbOKAKWpcRk9qxbb5p8J61vXvzRNkViWcW28yOmaAOwsVKwLn0qxUVt/ql+lS0AFFFFABRRRQAUUUjdKAGlRmjGBxTVJzSSsVXNAEEi5c1PCpHeqxfJ5q1AxKjNAD5PuHNczdJuvjxxXSTnETH2rmbm4EdwxagDUiICimySqM1z93raINobBFZ76+BwWFAHV/aFzTxIp6muFn8RIrdakh8RKyUAdyHB6EU2Tla4+HxApbG7mtGDWEcgbqANG4ACmue1ABn5NaF9fqIjtPNcndaludgSKANBQqnjFa1ggO2uQtdRBnKHua6awvUixznNAHTwAKBxU4Yd+lYL6soHy1XOtrk5PNAHUB19aMgniuai1YMeuav2uoI+MsKANG6GYzWZaAC5wa1VKSp1yKzYwEv1GODQB1Fv/AKtfpUlRwj92uPSpKACiiigAooooAKRulLTWPpQA1Rio7j7tS1FKMjgUAVOSeBV22BCjNMjjHerCjAoAiu/9S3PavO/EFy0MzHnFeiXQzC30rzrxRGd7cHHegDlbq4edtyk1WeOSZODzVmKPY+Awx6VJOwixgdeKAMZ4pEkA5PNWY9yfdXcauLAzNu3DHXAps8cwJIAA7YoAp7GMhcsVPoK0dPuGRxufI96qCGR8N69c1dggT5QQS1AF+7mkliOwkVgT21w7Ex/erduD9mhBboB3rCOtu05REXbng0AJb2s4cGRSCO9b9tE2wZJFQafd+awV1BY+lXrqYw4wpI9KAHMVMZUsc1VW2ld8r0qWCYNkyAgH1q3A6j7ueaAKbo8Qxg59qlgeUEEMa0fKWRd3pUS25OSqkUAa2lXJKhWNaEI3XAOc1zlu7QSc1vaZPvccUAdTB/q1+lSVHAcxipKACiiigAooooARulNOKc3SmHNAADmgjNRs4B5p0bA96AHqvpTxSL0paAGTDMbfSuE8Rp8zjNd3McRtXE+IlOGO3NAHFPF5bk4zmlcB48Ec1HcT/OVA6VCtxtyBnJ9aAJIEZCduTSzBieW5FLHMwUmq08rMSwB45oAJbl4wFG0ZrU0o5Xexz9K5idZLqQD7oB5roNHlEaiP0GMmgCxrTPNb7Y4yRiuWjt3hk3yL+YrsptTggOyQCojd2NyQpVee9AGbo0yT3ChSAQa3riF8jcflPtTLCxtBMGhADE9qqeLtch0W33SkZxwKAJdjHovAqWKVRweorntI14ajGHXIB5q+HJfOaAN60mQnaGGTWvCFIFcraIDKrZ5Fb9pJyM5oAbfQ7TuGam0eRjOqrnbVuYB4+lRWEOycECgDsrcjylHtUtQWgxGKnoAKKBRQAUUUUAB6UxsgU+gjigDPncKeaSGYE02/YL2qC1bccjFAGvGwIp9VIiVPNWlORQA2b/VN9K5TWR+6fPeusk+4a5bWgSrAUAedXyDz2KmqchUrnPzVd1Jdty4BFU4xt6c5oAaqsUyCaUeaFx2PrU8asCSelTQRPI7AgkCgDJlyj5/iNa+kqWXcwqN9PLT88c1vWMCxRqjYAoA5nVh5k+EHfmojFHFDgsQxrsJbXTmPJAaq0mk2Mzj5xmgCn4dSRQW3ZHvXn/xN87U9Xt7VemSK9ZgsktYiImBFcnqGledqouHXJViRQBQ8K6Y2nWSLJycDrW25UkfLgVHPL5e1QKeis4B5oAu22wkBWINdLp0aNGN3Nc7YxKWAAOfeuosISqjNAFgou3FOsUzNjPemTZQ+lTWLfvB0zQB0cC7YxUlRwH5B9KkoAKKKKACiiigAoPQ0UjHAoAwNekaMZHSqemXBOOK19Yh82EnGSKw9OkBcoykMKAOijl3KKtRHIzWXExHFXLd+aALb8qa57V0+Rhit92+Q1jakNyNQB5jrEIF2xJxg1UQFidp+UVs65B+9ZiOKyItxOFU7aALFv+8OMDNb+l2OVLN3qrpFnvdW29a622tljj7D8KAMOW1RJMsKhuPuHAArS1KMb+PWqhtfNThiKAOblTdLyT1qOdZIgGQs1bx0ltw5yDT/AOyCOd350AU9KlkeL95kfWpJ1G8nHNXobYx8EfSnywBlJzzQBzl1Eu4Ejmn20ZI46VclhXzPmOavW1kqruxwaAILMbZVG2uptP8AVg9qxI1G/CjFbdsu2IZoAgvyAeDT9L5b8agugXbirmlwkduaAOht/wDVipaZEMIB7U+gAooooAKKKKACkIpaRulAEbqGUgjg1g6lYNFJ5sA59q22O096RmDrgjNAGRYu7j5xg1qwx4AIpsUC/exVlRgUANl4Q1kXbZyK15gdh5rJucA8CgDB1Sz81DhOaxLXTZRKAR8ua7B1LDrUCwhZMnGKAHabZpGg4GavSJhTikgkUHAAxUk8hC8CgDCvWwxGKxr67ktxkA4rcuH3Sncox2qlfQrKmOMCgDKtr64l5Ddalnup0XJOTTY8QN93gU+Z/OX5VOD7UAS6ZeyTna4xir0mFBOKr6ZaqgDEfnV+5A2/KAaAMGR1e4H1roLVR5IAwfasWaMCTPetKykKqB2NAEkyBZAQADWhE+YwM81QkGJAx5FXI5FZOCAaAGyIS3Jq9p+dwANVFBznqK09PUMw9aANVfuilpF4FLQAUUUUAFFFFABRRRQBDOuVqqNynAzV56rkHdntQBJCDtGampkZyKfQBHLwhrKmIrSumxGaxLhmJyBigCK4kCAnqayJr797jPfpVy6ckEVkSqNx4yaANeC4JAxmrJkYpgngVhwTMuBg1eV9yZJx7UALIDuyWyKo315DCn7wjNXCQVrnPEGntOuVcqKALUGp2rH5gCB61O+p2gjOMCuOgV7dthy+eM1YlMjpgRHNAHRRazCXEYOSegrRjkeRTgcGuc0Sxw++YfN1FdRGAq8dKAKU6MrAmrsLgoOxqCaLcQcnNM2lRxkUAXJpeAM5qKB38wf3ajgUk5brVnawYY5FAGrbHeAKvWzmJhkVSswSBVxeeOlAGqhDLmnHiq1uxAwas0AANFFFABRRRQAUUUUAIRmmlKfRQA1VxTj0opjtgGgCndydsisyc5JxVi8bLZ71mXEjAckYoAjlYZORzVN1BJJAoMpDc8ikfDHJ4oAbtXI7VKxwuKpyzFWwBxUkb7lBoAnU/LzWfqDj+LpV1pVHXrVS8i8+JgOtAFKOC2K7iVzUheBBgFaxpNNuhLzIQvtU8WmytjJJoA1I5hkYAxV6GbdwaxTby25UjJHer9pMrD5uKAL5wWBXNRyN8wwaVXA68g0wvmQYHy96ALUONuacrYcZ6VWEu3gdKekvPIGKANm2kOOOKvR574rFglI6mtW3kDr1oAvxPgirqnis0FQOOtXoWyo4oAlooooAKKKKACiiigAooooAKhuD8hxU1QXBwhzQBj3TZHXmsa7dskDpWjftsJxWM+5pCeRQBGWwcMDxSO6kHnAFOkzgg81UfOSKAK08yGTargnNW7eQJGR1IrEuI9t4CM9a2baIbSeh9KAFUmeTB61ow26qvIzUFsg3571LcTFeBmgCO6jBU4GMVWgJzgAVOXZxgfrUO9oWJxQA29VghJ54rMjnYPgDIFXry+V4ynANYod/PAAOTQBuwS7gMiq95K6DMdQRPNuw4wO1WLmItDknNACWzsVBc4NaUGWxn86x7Rzkq6nHbitaIjYMHpQBayFIGDWlZvwMVkgs6nb2qW3mdW9hxQB0qAkA1etx8tZtpKHjGTk1pQHgUATgc9aWgHNFABRRRQAUUUUAFFFFAAarXP3fWrJGarT8ZoAwtRBOSRWRtLNnPFbGpfMuM8VlrGM9DigBkygKcd6yJm8stuNbU0exCV/KsDUFZnJbgUAFhiack4OK0pYir5T5fWsqwfy5hwcVrXLtsDDPNAEsTYPNNuXBB6Cq8MxfAYc+tR3IYnluKABZWDZXJps9xIwwUp8DhOvIpZ5kJXAxQBSazeUBiMUW1o6yjvj2rRiu4woBFOicedvQjGc4oAhmQLt3ofrTJWLQnYOK1NRdZbb5RhsVlBWijO4daAKsJdG+fkVpW+XwBgD0qoqlzkVbtICHDHJoAtKjKDtI/KnRbj2GalyuMY5psaYbNAG1YEBAMVqwVkWJz161qpkEYFAFsClpFJNLQAUUUUAB6UnNLRmgBOc0tGaKAA+1UriQjcCOKuMcCqNyd2aAMO9YM9QQAM2DT79inTGKghZjtIzzQBdaLI4GRVG4slkbkVbd2UDrTPMYg7RQBmNahXAUDg1U8W6tZeHvD1zqeoPst7dNzevXGBWnv/eHOM1wHx90K+1z4a6hHp0byzRhJPLQZLhXUkY+goA8tj+P8cmqiNNPMdmXwrk849TXr+ia5b6zBHMkow3NfDTo0cjI6srqcFSMEH0r3P4SX2p/YYkKuVxjmgD6TRLVVDGQVHcS2ZU7ZV4964hhfyxHAYZrBvLLVVkJDPg+lAHbahqtvZ5cOHA681Vg8caYisJHCH3rgrqy1Bk+YOa5TUfDmsahciG0gkLMcZAoA+jdC1yw1NN0UwfHpV3ULiFgESuI+GHgTUdIst98SXcA49K7ebSWVtzNQBNpiQsMvWgPs6ghTVe1sWEXBqrNG6ybVJoA0V8vdwMikZQTwamtYsRDdULgJLknigDRsOOBWpExK81k2IU/MGzWxGyADNAE8RJqSoo5EHANS5BoAKKKKAA9KTbS0UAJtpcUUUAMkHBrPuFIQjNaT9KpzoMEUAc3dRkOdxyKWEqnUVcuoN3IqjISoAxmgCSeQuuFFVo5GQcDk+tSRc96bMck0AZuobgWYHk+lSaTdzeX5cqhkIxzTJi7OVAyBUtrhWG6gDC1P4V+Eta1L7dc6Rbi6Zt7sqgbj6nFbFt4I0zTowLOBY1HYCt+0BPzLV8nKnNAHJSR29p8kiDH0phNi65ITFTeI4WkRioI+lcQ8cyTqpZ9meaAOoFrZ3MoSOIEHvXTado9nbIrCFN+OuKwtAhUCMiuuGREMc8UAV7q8EURVAK5+W8eS4xzWleOS20rway/s5WXdyBQBpRXWE20IN75I4qvEoJGelW9gAwpIoAVp8fJzUBBYnnNDq4bjmlSFmOaANGwjCrwSK0kXOOTVa1j+QVeVDgelABGo8wDOatKvQ1DHnd04qwKACiiigAooooAKKKKAGydKqSA4q21QSqRyOlAGbcKcHBrLuI9zY4FbzJuBzWfcxKGINAGYNsbY3HND9DtGT61I0R8w7VO2pUjDcDigDOW2yxJByab5ASTLHI9K2WjCpjOTVT7M2ScZzQBPYOTwoOBWssZIz0qlZx7F6VfViFXrQBn6haGRDgD3rl73TzG2WUEfSu7LLwCvWqV1YrcNgHFAGXoloDGp24wK3fKwvWm2lv9lAQ9O1WHXAyKAMDUbeQOGHIqiy7hggg10E7BjtYcVXaCNsjpQBnxRlUwT1FO5/hxVlbbY3yninPGoBzjNAFTLDrVi1G88g1JHb5696t28AUjaM0ATQggDA4q2CAMGmICMAg085yPSgB0XJqWmpTqACiiigAooooAKKKKAEYZqMox9MVLRQBWMTZzjNQXNm0gyow1aFFAGOlhNghgKX+znVQF61r0UAYxsZtv3cn60sdlMOqYrYooAyxbzKR8mR7VOsEmPQ1dooAqeS/HGalii2nkc+tTUUANZA3bmq0sUpyF5zVuigDKNnMZAT0qZrRtvvV+igDLa1mx8q0+Ky7yLzWjRQBTa16bQQPrTkhMf3QTVqigCAq5HAINOVW7ipaKAEAxS0UUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PET image showing intense metabolic activity in the apical mass but no adenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18994=[""].join("\n");
var outline_f18_35_18994=null;
var title_f18_35_18995="Actinic cheilitis 2";
var content_f18_35_18995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Actinic cheilitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scale is present on the lower lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18995=[""].join("\n");
var outline_f18_35_18995=null;
var title_f18_35_18996="Brain MRI adult vanishing white matter disease";
var content_f18_35_18996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conventional cerebral MRI imaging in adult-onset vanishing white matter disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 408px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGYAZgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6N8aeKNN8HeHrjWtbeRLGAqrtGm9sswUcfU15p/w0n8PP+fvUP/AQ/wCNX/2pAD8F9YyM/vIP/Rq18j/CfwD/AMLA8Qz2DX8emWlvbm4nvHi8xYxkKoxuXJLMB19fSgD6p/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4y8R6LNoGv6jpF6oFzY3D27nHBKsRkexxn8azNinoP0oA+4P+Gk/h5/z96h/4CH/Gj/hpP4ef8/eof+Ah/wAa+Hwg44GfpQUH90UAfcH/AA0n8PP+fvUP/AQ/40f8NJ/Dz/n71D/wEP8AjXw/sHPAp0Vu0rYjTJ9hQB9vf8NJ/Dz/AJ+9Q/8AAQ/40f8ADSfw8/5+9Q/8BD/jXxtZ+Hrq5PyxH8B0q+fC8UKA3d1bxnOMPIAaAPrr/hpP4ef8/eof+Ah/xo/4aT+Hn/P3qH/gIf8AGvkJ9I0pEyb+2P0Ymlj0jSJB8uoWwOcckigD68/4aT+Hn/P3qH/gIf8AGj/hpP4ef8/eof8AgIf8a+Qn8OWzSbYLy2f0xIOajfwrc7S0YDgf3cGgD7B/4aT+Hn/P3qH/AICH/Gj/AIaT+Hn/AD96h/4CH/GvjGXQbuLrF+lVm064QndDmgD7X/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4jNrIpOYj+VMMJH/LM/lQB9v/APDSfw8/5+9Q/wDAQ/40f8NJ/Dz/AJ+9Q/8AAQ/418PlF9BijYP7ooA+4P8AhpP4ef8AP3qH/gIf8aP+Gk/h5/z96h/4CH/Gvh/aOcAUbV9BQB9wf8NJ/Dz/AJ+9Q/8AAQ/40f8ADSfw8/5+9Q/8BD/jXxAVGfuikCrj7ooA+4P+Gk/h5/z96h/4CH/Gj/hpP4ef8/eof+Ah/wAa+H9q9NoqvcACTAGOKAPuj/hpP4ef8/eof+Ah/wAaP+Gk/h5/z96h/wCAh/xr4TooA+7P+Gk/h5/z96h/4CH/ABo/4aT+Hn/P3qH/AICH/GvhKigD7t/4aT+Hn/P3qH/gIf8AGj/hpP4ef8/eof8AgIf8a+E6VVLHCgmgD7r/AOGk/h5/z96h/wCAh/xo/wCGk/h5/wA/eof+Ah/xr4lstGvLs/JE2PpWvF4ZjRA9zdwJ6qW5+hoA+w/+Gk/h5/z96h/4CH/Gj/hpP4ef8/eof+Ah/wAa+RFtNDgB8x97DuDkfhUYk0NSA1rOVGclT1oA+v8A/hpP4ef8/eof+Ah/xo/4aT+Hn/P3qH/gIf8AGvkdZvDQX54L3P8AdABA/GoGutB34W3uEX1IzxQB9f8A/DSfw8/5+9Q/8BD/AI0f8NJ/Dz/n71D/AMBD/jXx5J/wj0h+WWRfXK0n9naNcFhb3yKMcFxtoA+xP+Gk/h5/z96h/wCAh/xo/wCGk/h5/wA/eof+Ah/xr45j8NJPkwXMTDPHzjmlfwjdkfuvm+hBoA+xf+Gk/h5/z96h/wCAh/xo/wCGk/h5/wA/eof+Ah/xr4um8N30ZwY3/wC+apy6TdRjJSgD7d/4aT+Hn/P3qH/gIf8AGj/hpP4ef8/eof8AgIf8a+F5LeWPO5GGPao6APuz/hpP4ef8/eof+Ah/xo/4aT+Hn/P3qH/gIf8AGvhOkoA+7f8AhpP4ef8AP3qH/gIf8aP+Gk/h5/z96h/4CH/GvhKigD9P/Cuv2Pijw/Z61pLO9jdqXiZ12sQCRyO3INFcb+zp/wAkV8Lf9cH/APRr0UAZ37Uf/JGNY/66Qf8Ao1a+TvAnxEk8GeGNX07TtIs7i+1KaJpbq8VZoxFHkiPyiuCdxJ3Z9OOM19Y/tRf8kY1j/rpB/wCjVr4TzQB1PxL8WL428Uvrp05bC5nhiW5VZd6ySqoUyD5RtyAPl5x6muVz2pKUZPTrQAn41JFDLM22MZqxZ2ZlYF+F/nW9FLDahYLCAXN638Q5VPr6mgDPh0qKBVl1CURoeg7n8K1LKWVgU0nT1KnpNOMfjinC0t7ObztSka61BjkR9cfQV0WiaNqmvKMK9pbs22OCNcSP7ewoA5+6tnKA6pq7g9DFF8v8qpw6TBM5MFneXAJ4JXqPqa9UtPh7pnh95dT8QyhYoQDtZi3zn+Ef3jTW+IMMN1GmnaXbpaIcYkGWYfXtQB5xNo8kGDJozxgD+I1WkshGP3mjycjhgeK+mrvXdBeysXnhgaG5QHGASueo/OvPfFGpppki6fFBGI4mIVtudynkfoaAPFPKtpW2R27lhkkA81F5d3BIDF50KHo2416zDd2dpJDcx2MCzqeu0fNn1qfWrjS5beGS6sFDS5J2nHP+FAHlqalqkAzFqJfPYnP86kTxFqYkHnJbS9sNGOa7rStH8KancCGSSewlfOxm5XPpUurfDrUNORvsz21/FuwoP3+elAHD/wBvKf8Aj50iJh3MbEVLDq2huR9qsLuNT18tgan8TeGNQ0SNZLq3aEydlOcVz3nvFHsm8p1bqGXmgDo4ofDmpNthvxbSE4CXCYA/4FUGqeDri3i82JRJD/z0hO9fbpWZF9hmeI3lqyxbcExfzqxay3ml3fnaBeS+TnIjJyD7FaAMW4sZYeqkj1Aqtghuleg22uaXrD+Vrlk1jeMMCaDhCfUjtVLWvC0qRC6jj8y2Y4WWMhs+/FAHFAcUDgYxVm6tJbcnI3L61W4xkGgA9arXP+s/CrRb14qpcff654oAjxRRR3oAO1FLW3oWkC6ZprmRIYIxuZ36AUAQaPol1qcwSFD/ACrpY4tL0SQQJEdSvhwUQfKp9z3qzpiXOswvaaWDZ6WgzJcsMPL+PYVNbRRfaDpnhe1a7vG+VpgM49TQBUna/uYwb+9g063zxDF96mfZdDt8GaaS5kPPzV3+mfCyGG0E/ivUorSabO1Xbmt7RPBPhTT9NtLbUr22utUdGZAkmQ/JxQB4+l3a78WlkrqPVc4rRilvZCvk6Lvydowmea9BL2Wn6TqH2bS4EmXdg4yR2FcPo/iXUdJku/s1wVM6FGyM9e49DQBZt9I164L7NAi98rjH19Ke3hLxBqErRx6HbPIOCI5BkfhWPFrV/FK0wup8sefnPzD3qTTtUuLPV0uormVJA2QysaALkHwf8Vz3JkGlwRr/AHZJcVqt8HfEM0LGW00uEoeSJSePWvRZdc1O40+C788shQHcp6msi2+KE+nT+Rf2qXMB5bacMKAPKtL+HupaxY3t1pcbyfZJjAUVSpYjqRntWZNo93pbNFfrqFnKO+04r3rUviGtppNrdaTZJFHKx3ow6nr2p2m+PbbWQZNZ063kiA6KuT096APDbCXUSALTVlJ6BJu9aseo61b7hqOl2uoxhQBt4I+mK7LVrz4e6rehbrTLixJY5ltznHvisfxL4MvtM1HTW8J3VzqVheRvMkyDcAq9j6GgDmFvNGuXK31vLpsh6ZUlB7ZqC88KJcwvPp7x3MQP3ojyK6i60rXLa0R9Z0k3FpIu4SRrng98daxotHtLgmbQb2S0uV5MecAn0xQBxV5os0DYGc+h61mPEyMVcFWHY16SNZNu5tvFensxI2pcRjA+pqHxH4aiNslzbMstrJ9yRTmgDznFFWLu2e1mKP07H1qCgD9C/wBnT/kivhb/AK4P/wCjXoo/Z1/5It4W/wCuD/8Ao16KAM79qP8A5IxrH/XSD/0atfCiAZNfdf7Uf/JGNY/66Qf+jVr4S6UADc1fs7ZXZAfTLn+lUY+SOK15yLKzQJzcyHjHUUAWoY3vrn7JagIkYzK/p7VvaLY3V9qEWieGbZZL1v8AWzAfLGO7Me1Y8UVzaWdpptmqm/vmH3fvHPTNevapbp8OvBSaVYRhNWvYla8uV5PJOef0oA1NH8FaN4W0i5vUni1PVkGZpmYNt9cDsKxdW1OWLRRq2nT/AL/cY5AnWMdvzrh9Mvby2D3dsxKD5ZVB6g+o9K0/CV7FN4haG4RjY3KukkQ9CP8AGgDM1zxBqXiCSBL6aSbZ8sadAD649aqGylhPlSQuJvQjAq9qt1pqXJXTLCVZM5DO2T+VegfB3UVng1htZghntbO3M6PMASjDsDQB51eWWoWUKSXaPEjYKKT1HrWjq7XF5Y6bfXJZg37hSe+3p/Op7zVB4n1ZX1O4W1ErbY3YfIgz0+ldb4x0vR4tKsYrfV7drSxhCloTuLOTk4FAHMafptzq81vb26736celVNZzLrHkKMiD9wg7E55/Wup8Daz4Z0i9W5nvrsuuflaLrWDrr2N34oU6O7vDJKGXcMEEmgDntZsLmx1BredCk6feX0qxba/qcARVuZhsG1Ru6V2Hje1ju/FBgjYrKoWN3k4yQKqa1d6DosKW+nQLqGoBcPM/+rVvYd6ANfwbqTa7b6hYaqBM4hM8TSDJBUZxWZql54ekYNFolqqyoHL45HHOKofDa+MvixUuDgzxSx+2SpqppumNIIElUhlLIFPcgkUAbOm+CLbW0jm0+SKCOVjiJ+SDWRq3w51Szml8hSZYjwycbqz5dVu9N1AizuyhRsblPFd62nXHizSI9Ws9fkgeMBbiLk+WfXHoaAPHrskmS21SExzRnDSEYYfUVYtrjU/DgW4sLgT2TYJiY7lYe4rd8SeFL9TNcW11FqbRrulVTlyvrjvXJWd6iqYGLNbycFT1WgDqbiysdf0ttR0xRE4A863Jzg+o9q4HUbJrVycEKT6dPatoF9C1CG5s5Ge33AkHofrXQeIrO31DT11GzH7qU4eP+43pQB5z1+lVpxiTFXJYzDMyN1U4qpcD97j2oAhopaciF2CjqaANTw7pp1C+RDkjPauotrP/AISHUls7YbNJszhmUcyH39azL7T5dK0O0aNik98xRVHDbe/512em2clrBp/h/Q4zJq92BvZeRGD1ZvpQAJbXXiC9TQNBdLWzh+W5uXIREH1/pWjearbeFFn0fwuBCYCUlvQAZJm7kHsKzvFcum2UUWj6O8my1ZlnkYczSg/M5/GufkguPJEoBkj6bl5x9aALd5qt1e3Cm9uJZiRjc7E4qETtaanbtk5jcNuzx1q1pmlC7h3NIACOM+tdDb+ES8KFjvEg4yMYIoA09Z1izt9VuJOHs7yM5x2DDr+BrjbDSGvFlZFJTeQkmMbhXrXgrwNZHbPeiS5CAfu3+6PrXb3fhTTtYt44lX7IFzjyVAxQB89S6IrCGCL95LyCF61TvfD97YxF7mCSML1JXFfTuieDtG0fDQ2ytMP+WknzNWtfaTZajp89veW6PDKNhBHOKAPnew1YQ+H7eBZC3bHpXJaxBL9ruZScIOc+1e43HwT07ysWerXiNnK7wCAPSsrX/hRcw6FffZb37ZcJEXRQuC2O1AHC6q6r8N9CQqPOnuJXHqUGAP1qHw5PFa+EdfuZV3PCESPP95mxU8Fndak1jBLbS21vZQCEJKpBLZJJ/M1Dovh/U9Q1R9Aitptk90ssjhTtCLnnP40Acle27RxLNKTvfkAV6j8PfF83hz4ZaxcKPOninWK3B58suDk/pXIfEKzGm+IZ7QoyRx/JGOxA4zU2klW+GniEAZ2TwNnsMkj+tAGZF4l1m01RNThvJXbdvO85U+xHSuos9c8PeMdQSHW9PXSrx/lj1Cx+Xa3+0vcVwcEhTTZUZdysAFPoa7jwToVlLZedKwWQDLE0AQ+LPD+peF3+zeJIkvtIuOIL5BlT6Z9DXHymfwvOrRn7TpE5wUc58v6elfTnhCO213RL7RtVgF5pyrtAbng8ce9eF+JdB/4RnxDeeHdQiml02Yn7HPMpGQR93PcigDmvFGixNbRXVq6yW1wnmBh/D7fWuAkjKOyHqD0r0fw0GiuLzwzqGc8vbu/QY7fjXHeIrX7PcHbxsJQnFAH3l+zr/wAkW8LZ/wCeD/8Ao16KP2df+SLeFv8Arg//AKNeigDO/aj/AOSMax/10g/9GrXwj27193ftR/8AJGNYz/z0g/8ARq18JhSxVQMk9BQBoaDZS6jqMNvCvLMAPrWwscU/it0jwbex+UN2JXqfzzU2ltFoOjT3rozXUimO254DHqx+lYNrJLa2MzJw0ince5z/AProA9I+H3lpc3vjHUI4mihYxWqN3Yegrp5/iFp2qy79a0sOBlTsbqPxrP1vQ5Yvht4ck0u3mMMNvuul8sgq7HO41zejtpmoMlnfQm3lPCzJ0z23D+tAE2uWcOnzx3+lyMbC4yUVuoHdTVK2En9pW1xpwIZnBVV52mrWsXVq+lrYwSM7W8hIc8KR04o8J6kNONzMeGFu4T5c/MRgH2IoA6iTTdPh1aSQ3UC3rwMXhJwI5MHv/SuSi/td4pLK3LCCRsuqnAb61miRpZ3LFmLZJPU596cJ5WG1Ziq9OcjigDo7TwveagqWkd/pxm6LD5wzmpG8A63BOyXaQW8S8mR51249feudjmWFcQpJuP8AGDjP0qOY3kmPM85o+wYk0AdqfCejRpgeJLS4cffVDj8s1bs9T8J+GruOW1s7rUtQiO5DKwWPPrx1rz502ffgkUjqat2F1ZW7BvIaaXtv6CgD0HUNf8O+KbxpdUjm0m9k5MkfzRsf6Vmx+CBI91dI5ubKGNpi6OMkAVzMlul+jSSXEEGD/Eev4Vb8LzG1v2S1vdyupjdWyqsp4oAr+EWaz8T2c0W0SJKNqZJLc/drsIIb1NT1GB4B9qdpWWNf4ASSAPcVxdnezeFfEXnCBHlt5dy7hkZB613WlfFWCbWUudQ0m3Qk5Mkf3h70AeU3SmOd1cHeCc561f8AD+v6joV00umyFWkG1lIyrj3Fdtq83g/Ur+a4S2vVaRt2EYAEmpraDSbe3NxbWQtraMbmnlG9hQBB8PLDVNY8Tpf3qi3tI282aQjaqj0x79MVF8SPAmmyPd6roc0cIVizxg8HPp71lap4mu9Rmjs7WQ2thu6A4Le7V6FqegjSvBtrdXUiXRkdZgqNuDAe9AHhVors02m3h2noCecGtDwneeTfz6Je8iYFEJP8X8J/pUfjSFre9F1HgCQ71IrB1SRj9lv45CJsjOOCPQ0AJ4ht/JuvmHIJVvqKwbjHmfhXceMo1mgt7tEA+0RLLwc89/61w05/eZFAEdb3hrTjc3iSThlt15d8fdHc1Q0iya9ulVRwOtbmp6j5EC6Zp/yqx/eMP4j/AIUAW73UJNZ8VLcQRmW1swscEZ6bR0/PrXofwZsri7v/ABVr0LO2oWcflW6A/KzMDkY/CuV8GW0VrbXJ+VpVjJLE967T4V6rBoHg7W9Rk3Kbq+McSxjuq8/hzQBweqQ6ncXUzXunuszsWc+WRzU9imo6G8d3aHzIgMyIRuH0YV1F9r8uqTSG11BopHBHlzcA57A1hpdapYX6STxHIwMbflcfyNAF9ruxurm2m02GRbmdgGtVGVLe1e+WOkxJocEFxBiR0DFcfMpxyK8n+F2my6p4rbVYLNILG1b94PRu2BXvVnsaQliGHY+9AEOladb2lvsiQ5IwSe9WhAoQhBtBGMjtU8tuTjt24qxaQqrkM3OB8poAoqpUoSSRjqe9OiLSQNnghvzq1cQEkpgFTzioolZd6KuRjvQArOIkYk84xn0qubtVckD5AnJIpzugg+cHggj+tVbeeC4Q7XBLc4PagCea2t7mNXmgidsZ5UZNSxrDDBmKNI2YdVAzmoLh0Ug5GxBkkGqltcpcXRCAkrwtAHiHxpjihRZLpA19K5SFB1A7k1yVvbPYeGhoYz9uv5VubpP+eUaj5FPuSc4r2r4hfD6fxRf2t3YTmK9gY5Y8oB/jT/C3wyt9GzJeSm7u5Dud36k+poA8YtvDkh06dXjI3KW+mOlZdpqFzb2y2UBJkzgkd/avprUvCEK6ZexWYUTzRkDcO+K+dWtL3w7qs7XumSuyElSR8hPqT6UAdlq3jGTwT4St9N0xgdZvl82aU8+Sp6AD1rN0U654/wDDeoafrcstzLEhubCaX78cq88H0PSuH01Zta1832qMXUPvb39hXr3g28uXudQNiq284tpPJYLuCtjjjvigDxPW7qaWx07Xo/lvLZxHLjsRxz+VO8bwrdRrfIqKt1GJMJ0zRFbyvLrmlTyCR3BmJIxlupI9OajsHN94KG4Ze0k8s+uDQB9ofs6f8kV8Lf8AXB//AEa9FP8A2eht+DfhkDoIZP8A0a9FAGX+1Jx8F9Y/66Qf+jVr4p8P2azzedNxEvzMx7AV9q/tSf8AJF9Yx/z0g/8ARq18Zyqbfw4hUgGZtpA64AzQBBqF5Jq96rt8ltH8kaDgAUy7Qw3kCOP3TMhxntms1pCFCqTgYpZp3lALcleh9KAPWPEni3Wb/VpFiuZY4kbZHDGcKFAwBjvwK5kzTR3yXM0JQg88YBra8ZQwxrpV5Ccfa7GGdgv97bgn8xVOOSZtMNzg3Fup2SAjJX0NAEOtRQreLJbZFvKBIm7tnqPwOavXbi20+1jtYo/3sZMkg+bcc9Pbio7+ESeH7e4Iwm8ovqPWixlspdAkt/tG293gorDgjuM9qAIdHjt2eWW78zyY13MqdW9B+dex+DPBEOp6dHPfR20VvIPlSL5mH1avE3+0Wb5VDgjB7g10fhn4gav4fYC1kWSAnmGTpQB7vp3gHTtPzGtpBcR5yryDlfb6VrJ4K0yWPFygcg8BVACisfwT8QdP8SW6qSLe7X70LH+R7iu3juFILDlccYoA5e++H9vKzPZ3CoSu3bLGHU+1eYeLfhbq9tFNcx2sMqKOtmMH/vmvd4boM4VTz3FaStx1G00AfE91ptzYO7lC+z/WKy4K/Udqp+Zne6ts3HAQd6+p/iN4Eg1u2e+0xUi1NFORjiUf3TXzfr+gXFlLLJBG0c0R/e25Hzx+49V96ADT9ZhjWSDV7RLz5CE3kh0Pbn0phv7S1kCXOlxcAHAYg4rJS4IkVIox9oJ5lfmtjTtOWa1ur65uo5bmPGyEn5nPr9BQBp6dq4t9QtFg0q2JkI/duNxxUPjnxI+s6o0NpGIbCH5Uhj6Ejqfesuxa8+1yGKCWS+m+VGA+6D1xUkN1/ZT+RYRrJfMcPKQGwfRf8aAMp5e/klcHqRius8O+LWtdNk067DTW5O6MZ/1Z749qyZJdVlDJdzwqOp8zbU2irotrcGTU5ZLqQciOEYUn3JoAoePY1WygZP8AVunmKD2OTn8K4glXh2kZbBr0b4lalDqtpHNbQJDAiBEUdgD0rz6whEuAz7TsJ+pHagDo9VQTeEdHnH/PNoz7kE/41wMvD49q7+2la58ExRBAfss7KT6A81wd2Ns7A9RQBtaE5h0+d0HzHjPpVGUmO4eU5wfbvU/h+7jikaG44jfnPoauI4aQ27GJo5M8sKAMuPUrhPljkZV9Aa9JvdXjtPCOl6NboVCxi4mlxyzvkn9CK8/n0a5imyseATjBPB+hrVXUrmKBLfUbJ28obUdeoX0oAVp33nykdlPQ4rT03UbueWG3vftL2gblE+8R6CqJ1i0Xy1CyR887l6VsfaXtyklpKr7lzuUg8UAe5eAvEuhHSTBp8X2BEfa8czjcT6n1rrJtb06CPfNKI8H5SG4b3r5mtJLGTzGaFzcEfxHjPrUVtrV+qyWykSxJkkSN90D0NAH09aeNbCVyjXQYcYqxqXjXS9Miae6uQEx8oXkmvm6KUvaxXULlQ/XJ+7UWtaiJIFE7b5AOAOn40Aema98b5xOV0axUKOPMnOSfwrB/4XX4g3D93a4zk4TFeVSPLJIeQAe1VGdlYZPFAHtEfxgv5GBuLaFieuDjNaWk/EewnMYlDWbLnjqrE9jXhSS5Yck1IjNnOTgUAe/zeKLq7v4IoGzaykE7e/tmvTNAtGQoylQCCT6jPrXzR8Ota+y6xbx3PzxbuM/wn1r6Q0q0f7Nvt5JvMYFix+7k0AdIXVVCw4OBkn3pQoUjcx3nrVTSnYbbe5ULOoB39nNakZAcoY+R3xx+dADJI18oySEcDJJ9K+XfiL4nu/FWv3FnE6WunW0hiA6FsHqa+ntYnhjspTMwAC8KOfzr45vltX8QX8l1crGpuGY/7XNAG5bpomi2fmXd5JcyY4t7dcf99MelMh+J1/p+Y9AsbazQ8MxTe5Hfk1gaxqmmrD5VkHmcjlmHArItJpE/1MYLEjtnJzQA9ka08QW0oLsbuF5HL8ZJJz+FReE2WRfEGnlmUspkRevINb3xF1aLVPEnh6SO1jtzDZLBKqDALjOTXPeG5Fi8e+XH92ZWjIHutAH258Ahj4QeGx/0xf8A9GvRUvwMXZ8KPD65ziOQf+RXooAwv2pP+SL6x/10g/8ARq18ZTzF9Etoy3AkIx9Vr7N/ajBPwY1gD/npB/6NWvigh3soIVA3btwPT9aAMo9SDnNPRNrDdgKe1W5LRQW8zAYdMHrTB5Ly7PKYsejbuhoA9JvriC6+H/h12ty91GjwiUHjardD69azbC9uLDS5DBgLJJtdeoYAdCK1/ATWVzocul3zyGNySgH/ACyb+8KnvvB93ayeTHcRzRPyOxNAGK/iISaadPlsohbs29iBhs+xrPlGnzKPL8yI+p5ravvDuqabGJ5LRmh7Nt3Cs4MGjKyWik9yBigCorzRL+7n8xQeM06VopI9xiKyg5O3oagkg25KZAzmrFreiOQK8Q344Yjt60AdJpGnqLW+udPmMc9psuFwedhHI/A122g+P7wwpDcSFugLA4rzGO7uhbxi2+5CSXI4+QnkH1FdiPCMsMkKTzAW9wu/dG3IXjHPbrQB6Pc6hfLZxX8c0ptgdxWHl2Fc3P41uINQuAsNxPbOwMYklIaIgYOCK3dFu7e2077Md2IxtQk9vWufg8Mqftc8N353mEsqN2+hoA7Dwx8QftDR2szmOb+HzT8p9s+tani3w/aeJ9PM8Gy01SLlZh1Pt7ivPtO05bKEXEjJJPnb5ZHDA9Qa1tM8VHwlPs1MfaLKRWa2UkFh/smgDyTxLo8ukX0v2+EQ3XJBHCv71zTAwMFkYh+pA7Cuo+JmuXPijXZLs2728O0eWjDGxfeuUW2mkt4ZVQsrHG72FAHU+D/EMugXTajJ+/UIY1iY8EkY5qhd3Wn3s7SQwtZOTn5G3Lmo/t0EWmmzt7dJZGO6SR+cf7tUYIJpgyxwlyfQUAWL+wt4rUTpqSTSE/6oA7sepqDSLM3c6hpBDDn5pZOi1I1tFauWupFVlH+q6k+1RXLyz26zy4ihY7YY1GAfegDX177G/ht4LQNIEfmdhjJ+nauBiO0xk54bHHvXaSRu3hqbaPl8xS31rnfDtrFdazZxSruQzHcp9KANDwwZG/tPSZBh5U85B3LKOn5VxuqKVvXyMZ7V6Fr9tFY/Ea1jst0URVEGOSMjFcL4iUx6tOjZyrEc/WgDNq1a3TpLHu+YAjFVadGAXGTj3oA9Aezm1+K1gslbfbqdxBwuP8a34/C95a2oe4hMikcZ5wam+G9tHJp8ex8s2Mn6V6HcXUlrbOjRiSMjoe3vQB5R/YKXEmxiiTH+FuA/0rB1LSrjRphNBlGU5KHofwrvxqds8FxFLBJMVOVXHP4GpdWTTJ7eJbuSRBIgP70ZKnHrQB5/Y6pBPP8Av5RA7DrUskSm3C20gm3NyRU+veHLKNfN0+582LPKupHPsaxbOO5i1uOBxJDIDgFP4D2JHcUAaImmt9kMcrYPDA9BUdw0puN02SDxU8vmTXL/AGhALgHLlRwfergsLydFuILdWjzh1Y449R70AZjA5+UDkVmTs2/GORz+FdhdabZRKWW+BJHC7ayEiV45InCMrnk4wfzoAw45PmHpV/dtjBPU0y50i4t1MoRzCDwwU/lVdyWO0Z+lAGhotxs1e0YvtUyqGPsTX2d4bvFj02C3LghP3WfUgZ/lXxdoWk3Oo3yRhDFboQ0s78LGvck17t8JPF9smq3+mysXsSxkgll5bgYyfrigD3Z7dJ1ZTuXcMZHbjrXBeJfiDZaBpS229ru6jJicA4IYetJJ4yitpmf7USiKwEeeP/r14B4zvxea3dzQtgStuYA96AO88QfFI6tp4gtENq6KdxJ6ntXjrRtfXDvK3zMSSfWti4uNPOkW0EluFvDndOrZ3DsCKxZEktXPl5YAZBoA1LPTYY0LtESP7zdKVNVRJDBp8C7u8jDk/Ssua+vLmNY2kYp/d7UkVnfQFpFTyww+83FAFjxoi262Hz77pB5kzjpljwv5VlaPJGPG1hKRlXcZBq5rdsf+Ee+0yzo7NKEIByQfU1zyyEavZurAFXUD86AP0G+C6eX8MtEQ8YSQf+RXoqz8KozF8PtGQgKfLYkD3dj/AFooA5j9pkqPg9q5fOBJCcev71a+IvNlchmUbR0XHAr7g/aUTzPhDqy/9NIf/Ri18YNb/uQvGMUAZIQhy7k7TTraJWucqPmrQeEnagAKn1oltHijCxrz/EV60APtNRvtNuvNgI6d6uP4x1qUAm4kJjPU4OKpQNFHgXDYPTkcVONMi8hn+0Dc/PHpQBctPG2vxktDqMyofvK3zKw9MVn3/i7VJJ2JMGeoPlAZqv8AYLqBTKqbwgzwMj61HdWR2xOxwrjcfagBn/CT6hk/NFycnMYNbfhG/sNY1i207Wd1sbh9iXMQ4DHpkelcWxUsxThc8Z60+1ne1u4biPh43Dj6g5oA+nbD4e6l4f8ANmt7/TjAVw6ywGR2XuK0b611W+06GVVsLe1hTIY/u1C/U15LJ431/wAQzqv9plUxkIrBFxjnNS23iC/fw5/Yj3BltDIZELHJOf4c+meaAPQY9G1nUzbpplxZi2YESzg7ivrgd64XxTd634eu/KW7EqKSA6rirekeLx4R09iDPe3M0rKscj4RQMDjHasvxN45j1y2MN7psMJzuEsB5B/HrQBi3HiS/uk2NM8ZY5JU9a7j4b6nF4l1ePRteiE6OpMbgYJ2jOD+VeY71YB1HfIrvfhV4bfXNXlvUujbJp5WYhPvuSeg/rQB6Zqnwy0jU/ECTC6nbTljDPBnoey59Kh8V+DNFk0maHSJI90KASbD/qx2FR+PPEUNuj2ljdlXueHeFuAfTPtXlWja1dadbaurSPJNOVhYE9fm5P6UAZ9vp8GlatJBrMxiUAlNi7iT2/Ci+N2qrIkim2Q/K0XGPrXZ6jb6d4ljCRRZntlCK2eWIHzE1w9pdXumXE0EQZSSY3RlyD9QaAM8NCkmcG6l64bgVe13UYNQt9Plt7ZLdkXyniQ5XI7j0zU0OoTrNdaZPb22LhCC6oAyEc5B7e9YtpGs0kaO+1RwTQB02kW8t/Z3FrbqWzGZCOwxzWB4Ug8nxbCrYOxmz+Vbiah/Z1tLb2SNH9oXY7Z+YqeKzPC1m/8AwkUmSSEJXJoAm16bzviLphQZG9On+9XIeNwF8TX4X/nof5muvdTd/E6zgjO4o6AY4964vxcwk8QXjjo0jH9TQBj05F3HFIAeuKuabbCe7SORwgbqT2FAHZ+BL9rIKgdgp4z6fWvQrjUZpLIqpWZmGFCnmsHwxpGl+TsjufM4G92GMD2rsNPTS7GRBCFaTtuOaAObTSrqIbnRkdjuY46Uy8sbqeBABkbhyw9K7LVdeurW2b7LApRersAQK8v8QeJ57mcxy6im7uA3H6UAaNzpdvKjC/vJIEPJRSCAKwZ1spNXhigmllgjGBJj5s9hmo7C+01JUfVZZpS2CIoh94fWtfXLsM8McFjHYwKcqoHzN7k0AO0nw89xqYuNPvVjMZ3NFdHA496ueJNXa/uFG1IkiG0rF91m9R7ViecQCRyO+TTFzLG7gcDigAkbzPmPK5x9Km06RLa7jlkgWcLyEY4BPvTL27thpVpHHCUuo2bzG7OD0rKN5cE7Y1Kg98UAd5o/iRbO/e51dVNoVO62TGH44GK5jV/EdtcXUkun6bb2aseEVcke+fWsWKCS4kHmN+JrSWyigU7ly/0yaAKc99qNzGfNaRoic4zgH8KfZXV3AzSQSNHxhiD2rR3NLAqRxHAHK7T+dQzW8kkawCNwN3AA6mgBkWoR5zc3U+f9k8mnXN1YS48kTbscljnmoLiy+yMY5osSD+EjkUkcCY8wqB7UAX9Ais7jVbeKdyLbcPMLjAx3rr/Feh6dbWqHS5d8EjcSDnA9K5C1MaAZUfNwane7uLKDIlDwZ4UnmgCbTdYttEun36ZBP8hEbTgnB7GsW6u7zUpnmu5WZSc+g/AVZvJ1vUX7ucZ/GqUkExiOGUAdvWgCjq+57IrECVLD5ao6pbfZZrOTbtd8Mea33ux/ZMlqII0yctKR8x9qzL1TfazpsGMkhM/jQB+gPwpl8/4d6FJjG63Bx+Joo+FSlfh/oyN1SNl/J2FFAHO/tHHHwl1Un/npD/6MWvj+2ETxEqVLnjFfX/7SK7/hHqyn/npD/wCjFr45t7CQQsyZ9aALNxwQwiV1AwRUNxu3LJjO9eMelQt5yqysD6HFW7VQyYIOMflQBVeDzUGIw5PrVF4bm2dVVGj3nA4yprordljkSOQYAbhiODWxJbQySLlgEAzigDmImmjZopZPKyuMqeDWFd3ElvcNu5UcAHpXYXsEHlsu1QAfXrWFqOmRzozRud684xxQBysi4JIII7Ui8qc9qsXMBgc7gRntVZe49fWgByMUwQCDXYeEHR7UszZeCUfKfQ1xufm5rb8OSFdRkiXhZUP4kc0AbOrsZbeBuSI55EJ/EGqN8v7vHFagiebTb+ED54JBdBccspGGx9M1kzAtHkdMUAMtWwGTHGMj611WgX93pUN3cWcjoJoTGSO2e9czaJuZ/pxXtXw98N2t/wCGY/tiK8V0jIxHVTn+dAHkySOLaP52ysoY8nHPWlu5x/aLSeuCV6cgVp+NfD9x4X1prGWRZYWO+KRSDkeh96paHZtfXyO93DbF3Cl3P3c+1AHpfwlgubu9jez06NrcHE082e/XArP+NVteaXroiijiS0f5laMDJOOdx9fao9X8am00O00jw/cyx2cE5SS4OFefBzu46DNVJX+3+HL2e9lmnO8SvI4J25PXJ+tAHF6ZELi/MTMVaVCofuM0yWBYHMD9EYjeO9Q3Qa2uBJBMrlDwU5zU1rKZzKZAC0nJJ6D3oAty7rSIXk0iPGigop6k9uK1vAVu8cF1ezBt+0sfxrF0/TJNXulZQTZx9z0cj09q0vE+rro+n/YLOQCSQFTt649aAMnwjcLc/EJ7phuSMyS/gqn/AAridWl86+kk/vEn9a67wxAbHRdY1ZztIj+zRZ7s/X9M1xd1zMcd+lACwxMyO4GQBSiQqAwGG7Guk8P6X9p06d+oUc+1YepWpSRjGCUBxQAn9qXoUgXDjtwauaZ4m1PTi5hnzu67xurFNANAG1qnibVNTTZc3cmw9UU4X8qxiRjjrSUvUdOlAHS+DjFJdASp5kkfMe7oK2vH2vWt/qkUVoDGsag7yf4v6Vy3heXy9WjBOFcFCfQGo/EkP2bV5oN4cxYQsDkE4oA9Ru9Mt73wnY69YSJtZRHdRA8pIOMgeh61ztvujmx1UnkVymka1PZW7WpdjbO24rnofWtpNWgABzyOtAHaWmk6Zf3qJHJOkWBuGAee/NVvGtnouiOttYreXVy38QIIx3rCi8Z/YYgsESEv3xyBWmhtb7Txe73F7uznpkUAb3w30/Q/EUrW8wlhvv4YiMcVq/EHTk8JzacunxgLIp3u/wA2WHr+Fcdpd+nh3xjo+pRyF4WlHmcY47ivZPHUMfiOxitJoo45njMkN3nEcmTwgzznpQB5VN4xvJrUwNBaKMbQUjANZEd9cEhi4BHTNUr+xubG6ktrpDHIhIINRYePkqXFAGo9wb64DTAHjBfHJqWC2sivmNIx5A2Hp+dZPn5wCSo7jHNStc+ZtjjRmHTgdaAFkby7hjMDyeNvSoZwby6S3iOV7EetdNo+hXlzF5+oWzWulqDvnkIBH0B5J9qyrjTFtjLc2d3HcRhSymNTu/4EvUfWgDA+feYkySp7U+NJZJNokw68getSwtCkTuLiLfJlQN3NV7iUWkoWEiW6I3LtOQvuaAIdRlIHlMNr9XPTFW/BNu2peI/tsvyW1uN7MegUdPxrCurmW+dICxZicyN3Y13Mif8ACOeA9hUx3WoNnkY+QUAfZfwSuPtXwu0KcHIkSRh/39eiqP7O53fBjwufWB//AEa9FAEP7RpA+E+p7uhlgH/kRa+YtLgj8kbiDxivpn9pSMS/CHVlJwPMgP8A5EWvj+LUbi3jWG3k3r6N2NAHTS2MJlYHjI6H1qCGwX7Rw2F7Vlpd3uFMowepB5rRhvCqK7jBzkZNAGomnwzDyZlDI/6VlX2m3lmXED+dEOm7hgP61dh1BGk3K+D1waluLppEbDcNQBzrSycpPG2e+RWZdq8MjSQbghGWQ8it65JJLDv61kakzSKUi6kcmgDFklinnImZdmOpFUmgiLZB+QMBu9BVWZmVzHnODT4LiaEbVYFT1UjINAHZaB4X028like6+0LnmMfKTjtV290WCzu5LizheGSE71U8j6Vx0E8sBW4sZWRkORg/d9vpXqPhrxBDr2nD7UyGRBsdcAGgCSC3tY5tC1aNVNtNIY5h1ADdQf1qt488HwaBIJraYvY3DnZHjmP2z6UzQJo1v9Q0CeTEMh860c/wsOQK1vHE1zc+GI2u/mnSUM7L93pjIoA84bZtIjHA4Fd3Hrl3YeBNOsYZvKZpWkOOGK/X0rhlGXAAypNbmpvK1rCI3Hljjaw4oAr6jcJcxMZ98svUyMc4PtWdZ2u65SN5TEZF3Iw6E+lWrURmULK2QeDsFJc2/lmJI1bMTnDH09KAC1W40y9VJESR0Gcuu8JnuB3romkh1LR72RNQuftkigHzBhCBzxjtUM91bSbJHgXKgfMvr/hVXVL63ishuCxGJvmK9HXtj3oA4SGG5E5IDRY+dmbp9a37GxuNUCk/urNcE4GGk/8ArVraVp03iCdb28TytNgXCIeN2O59qo+I/EEMBa10bDkDa82OF+lAGtqniCz0WD7PAiLIVG2KPnaMdCa8+jW61nVo0RWluZ3Coo569BUJRpnDHdI7Hqepr2DwDoNr4T8Py+JdVAF/ImLZHHEan+L60Acx4/ji0LS7LQYT+8hG+4PrKetebTf60CtvxDqUmp6jNPM253YsSfWsS4z5vI5xQB3Oh38dt4du0BAkZNpHesm2t/tNjMARvyTyf1qhbSFXCk4QgE1p2TNslKHqDnHpQBy8yeW5TnIpgrZvYYrplaPAdhzVY6TcLAZ12vAP4lOf0oAzjS4Ix709oXVsEUqwSMcBST9KANHw2oS/WaQZjj5arus2MV3MtzASjyDdKr8ANnt+GKrWcYgKRH7xIZhVlGMt26sRk9AelABpmgFnMk53RgbuOBVjWdOi2RlGyw4IXAFasu+108q8jHPIUelZQkjELbvvHnOM0AZjbowBIGcJ0A7V0mieILZFeGWJlJGFZvmwaxdPQXly6MTs2ljz1wKSz0h5EknEoRUyTnpQBe1i4jE6Lby+ep5U/wBwjpXqfiebUPEfgrw5eWsha2t4/JuAh+5ID1+leNwX32VzIkUTknneP5Ct3RfHdzp3m2jRquk3eFuLeP0/vL6GgDU8SSGUiV7hp51AXPXAFZ9tOHQYI+lLMEwrQyCWF+UcHqP8arlVOSAAaAL3leYpK8N6Gk+0XVs/yKwc9NoHFR28kiDcG46inSSNcsD93B7etAGhbWmua0hMSSyqh2nfJnH511emeB9WsALu41G0hmkAygkDMVPYj0xXDxS3aSCMTtF7ljiq+q6k+mwO1xOz3Dj93h+vv9KAMfxtpdrZ+MdUtdHYT2cT/K4+6DgEj881kWfmMWijbaXO15D0A9KtRRTXFlJKxaOzVtzuesjnsPWuv+GOk2tzJc6neor21nykT9C3Yn1oAu+DvB0Ul5bh1k3vh8OMfIOS59B6VhfFDWTf6y8Mbk28P7uFc8Ko44r1rVbiXw74PvdTvyI9Uv8A5IwOCsfYY7V86Xs7XNy8rnJJ70AfoL+zp/yRXwt/1wf/ANGvRR+zp/yRXwt/1wf/ANGvRQBW/aVcR/CLVWboJIP/AEatfGb2JuEaS2+V4xuGO9fZH7TeP+FO6xkZ/eQf+jVr40025eL5M8FcY6daAHvrDrHGJIN7BcZB5pRrHz7YrKXcR/fqC6e2jkcFslfurjk1RmvGTOG2u3YdaANIXmoSycKUwefmAzUj6ldQlRIpJYYADd65qaZ2YnLcn15pyNKwHzH060AdE+oahLkCJeBwTWfdahcLuSSNQ+OgPSoYrue3OJF3p0Of6U69KuRNEc59aAMlssSe9KvPPartzFG8Akj/AC9KokNx2oAt2Stj5GwOhHrWvY2FxaIl1ay4lJxtPQis7SpAgfcvPJq9BKZLfzpVcwK4BPYE0AWrjVpotRs7iZDFdQyBiAPvD2r1zbFqWj3MIZWWeHen1xmvLQLPUHEV042q37l1PP4n0rr/AAhfk2H2d2y9pIYSR1I7UAcnCmyRgei1pajY3aWlm+xj5ke/6jJ5qtqMQi164t0+60mFHsa9m1nw1He6ZpySKIpbeFYW9CpA5/OgDxa1VopkLqFOeldG6STyRyLEoiBLOD068mumi+GwiL3NzfW8dnEDI8znhRXnHjXxTFfSHTNIJttFh+VpQP3tx7n0HtQBX1TVoleXT7Ied+8yuwZyfTPpVFYYbeSOTXZS5BylrGc8+9Zkd+EAXToPJQfxnlj+NT6DpUms6sEeVkgzmSUjJx6CgDZv9SvdUjMS/wCh6ZGP9Wh5I96yZoYHIjtYtqBfvMe/rW94me3th9ksIWWAYAL9fxrmdsk7xwpyzsB+FAHVfDDw+NY1PdP/AMe8J3NgdgaufFzX/terG0gcGG2UIAowAR2rtrWzj8IeFPMLKjLDukP+36V4Pql5Je3sk0n35GLnHqaAKg+8c/nTGTfdqPapAMdBzU1qMOzEjPQUAKUJJyQO2K1YJo4LJow3zOME+lUI2X5iRyRgVPbIsgYn7qcmgCbT7RZtwcH5eK6ey0y1sorfZK0MjDD4G4fkax9FmE2GQDg4ar13eKJplYndEoP40AaSaHb3Bf8AeWrspwWC4/Oq66XbsmYZEwvBKLgk+1Y+j6oyC8lLAgqSTWp4RuxemdEGWA3fSgDmdYtZLKbzQhSPODk5xVOwb94GbjPGf6123iswf2YbdEDzzMFJ9PeuFgO0tDuAKHGT60AdVa3K3UEkZG+4HAT0rPm0m6+0FZUYZ7etSaRL9h1CK7gUOcfODz9a7W7uPPtY5Ps0hhU7iznGT7UAcHb2piku0QHckTEY+lUtNu55LO6skTcsg3j1yK07W7UX93KQdu1sU7QLeeBGkhUZcY5oAy7TRXuW8yVvIK4yrCrGsaS07IbaMBUXbtHX60t1qd3BO0bIWGeTSJqc8syBlITPOOtAGTZ31xprmNgWiJ+ZG6fhXRWd3bXQzC+1/wC43BqW/sIplV5Yxlvug9T9aTTPDF3fzss0MUUI5EryBFUfWgC5HDI0RYpxUMhSC1Mk00aBW43Hk/hU194Taxt9zaxC+fuxRTEnFcnd2gEoWFw4zguTmgDWvtfRhm1QtMP+Wj8KPw70/RrGwZmu9caS4lcZjjztX6n29qwHWOA7mbe3bnipJ5HNuvmMQ0uW+i0AXb+6l1m+itLVdltGSI0HC+5xXsvgLQ0toLKzkjYxQgXU5Azlj91f6/hXlPgSyW41GHrktkk8bVFfQ3h8NZaQ9xNhHmHnSZPGAOB+AoA8j+PGvNeayLJHVobdeqnqxryKtvxfqB1LXby5zkSysw+meKxOMc9aAP0M/Z0/5Ir4W/64P/6Neij9nT/kivhb/rg//o16KAKP7Tpx8HdWP/TWD/0atfFFrcBrxSQNijqa+1/2ncn4OasB/wA9YP8A0atfEGRuwMH6UAPvrgG4cxcE/wAWOapuASGHJ75okGWOAc+tTbAuM9fSgCo5PHapIWYrx6064CnHGMClgGEAFACyFinzE49aYJCgUDnmrEbKysHAqOeHCgg8daALUKq8G5RhecrWfLGQfk5BqzHI0cClW6DP1p0CGTDY46kUAQab/wAfO1j94YqR4bgCCHnY/wAyjPHWoUYRXgIHCtWtAj3GpQpFnEZZj9M5H86AIbuFobEYDLg8HtWz4GvJYzdyEk5K9fWq2r75YnLruC88dqteH4ibVmAABIoAuX8puPEqMc8uma+iNQuohYMzuAEUZY9OK+dRz4gj5yVkQV1HxN8UzJoi6fA3lyXb7HfOMIOtAEfjHxrJr8UunWR2adG3zEf8tCO59fpXBWmky3zlLaBj1JJ6/jU3h+BnzBaAyIT8x/8Ar11EsKwxC2t96jbmVkOAT6UAcrbaWsTkH52QEvj+QrqdLiFnpUdwVWNmyygf1qpawNGZEjQAKh3d8A1LeXanSoe8aqyjaRknPpQBzOvXBuLzIf2rb+Gmmx6h4mRpCHhhG9jjg4rlLuRWlYoNoUZIPWvSvhsn9n+HLm6MW+echUGcc+v0oAj+M+rsRa6cpwZP3kmD2HQV5Kw+fgd66jx/cvc+J5llOWiRUOPXHNcv/wAtCBwc0ASMp6j1ohky7p09KcxwKozkibKmgC2zhDhjzUsVxJHHKo2hJBjcT0rOdi5y+SelTRxmWNlJwc8ZoAtWN1NbQTRwn5HI+Ye1NlmlmDZmfe3DE96ig2RkrvOQeeOKZNMjuhU/d9RQBJazSR288JX5XGG9RVrTb6fTp2NlIU3psJqpvj3tMrcYwwxyTUULJ5o54JoA2LSa6acSTztIVOVDHIJqvfQKshYKQxOTUsTBHUHt3qa6IlgJDYOfzoAt+GXTzQZMkDrXcajqSSaeBgKgG3GeelcFpamJTx1OcVHqt1K80ShiEDDjPGaAKkkpLyqOFOc810enXuyCLYQyKP1rmHiPzljg5IwKs2l0Io1ib7w+Ye9AFq8vMzM8gVST92qkGoCK4Z3QBgMJnlTU8bxtOksoGCMgGqepyW7tuRMN7dKAOms3jutHlnWZGuIRkrnkj2rJOvzXdmbWGMK6NvDf3h3FYMUrh+CRnuOK0dLmt451x8kxON2Mj8qAHGS8uHAllOwdz2pbphCgjAwAMe9bWoG3itWlRAZxwSD+tcjcytI3UlicmgBIczTDf91eT9KWWXzZmduh4Uf3R2pinEDDuxwT7U1G3MBj6UAepfDPT2Gny3TJuknYQx59zyR+FeieOdTXTPB166MFBj8uNc/MCeK5nw9ELWw0W1VSu1DcNk4PtWT8WtRVdIt7UD5pZS7H2FAHkMzbpST9OaaRxRwcn3pD1NAH6Gfs6f8AJFfC3/XB/wD0a9FH7On/ACRXwt/1wf8A9GvRQBT/AGmlLfB3WAvXfD/6MWvhlAEm2u20Dr9a+5f2m3KfB3V2H/PSD/0atfDEqq0+VOQR196AJnikOJCh2seGHQ0SSDd8qnNOt7l4ZPJf5l3A4qO4fLkr0JoAZNksScZ9KesWQpB57iodxy3OTTvMwQRQA5kYIQQck0krfJwD04q3kMBxyarzoA4B44oAYWxbgH0p9tc+RD17U8pugyOeMVWMeUYdCBQBC7Fn3eprotClWO4yTglSORnNc0QVODW1pJJjJyMqKANC/dmhYEjG09BV3w1KP7NXHJ3nrWJLeRbjGZM5GPpV7w9NugaJT9yTP4GgDRs236/n/pt1+lVvG1/Fcap5Aw4gABPueTRbOqam754Dms3CvFJMwBeZyc/jQA+21V4YRsJU+i8Vet9fkE4EqOkXQyZrGktmO0r061r6RIJRLbTRqwCZGaAOotpUSb7RGVZCmCccEGueu2EcsyBBvB3BhwauzTrBZgBhscAAjtXLanfOLqRgTknGaAGXsILoyjAl5x6V6j4dfytDgiB2DAz6nvXmKSCcoDkyKQige/Wu+tbt4Lbyo3CYx2zk4oA4XxZ83ii8OT2/lWImPNP1zWlrc4m1i7lX+NsZrMQ4kBNADnbJ4qpMP3w+lWWGDkVVnJWUH2oAmWMhPc+tWIyqc/xVXR9y8nk0jkgc9O5oAcnE52jJz0qNo4xJIsu6M9V4p9vuNwjDqWrRntmn1JfNUYK/yoAx1/1bgDjPWnRLhgxHy1cmthBNLGfu54pg+dgFAOOlAFhJflz1BpUdWfEhwtRCNucA04wscMDwBzQBfivY412jLNVcjzbpWk+7uBFVIlYMzbgFBz71PHIWlToQhDGgAnlAusDgbyD9KkaWPahEYbGc+/tWddNmeQf7Wavaf5ckgjkJCnkMOcUAS+X5kMPlEAjqP6VTvLeSFQSp2nv1rblNqumhYYSRvOHJ5aqtrcxGX7PKmVfjk0AYqKxfI7VKkZ43YHOetXLq2iglIDEHrtqFUDLnIwD2oAuPM0tl5eeRks3qKx+v3Qcj0q48gWPr14FUgGaUog6mgBTkqMchTUlnGZLmIDks2KWcBUVF64yauaGm+/t0JGQwJPtQB6rLeAalCsDpIkUAVvwxXC/Em88/UokPRI+Pxroo7hQ8ki4XcTjHHFef+Jrk3WrzMW3bflBoAyaKKSgD9Df2dP8Akivhb/rg/wD6Neij9nT/AJIr4W/64P8A+jXooAoftQEL8GdYJ6eZB/6NWvhkMnlb9wIzX398c9ctfDvw21HUr7S7fVbeJ4g1rP8AcfLgDP0zmvlkfGjw4F2/8K20PH1NAHl1xEHhWeNwWQc81UaRS/ykYx6168nxs8PouE+G+hgemTUf/C5vDf8A0TXQvzagDyIMu8EEc+9PLLkfMMivWv8Ahcvhv/omuhf99NSf8Ll8N/8ARNdC/NqAPN7aSMqPmGR70y9KhgQQc+9emD4z+HR0+GuhD8Wpz/Grw+4Ab4b6EQP9pqAPLYZUUFS4x9aMr5n3hj616f8A8Ll8OD/mmug/99NR/wALm8O/9E10L/vpqAPKb6NFYNG4we2aZFI5ULHIAW+U89a9Yb4y+HWGD8NdBP8AwJqRfjH4cVsr8NNBB/3moA8xFnHG+JJA30NXLGVLW7dAwCsoPWvRW+NHh9jk/DbQif8Aeak/4XN4e3Bv+FbaFuHfc1AHAvKBJcMrDJz39q0tKt7CXSYnKlrhV5G7v9K63/hdGgZJ/wCFb6Fk9fmanJ8bNDQAL8OdDAHTDNQB51e5gO6NwFyQM1Dp94YrhWDjcRjGa9Kf416DIAH+HGhMB0yzVEPjH4cDBh8NNBB/3moA428vQoMbbCrKCMmsK82tyrAqD616k3xn8PMAG+G2hHH+01J/wuXw7tK/8K10LB7bmoA810h4/ODlhuDZAJ6V0d/erDZtIJQCvOM9TXUJ8ZvDqcp8NdBB/wB5qfJ8a9AkTbJ8ONDZfQs1AHkPnAysxIJbnNRFlz1Ga9eHxj8Nj/mmmg/99NS/8Lj8N/8ARNNB/wC+moA8hLDA5FV7gjzeOeK9m/4XJ4b/AOiaaF/301B+Mfhonn4aaF/301AHjdsVYlWIHpSTt85UEbeleyj4x+Gh/wA000L/AL6ag/GTw2evw00L/vpqAPJLbawUhwCD+db22IxJIzDcnPX9K70fGTw2DkfDTQv++mqY/G3Qdu3/AIVxoePTc1AHkOosLib5GGPrUTDyV+UjOOxr1/8A4XN4c/6JroX5tTT8ZPDh6/DXQf8AvpqAPI4rgY+ZqtwXUOCrPxXqH/C4vDX/AETTQf8Avpqcnxh8Ok/J8MtCJ+rUAeT3LR9FYHd+lR28wSYlsEFa9iHxX0SQ5Hwu0Un/AIFTv+FpaKfl/wCFW6Jz2y1AHity6s5dQOTVmwkQqQzAH616+fipogHPwt0XH/AqZ/wtrQV/5pfon/j1AHlwkVIIkaQN1IGelPt7eOWbzDKoZRkDGa9Pb4x6CFCt8M9DAHQEtTY/jR4ejbcnw30JT6hmoA8qv7j96xchx3z1qgkm4nHyjqBXsL/GTw2/3vhroR/4E1IPjF4aA4+Gmg/99NQB5ArKWUMeKn86GMkR8Pjqa9Z/4XH4b/6JpoP/AH01J/wuPw1/0TTQv++moA8cEu5txxurQ0Fl+1lmbkKe9eqf8Lk8N4/5JpoX/fTU+L40eHYjmP4baEp/3moA4ue7jijOHGFXg5riZ5DJM7k5JOc17a3xs0BgQ3w40Mg9eTUQ+Mnhr/omuhf99NQB4nSV7b/wuXw1/wBE00L/AL6al/4XL4a/6JroX/fTUAfT/wCzp/yRXwt/1wf/ANGvRWv8IdVt9c+G+h6lZ2EOnW9xEzJaw/cjw7DA/LP40UAcn+1X/wAkT1r/AK6Qf+jVr5p+C/hHw/rngzxRq+u2NldXGnz20cP27VDp8CiQsG3SdAeBjPfivpb9qv8A5InrX/XSD/0atfGPhDx5rfhPT7+x0lrJrO+ZHuIbu0juEcpnacOpHGTQBofGrw1YeE/iHf6bosM8elbIprUyyCQOjoDuRx95M7sHrgc81wtbHivxJqvivWJNU126NzeOqpu2KiqijCqqqAFA9AKx6ACiiigAooooAKUAscAZNWbSzkuAWAxGOrGtPTlCXCR2Vu1xOTjpkZoAZpfhrUtRQvBARGOrNwKsW/hp/P23lxFBGpw5Zv5V2dv4W8S3turX1w1pbkY2j5cirdv4F0iO4jTVNVVTKM7i+cUAc7B4b8NIubzW0iGPQsfyFQGHwdagN515dtk5CJge1dFqFr4M0t5Iw5uSMgMO59ayrnxL4etoytjpiu6nALDgigDm0u9KW8nWe2kNp/yyKjDfjViGz8PXrbYrqa1cnjzRkVB4g1y21dE8vTo7ZlP3krp9Bm8Iz6XHb3kXl3IUAt/eNAGLJ4NaZ2Gl6ha3YHUK2CB+NZWo+HNRsJfLnhO7GeOeK7eXwhpNxLu0jVPLcjIAPSnt4e8V6bl7e4jvEABwSGJFAHmEsMkJxLGyH3FR1397qk+6RNe0QbcbSyrgqfWuf1LT7GVRLpk42n/lm3BBoAwKKfLG8TFXGDTKACiiigAooooAKKKKACiirNjZy3s6xwr16segHqaAK4BJwBk1vaV4Xvr4CSVRbQE/6yU7RV+1lsvDxV4o4ru77O43AH2HeteDQfEniSBr7UJBY2PUSTnYCPYUATQaV4K0iENqF7Pe3ABysQwoP1pV8VeGrePy7Hw874H33bJJrLuLbw9pSEC6/tC67t/CD6U218Tafa3G82AYgdF6UAbUfxAn3OdP8N2yyPjLCIn8Ko6jquvahd2V2NCWGS2fem2LCt7MO9Og+I91aYWx022AHOXXJqlqPjzX9QTLeXHHn+FeBQBavfiRrKXLedp2mRSjhlFsB+lFp8Qk8opqWiWcqklgY12HJrjLyWW5kE9woYseSverk17ZNbrELaRD7nNAHTJ4h0K+uM3Nn5EbJtIQcqc5yKU6HoWrnFjciCRnwu84yPeuEkSNmHlHr2ParENrdL80Ybjpj1oA1tY8I39hLIqBZlTklDmuddGRirqVYdQa6XTtd1XSp45WVnCkHDDOcdq1JbnSPEqD7RGtnck5Mqe/qKAOEorU1vRrnSJ9k2JIj9yZOVcexrLoAKKKKACiiigAooooA/Q39nT/AJIr4W/64P8A+jXoo/Z0/wCSK+Fv+uD/APo16KAMr9qv/kietf8AXSD/ANGrXwPX3x+1X/yRPWv+ukH/AKNWvgegAooooAKKKKACr2mWX2li8h2wp1PrVe1haeUIo+p9BXQRQNcy2+mWKklsFyOaANHRNHufFOpR6fpq+RZx8O/YivW49J8LeCbRG83ztQiAYpuwDkd6wWubfwToSW9mwS8cYd+4BriDfSa9dzyzB2Utku38VADPFXj3U9UuZo45GjgLEoinhfpWVBpt7exrLdzsqHoM80+9s4U1G2OzjcMiuoIV9qYwCOMdqAOG1DTWhuFSLfIT1HWte08OM1qJJHCuw4XFX7aJ21G4IHCHbn1rS+Y5Qna2MDHagDhL2KWzm8shSvIz2rR03w413CJpH8tcZwKueJoVhtV4yxbrjpWvphZbGHPR1GDQBzk+i3lo26yuHOOcA4p/9ta3ZooEsscikMWJPOK6IzbJgZFIQnbu7VNPGr5BjEh6AYoA5/8A4TXU5GT+0HSdQNpDLnd9a37fQdK8VQ+ZprrbXarnYp6nHpXE69YSRaiI0hKs43BRU+hzX2hX0V7Gu142DAfSgBbqwkgujp+oL5chJKSno3oaxr20ls5jHMpB7H1Fe3ammm/Enw0JbVfs2sWiFwMD5++BXmEkb31pLZ3g23trkLkcmgDmKKVlKsVYYIODSUAFFFFABRRTkVncKoyxOAKAJrK1e7m2JwByzHoo9a2oVlluYtM0mMySSNtAH8R9TTLlG0yyW0QAzzYLY6+wrTiRtGgjtLZiurXGGlfvGPQelAG/Zx6P4FmEmoJBrfiEDKxI2+KA443eprM1+98QeKit1qEw8pR+7tovlVR6YqTT9Lht8scvI333bkk1oQkwR46YOPqKAOQi0qcvsEQiIHJIqew0aOQu77jt9a6W+OAjJkkZziq1ihazD8hnyTn60AV7TSrOQAGLle9aAt7cRiFY02L14q0NPuRamSNCEI+9UOzZ+7iG4qPmJ7mgDm9csliu7dbZABIdpA9TV2PRYI5QZQCxHeotRuWOo2sRRso2/p2rZA811ZDuUUAU30axkDK8YyRwQMYrnGsr7TZneBmCI3yk8giuxt4ZZmkZY3IU8HHFSPGrx7LjDcYIoAwNK8SWjbIdbtQY88yRjJqxP4e0rV0a50HVIEnzxbv8rH6VR1LQVdolszhpGI5p50KO2iTc37wfxrwQaAIIri6szNpOrRkA9Y5Oh91PY1i6zppsZQ0beZbuMo3p7H3rrIrSXWxHpOoS7rtVJs7hjg+pUnuKx7ODytTk0zW1aJgTGxYfd9GoA5mir+taZPpN+9rcqQw5Un+JT0NUKACiiigAooooA/Q39nT/AJIr4W/64P8A+jXoo/Z0/wCSK+Fv+uD/APo16KAMr9qv/kietf8AXSD/ANGrXwPX3x+1X/yRPWv+ukH/AKNWvgegAooooAKKKmtYTPOka9zQBoWgjtdOefefOf5VTb2rufBVqNF0s6pcJmdxxkdq5vT7FNT1+0sVdI4Izudm6ACup8c30UYjt7QgQhQAB3oA5y+ubnXNWdSzMCdzE+lasUkVtGIP9XzgYFZ2jWlzA5uZAGgx8wHUe/vWvcwCeNWiC7hiSMjvQBma3at50dzGp3oQcdmFdTpNit/bfaMlUCbs+lUFuI5MRzDYzDgMOPep9Z1AafowtbN1Hm8OV9KAJLS1hW+dXOVc5+Xv71JqdtHa3QWIj5ufpVTwtKrQG6myY4zge5qxfTS3Ny7rCpUjK7uMUAYXiyNWtYucZYCtGC3EFpGqksBjGe1c7ftcXGrxwXLoF/hUdATW69nPaoHtpvMdD80bdGHtQA9bZ7mOVApw5GDjp71PqMT2Qy7YwmSfWtOyeGPTprh2KgqDzVHUUN5pkc6kOh+RjQBz2meZfXUl7MuABsjB71FqsUszuIId6LwxJxz7VpxFI8BcAbgqrU82EjCgYVB+dAHNeH9RudE1dJId6rkboycZFavj62RLuDXNOLGC4A8zj7p7ioNSsjeJuiIR4+Q1bPhiF9Y0O906Qb3VSQvvQB5/q0IZUuY+VkHP1rMrYihl/wBKsJM7oycD6VkHg4PWgBKKKKACug8P2QjhbUJx+7X5Yx/easext2urqOFSBuPJPQD1rpJbhLScLA6vFbnCEjKt74oAueF7OObUL/WdRObbT037T/HIfuqP89ql0WNdTa61O5cG5lkPJ7Cm+JI7vRvDun6TNEYri+H21wepD/d/T+dSaFbG0tfLKExN830NAGske87FIbPGBW/pGixzRStdOFkC/Ih6Vz1oyo+5FCHP41f8RanJa2iTRkgSLgn0oAranbiH92BkHuO9O0uILLsmAEMQLliOMCuXt/E9wkgjaNZQPu5p19rt1NC8EpVFkP3E9PrQB2uj6o2q3Mpc7LUIcAe1Z2w+a2xOCeD61Npjxrpm20QDKBTjrUMcUzsHYmNAeCTyaAIL7bFq9psiLv5bb8D7o9ae9zDATHJII2bpuXApt1PDpl+skxkc3ICZAyVx/StK2t/ts4jGySNuAWHSgCewuTZWSzRkOiPmReoYGqGqQ+feGW3B8hxuGO1JrKW+jabcW5lXzZlO1FbIWuYsdfutPiEZ2mPHUjOaANhw3261VD0B3e3FTXMD708xSOOM96g0zxBbXNyp+y/vCRz2zWt4gvUupkcgqFQL8oxQBy+tx3Vs9tf2z7ZLdgyEcEGtbxekfizw5H4msgRqNsQl5Go6f7VVb2OW6tWWJDs6/MeTR8OL37L4huNImKrb6mhgYSHC7j0zQBh3xOtaEtwzl7m1AU7jklO35VytdjdWcmga7faXcpg28rRyBTkFTyPrXP65YtY3pUqRG43pnuDQBnUUUUAFFFFAH6G/s6f8kV8Lf9cH/wDRr0Ufs6f8kV8Lf9cH/wDRr0UAZX7Vf/JE9a/66Qf+jVr4Hr74/ar/AOSJ61/10g/9GrXwPQAUUUUAFb+jQrBp0104+ZvlU+lYcal5FUdSa3NR/wBFtYoo2K7hyD0oA7H4fWMFrpuoazfRq+1fkDd/SuWubmPU9UKyOFUnjnpWv4j1dE0my0ywf5CiK+O571FbaZDFAFZFLHmgDbwkYQJIiqAByetbqWVpZaYJkcSGToMfdrko4raHG1AzDuecGtq5M40iO4t3H7s4IPQ0AUII2u55RMQhibv6etYHiTU4m1ARRFXVEAyDWjNdhF+0zMFOCMDvXE3RLzSSEj5mzgUAd54SvPttm9kpCyqcrn0Nac9s1tOEleUsepJ4ri/CMhTVYQOjHaT7V2180st7lslF4oAwbq0htdZgZgxExwPY9c10ltLEbtVdAw6c1j391D/bkEZwWRP1Namnokt4ePnHIoAwPG+pzRA2aHYm7dwO3YVS8P67NEwtpGDW0h+dW7e4qp4zuJbnWJ8lQEO3FYlvuDnH5igD0K5snN+si4+zxcg9iTWpfiG6tT5RVmVRnbXnFvf3Cts852T+6W4r0Xw1Zyy6U8wAOEyVByTn1oAx/nhjKuAPUj0pvgO/ew8UBC3yseueuatywuZyZBtHTbXLX4fTNdhuF5QsCPbmgDX+IOn/ANmeMd6ArHcruAHHWuK1GEwXbqRjvivUfiXGureHNO1iE7mh+RzXn2qRLLZJcFiZOBg+lAGLRRSqCzADqaAN/wANxLFbXN7Im8KNqA9CTU1o9tJfabE8QdVlHmAHhxnOKW8V7PT7a1wV43tx3NZvmm3xMhG4KQvsTxQB0vjHU4tY+IEssHNvHtjQdgAMYFa0zPtASMjI6Vzvh7RmltFvXk2lmJHqfrXRB5lIEkYdP76mgCOLe2AyfQ0ni5JJdJtUi5Kk7hWtpVoJ5XkQlo05Oaz5hJ/abrJkoeR6YoA4qIC3ieZx8w4Uf1rPadzKXZ8gdq6XxfbiFgIhtU9q5ST5cr3FAHW+DfEEVhqC/agXt26qe1dtc39rdT/aLaMmJfuqpzivGxleR6V0Hh/V5bW4UhuMgHPpQB0GkefP4muLidWEPIUNyFFdGdQ0/TUa81ByiZwFX7zkelZeua9FpsQNrEgndepGcZ715zqF7PezmS4dpPTnpQBf17Wv7R1GWaFTHCzZCk8iksG+228sTjLxjeorH9zW/wCD1J1RWIyvcUAR6WsseowybPkDjJ9K7zVIWjlQsp+Ybvas4WDNdNEiAYbg+tdJq8PlWcAOC6KM0AYnmeSV3sBnoO9c/wCK4/s08N5Gu3awIYetb3mfxGM+5xnFVdftzfaNOq8so3KPpQAzx1BvGjarvbZfWih3x1df/rVz+pf6dpYbeXkt14z1K5rorrV7G/8AhnpdvcE/bbG6KhfVD/8ArrndNUC5KP8AdkUpg9xQBzdFSXEZineMjBUkVHQAUUUUAfob+zp/yRXwt/1wf/0a9FH7On/JFfC3/XB//Rr0UAZX7Vf/ACRPWv8ArpB/6NWvgevvj9qv/kietf8AXSD/ANGrXwPQAUUUUAa/h60M9y0pGUjGTVi6Ml9fKoUOIQXOP7orR0tfsfhx3OA8nIzWr4AtA9p4g1G44hjtzCTjP3qAOZ0uB7zUkbA+X5q6uchIx8hBHBArldFtr1pzJZOFCMRz3roX1Ga2lWPU7fy2bpIvIYUAS2/kliZHCf71bdpd2slobV2KqwwWXkGsefYyAqFZTyDjtTYkQDBJGfTtQBleKrGS1nUlhJbN9x16fjXOOgD9ee4ru9UMFrokwucyeZ8sanrn1riLhod2ELe+etAF7w8xj1SNlGAD3rvhKVjLcZeuA0FVa/RlywHavQDblokdmGOwFAHJ3Vs7a/G/JMnJ/Cult/kO5SQ3TPeoLhEXWjgZ2QgfTNTRqXRivagDz7WnJ1G5dhnLmqqK0abkJKmpb0MbiQFhkuc57806FGc4XrjoKAJdNhR3dnxwOPevTdKZ7DSke14Eict615xpNjc3VwQpCxj7x9K9A1CTytOtbaLI2IMmgDNuJ5mkwTweprN8QWyS20bMC23JyDVxUkc7sEc5zVW/uUVfLC7sHnHNAEGm6ur+DNRsLiQHA3RRnqWrBtgZLRlbJO3pUc7bbmUohBYYwR3qbSQwAQjBORQBjEYJFaOgWwudThQ/dByaq30flXUijpnIrd8KQwiC6luCU3IVRvQ0AGp3QupyVJIQ4B/SqEsQjniYjcJMlRnrjil2kSeWpyd2F9/SrEsH22/ZIWPl2yiMEeo6/rmgDo9JNxZ6asVxCHQZIC9cGrUNxbOwCSvGx/hcYqeOTdaxHPzBQGqMCCW48u4CnHK+9AHWwRRLpiC14LffPfNYDIwvSJFyK1PDlwYZpYtm5GGOe30qbWbUvdKUXHmde1AHG+KoGkZTgkH7px2rhruJ1upPl43Hg169q8C26wFwxwucMOPrXn97agyueuSSKAOZOfQjtUls3zY6elTXsQicYPWq6jDZzzmgDS1yZpGgDtkiMZrLA7irWpPvujgdFA/So7ePzDgdKAK4z6c12/gayxuuCvbAzWLDYq2MivQdJtHttIhjjXIKk8dcn1oAqzXZS6VoVLupx8orQ1F53tgWTaX7dTVjTo0Xy422KwGcY5qzqUXkw/JzxkZNAHKs8UZKvIQw6gU57i3gtJZjKCqqTj19qkc72wYw30708LHFlp1t409Gx0oA4S1szcW14hYRSBftESt/GO4H+e1OtJArxSOCdrDAJ9auMVuPEQXT22xyP5acZHI549KrXCWymFIC52x/OT3YZBoAq+JkUamzou1JAGArJrf19fN06ynAJAGwk1gUAFFFFAH6G/s6f8kV8Lf9cH/9GvRR+zp/yRXwt/1wf/0a9FAGV+1X/wAkT1r/AK6Qf+jVr4Hr74/ar/5InrX/AF0g/wDRq18D0AFSQJ5kyIP4iBUdavhqBbjWLdGbaCw59KANvxIRDFawqpXyowCfU1rWc/8AZ3w3kTO2W+lLn3A6Vk+OpU/tEwwKRFH+7DE5LH+9+NWtdBeDT7AEbUhXj8KAF8L2M9s6zGQGKQfMrDita+thewSQ7wJFOYyajs38rToEb+FQtODbjwc/TtQBQtFkhUQ3Q57MKvW0bBxtIdT+lLdLuG4ctxgVuaFZJ5ZmlXCqMkkdDQBx/jN2DW8GAU27iPeuUEasSc4/Cup1cTXGtXE21WhT5Rms1rJlt/NYp8x6CgCTwsp/tBR5RKnjNd3cK6Mi4+U9PauZ8NpL9ugeRAsYOM9OK7rXY0Voljx93PNAHHx/Nqt64bOCEyfpWhFIsVjcOwOxQaoaam63upfWUg1vW0EJ0O4eVSU2ndigDymR0mkyflyc8ir+lWLz30cMTDnuagksmW4IUh0Lcc4Nbuhqbe9S4khYBB90elAHQR21vp0KpFhuRuPqaW+1K2lZA0iKVGCq8k1Z1TTPNQSxLujdQwyazIrWG25EKoc8kigCArJdviHfFF3bpUtrawwuxVckcAn+dTSO2zKn5TxkURBFJ3ufagDD1aIS6zZ4Tq4HHGayrhTb63dQ5ICzMMVsC8ibXrZm58t+n41m+J1+z+K7o9AxEg/GgDO8RxBLmNgPvLWza3Mlp4VitSsYS4mD7iORgHvVbxPGZLW0nJ3Z44qxrHlf2TpUSRlZEV2Zs9QelAGfYgm4nuONlrGXyfXoK2vCSRrYODtNw7bsE9RWAAy6MQCR9puNp9wtdba2Vra20RCZO0EN3zQBZZmA2OuFz2rQ/sRp4POiUMQMg5rL87dkNtweM981uaNdyoghcMYx3FADbJZLK4WWcHC9s1vNJFeQq2XL549qpyvHKhRlDoeTnirulrGrIsWT8wwKAKvim2YwQFiCu3afXNcDfxBGbbjj1r1nxREi2uGUZxuzXletYQbuACM0Acfqki/advp1qrGB5ijuTii5y87seMmlhQtNEoPVhzQBJdqTdy89DirGkgNOyHjior9Cl/OAejY+tP0htt8NwODxigDrrKAHb8uTXo+mwwjRNz8MwC1wunpkADrmu/0+NW0qTa33OcGgDndQkS2lV0XDkcMetZ8147w7XclT79qualH5z72BIPQelVo7BnTkjntQBR85pQ0dk4jRR88p7fSoYLO28wsqPcP3kkOasz2rLMIfuxLycdDRuX7ik7egxwKAMXUZbW08VaVPEFCrIPM29OtZOtWv2PW9Qttx2xzMUz3UnI/nWn4l05WtJLq3jwyYPy/zqj4gk+1S6de85uLZVf3ZeKAJdRhjbwupjfeyPlvRfauSrtLNGfw9qcOOFKsB71xdABRRRQB+hv7On/JFfC3/AFwf/wBGvRR+zp/yRXwt/wBcH/8ARr0UAZX7Vf8AyRPWv+ukH/o1a+B6++P2q/8Akietf9dIP/Rq18D0AFbng4Z12DjIrDro/AUXm+IIBkjnGcZxQBFrJM+s7C5IaXHP1rTjvIzruyRN4GEDHpVPXlWHxMyxnKrNxkYxV/TtPL3css3TIKgUAbjxiGI9xnNRkRbQfMCg9wakmIWUqWyCPung1DIkTIAU46EEUAaGl+Ut0i3LZgPG8dq7jUorZdLC2EgFo33sckn3rzKCwnDubNyw/wCebnIre0Ce7RXguEKxuCGAOQPegDI1exGnedIoZt/JBP6VzZlRpxsGzHX0rrdYjMkpiU5zwMmqlr4elur6GGRdqN1YelAFrwjb3DSrM0XnKv5ZrovEsUyzGXJGQB09qz5dfk0qcWtrA6xx8AooP51HPqkt8wkbeecnd0oAo6VkadMjKAolOP8Aarp9OSz/ALKe3aZl3ggqR1rldPbz7CVuwkbA/GobOMLcYlkc4PQtwKAINX0O2ixJHMwO7lSOKWztnjSWeKdF2cYY9fwrc8SMHtLeGCMMgUFm7k5rGtDbvOqTDa7sDj0oA6zRbsz6eIpUVuw9vpVPUrQxqd4IVh36VZg1Oz0s7WCMc8Mf5AVQ8Q6vJqMm5UCpxtAFAGdtDrsThV701WjDAY3tjHqKSMZADfMcdCeKdPmMKI0Lgj5scYoAwdSj+zzRTOu3c/b61D4zZW1qCUHIeJc8e1XPEayfY4LhVBRX5rN8WYNxYv1LRjNAF/V4LU+HbOWHesu8bkJyD7irPi1La30rSUik3zPAzycfd54FZ+ouh0e0QMCxIJx2rR8ZWojsdJduslsTwc8ZoAx7W3Bh0R5seRI8h59QRXV3QXCuwLRn7oWucu0b/hEvD6oC0jTzFQByR8tdFBATDFv8zIHIHBFAEChZTg2siHsRXUeHnR0a3lxuA+U9658zhQeXz2Bq3pU4W7Tkqx6GgDpbmxQHeCrL0wO1R6JG39onDMI89atMSIWB+7/OsfS7yW31F415DcgA9KAOg8Vsy2VwY8uyqQSa8n8TSeTZQAn5nFeyakgn0ya5bODHlvyrwHXr8X97mMFYY/kQHv70AZLDJPar+lW7S3sIxgbhTLW2MnIGfaul0mx8tTMQQIxnNAGRq1qsWpXAbnnINULc+Xdg9s8V1mv6eDMJI/mDL1965y6iMDBsUAd7ZQgeSCRlgGJHNdxp0LR6ZMACcLnPeuD8C3LajJaRIf3sTbWyO3avUZWW0sZyx5YYKkUAcNqOWcKCVA54FNjmIQBQWAODx1qS7RrjjLRpuznvihIliwpDOD0NAGdfhjl1HGOh6VmGTcMBT1/CtTULhp38qNcKOpFRuTHACipkdVI+9QBBco0OlXLorTMyEbV7DFcfcZbwzpbrnKXDpn611MeuWEHmK4ljlwQY8dT7VgSgP4KabAGNQO0d+RQBf8MJPLa39tHavKJICXkxnyyDwf0rhZhtmcejEV6h8P8AUrjT9I8TtFNGkU1n5LqwyzEntXl8v+tf/eNADKKKKAP0N/Z0/wCSK+Fv+uD/APo16KP2dP8Akivhb/rg/wD6NeigDK/ar/5InrX/AF0g/wDRq18D198ftV/8kT1r/rpB/wCjVr4HoAK6n4cXFrb+JrZ78ObbcN4Q4bGe1ctWhoUph1SBgcfNQBt+I4bdfGUq2ZLWzXX7suecE966iwRlv9RhlQK0TbQPesX4h2q2+o2lzGNomjSUcYye9dL4o0u40/WdJuZrtJBqcCSFkPQbRgfWgCvdRK8eLuIj+7IvVapLDPAn7u5SSPsGXmtGWFIWKxBndupZs5qpKkwcsW+TuFHSgC/oVyYL+KSRVOCO3FbvjG6vdOn+1WyxtbvgAqB8ufWuZhIEcZUksG6d6vW98z3UkMwMtvkBg3QmgDEuNzDzlbhRvY92PpWn4b1CW8vgEJV0TJXrVPxAiWUly0fyQFQUHXGT0o8BDbqFxe3PyxRoQfegC/fSpcSuUUJJ0bHrUDyGK1kMgyVXJqK+kjkuWkgJ5bOM0XbbtNmU5U7TzQBW0Ng2nKyfxsS31zT5Ydsu5ievNVvCkBXThM0o8rJAXHeptUkAU7GOTwKAOmuntxp0MrMpUKeemOK4sanE1wkyKMqQOat+JZPsPh/Tbffh5GLNu9MViwS24aMbQGICtnvQB21paWWrtt3RiRh1J6GpNS8JXlhbfaZLkmL+HBHIrG8J2Qtnub67VzHHgRoe59TWlfazNfErIxkHTbn7o+lAGbEkcZOAzN6tTPtUxyFiwP7xq05yO6N2O3INRLES4eSUOOm0DigDE1azm8rfLI+xm+72yao+IRuuNOQk7xHzXTa7C0tjFCv+teRQB681keLoP+KuhsYtp+zxJGceuOf50AV9ejWz0i1AwHZwxrT8SXH2vw1oj4AEYkiJ7kHBFZnjt/Llt7YD/VooP1xVu2dLzwPcox/e2zJLGO+OjUARaRciPTNKl25FvcOjZ/2vSulu1LgB2ZQeVlQ8r9a5XQ5Fk8NahAUy8E6T59F6H+YrqInP2UbDujI60AQKLtCwby5kxjevUj6Vc0i2ka63FWwBxuFRJGSMBdorq9Plhk01G3MHUFSMZ5oAmu2Eemt55CPjiuF07UoYtWmZpcHBC/jXSeKC9xp2IpC7AYxjFeUv5qXJGCCDQB6hr+pyw6BKIHZklwM+g715qll5r5XgZ9KvyajKYBGZnIx93PFafhe1fUrqGMxFU3fM56YoAls9GWC1jldeWq+Qq2jAD5DhT+Jra8QvFHIltbDMcQwT61gakzPDbBDtHmgMPWgC3dLuiMYH3e9cx4htHQREAMSOc100hbzjtUnHWp/Felx3OiwX1kxJQYlQdV96AOP8J30ul6qkyKRk4b3r10ao188ImKMrDqO1eImQxy43ZIPfitmx1qazQqGO0nnnpQB3+o3axxFI0BYN1FI0EslgXjGTjOe9UvB8lvqF2XmYqsgLAnpmuyvLeGCCRbckttycdDQB5pKzq5AUqR19akhViRwc+tTahHJHMTtVQT9TUKCQ4BkI78dqAIZtKtrm5R5s+YOQV7e9c/qmYfCNvb9Q2oyYb+9jFdDq14dM06SSIB5SMf8A16wfGERsbPw/pxJ89LY3UwPZpDkfpigCTTong0C/ui+2OQCPgdccmuIY5Yn1Nd34iB0zwlp9mxAkmUzMB1+bpXB0AFFFFAH6G/s6f8kV8Lf9cH/9GvRR+zp/yRXwt/1wf/0a9FAGV+1X/wAkT1r/AK6Qf+jVr4Hr74/ar/5InrX/AF0g/wDRq18D0AFSQP5cyOOxBqOigD0fxFGdV8JQXTMGNqAg9dpotriTVPh9bTMxaXSpfL91UnIq38OI4vEWnPoU+1DPhUlPZx93PtVLwXbNYeKtQ8MasfIW83W7Buiyj7p/P+dAFmPV4J4hlWEpAOAKkN8JGOyF1iHVm7n2p+k2iWc17abV8+3Yo5I7ileSSRCPL2KDxxwaAKn2xpiVtreQBf424zWhoNjPM4zljne/oBVKefDDBIPQiu38HfPpl5bbAGmTYX780AeX+MdRa41X7PESqKQuPWug0XyD4JumUhZ/PIfnngdKoeK/CeoxX8155DrAGCL6t71Y8LW6T29xaToyHzBuz2J6GgCO0jMmGAxxU+pZGl3AyE+QnJq/qVs1hMIkT+EAN2xWXqywvpd0ZgSAmRz3oAdpRhg0qKPcI1Izkjg1ZttNiv2VYySzn5WzWfpaO2mwJMxxt6H0rqvDmnKyz3W/ZHDGxwO5xQB554znMl9DG7A/Z1KY96xo2a4kAx85IxTdQmea6leQEsXJIrf8FaNNf3yTTQv9kjbLvjA+lAHcXYTT/D9tZTupvgoMjA8YxwKwZ1gcqxbbKvRgcVp+ITFdXcjqmOeMHpWXapG4IZFZlPegCzC0zx5glQk8FXHBpxluUHMMLHrhTTDbl4yyOvHRV7UXUn2e1FxEhYDg+1ADNBka78SrJfAeRZIZWXHHFYmh58QeLLy+mXCs7S/L0AHart9dnT/Ctzcfdu9QbyQP4go61b0a3OheCWu3WMTX2VTP3go6mgDivFNx9o1WUg8Z9a1vAxF1LJYNjM6mNSTgZI4/WuWuZPNnd/U1a0S5a11GF1bb8w59KANnRll07xBJY3a7PPVrWVT2PT+eK6Tw+pj0YLKzM6MyP/skHFUPHtvNO1pryQiL7WTnYc/vExk+xPWptN1PzJ4LkbVtb3iVR/BMBz+dAGj5ijJ84kDsRWppF+kbyb/uN2PSqE6IWxjHvUcrRWyF5yAB0HrQB1eqW0F5ZxmznQTD+HPWvKvEERtdSljc/vAcMPeutsJpJ7yKRAVjByo7GqHi7w/fT6488FvJIsigjauQeKAOUhJJ37d3qK9H8ImQ6BNO8axgPhPXFY+neEtQtrNJ7mBkVnIbcOg7V1MsMFp4ZEMb5dX3EDuDQBj3ZZ5hjJJ96r6hDuhto/uEzLn86R38tvvEL2qpexvLcWcnmsAJB1PAoA1LmIb/AJNwz1was2Jch7VyQki4OfeqUlxtcKu5m9a0NBtvteogTycAFm9gKAPONeMkGpzQsoHlHAwOvvVWRyY1PPPYV0+uafdS6nO7w8u/cdB2rEn06eGTZKjAMcbscA0Adl4Ej82BPJLBUy0j54UV3M3imxhVrayh3qvG5yMmuR+H+mvb6XqQuj5SbNyMf4j6Cs6/toLlc4KMG+8hwaANG/uBdXDbl8vdyAKg24Zcg+gHvUNrCVjEMhJcDr61btUWQfPyRQBWubdb3UbDT2ZVWWTfJnoqLyc/lXM3M0ninxtPOil1lmEca+ka8AfkK0tXvxZW2p3ak+fL/odufQH75H4cUeDrE6VoNzrcx29YYAerMR8x/CgDG+IF2JtX8mNsxxKEHsBxXK1Yv7hrq6klc5LGq9ABRRRQB+hv7On/ACRXwt/1wf8A9GvRR+zp/wAkV8Lf9cH/APRr0UAZX7Vf/JE9a/66Qf8Ao1a+B6++P2q/+SJ61/10g/8ARq18D0AFFFFAG54U1FrHU4irEfMCpBxgjpXpPxS0+51WxtfGOnoiugUXPljlHXo5+teOIxRwynBByK9q+F/imH+yrrStQjNzZXkRjlTqQfYUAZ8upLqdgmvWkY8yfZFeqP4ZBxu+h60+5XjKnf6AHiszWdJvfhz4jaO4ja50O8AbP8LIeRn0YVcaOOyniu4HMunXBzHIDkL7H0oArTQtuDjrkZrQj1G4tVIhcqNwzjuabLGC2+P5kPOQaqsjNOpIwq5OPegDWl1+4KILhy+7gZPBrR0zTYtUkWWJlSUACRc44rjpitxeRleYYGz14LVowXs0KyyW8hV+hx6GgDovFzWfk2sdk4d4FMbOerelclqaKNJnJGcjH40NKXuJQx54P4UmqyqNFlBOWZlwPxoAmZPIt4goG7aOK6bwV/pDTWxYASIVx9RXOzMGSPjB2jIqxpF9Jp86yRrhs5oAmudG0jw/N5LRi7unf5nkHCknoKlvNXZ4xb28KwQLxtjGMn1rJ1y8e6zcyDa6yK/HpmhJhIrSAjGcGgB8pQSHK5wOcVAkIyXh+8ecetJD5pRiTjecjPYdqCs0bCRCOOgoAVIZGuBcWkyxsBh4nHBqXzvPU26wbXblu6j3o+0QSsgi/wBa3Ve+ag8SXtjZaN/Z2ny3EniG6fy5kUfIiHoAfWgDGt7G98XeKIbLRbSW7jg+VY4+SQPvNWt8Wr5Y7tbG1ykFtGsCoeqkD5v1zXTaPLH8OvCSm2lCa/eJmZl4a3T0z6147reoyalevLI5fJJyTyfc0AZ9KDggikooA9d8Az2/iLw5f+Hbw5knUTWsh/5ZzKOn49K5jwqsFtqV/oerKYRdjy4pG48idT8p/Pj8axvCWqSabqcbxNtbcCpPQEV6v8UdCt/FPh6z8W6CIxegBL2FCAxcD7wHc+tAHMRaiBM0F1E32yElJI/RhTJLWa5cy3xEaLykQ6/jVTS9QXUYxfMA19AgS6QfedR0kHqR3rclVLq3jmhbejc59aAFtZUUq6f8sxkitTUvE08tivlExRxrgBerH61keQQCQ3bFVnheSDy8H5WoA2bfxDeJbSRNIXjc42vzis4SPi6jkZimdy98AjpTJQrSvGvQpuHsRQrAJ5i534ww9RQA2IEAo/JXkUzUMMlkvVvNBx+FS4D4I5K9D7U25kijuLFnwGLEDH0oAWVgmFX7x45p9rMY3Yo5OeCRUFxLGgcgM8zDAA6A/WkCtHCowBxz9aAOot9UtDaf6TGrTdyep9KqxawglkR7eKaIYLI69QawSRGinO4kdaZcSGJ5X7Oq8/Q0AdP4h1mPUY447RPsqRKBtX1rB8zOPNhkDdC0Yypou1O/g/Ky54p1sZY4sLKB6ZoAkkkjVY235x0P+NS+YkrhLIrLPN91VP3fUn0ApJ2WOzlM20gjsOSe1Y17JP4U0eWwNs0Wsalj525KxH09M0AZUtq2ueJ7TSNMPmqj+RExOA7k/M355/KtD4ian9nWLR7QqttZA26bP4yPvN+JrrtF0TT/AAD4Yi1bWIDL4juBvs4i2BAuPvsP1rx3V7s3l68pYtk9T39TQBSooooAKKKKAP0N/Z0/5Ir4W/64P/6Neij9nT/kivhb/rg//o16KAMr9qv/AJInrX/XSD/0atfA9ffH7Vf/ACRPWv8ArpB/6NWvgegAooooAKv6TqUunT74icHqKoUUAe3eHfGmma9pI0PxFGZrNuEkP34ye4rH1rRNT8AzESqdR8L3Z3CVORg+/Y15bDK8MivGxDDkV6f4H+I0tpAdN1KNLqwlGySCYblI9vSgBxsXe1+3eHLj7ZZE8xE/PH7EVVkuZniYMBG20gg+tauoeFJPObWPh9dtsI3SWRb5wc9AO4rHfxNDI/2bxJpjW9yhw0gG3n3FAF/TYIhbxKjo/wAucA9+5qORDD5jEEhuoAqjBa6c86z6RqPlSA5CsauFdSaRiIFlUnnac0ADqrr5ycOB1PcVgatdtKqAFSg+YYPSrmpjVeYnt3hiLYIArmI/PXUiJgVjQkEHpigDuorxLq3V0AEhA3VBNc+UJSOuwjPvWFFO1u/mWhLY4wehqUXLyoWnyoPUKKAN21YXmnQkLn5AriqFyjae5ngYmI/fVqitJDBM32OSUKVHBXINXjaXuqIEEYRCeWbgUAaU6qbdpG2hGhzkH2rK029vbu22w2uSBzI3HHrQTZaTAItQvBL5YwI1Oc+1Fkut+KS8Gi2xtNPHDTEbRj3NAFaTUJreX7HpS/adUlJUeWuQmf610nh/R7HwdCdW18tNrZBZLdhkIT0JqzbXmi/D7TX/ALN8m71iVcS3UhyYz6KPT3ry7xBr93rF3JLcSu285JJ5NAFrxb4kuNbvJXkckM2Sf6VzlFFABRRRQAqkqQQcEV6n8J/FcWn6tbfbBC0ZJR3mG4RbhguB9K8rp8cjxMGjYqw7igD1X4ieA7rw5dDxH4VuU1HSZGLtLagkQk/wsPSs3QdSS8gMlgVS4HM1mTgN/tJ/hTPAHxCvdBnMUj+ZbSjbLC/KSL3BFdbr/gbTPFcEes/Dsi3vlRpbiyaXBBHdKAM6O6gvAQitG4+8jDoaSbdDEzZALEDJrmk1rY7Wev2sltfx8CUDac/7Qpbi6ubu1ESOJuc5B7CgDbGT5jgFjjaD6imoC4BHAxzTbGfdaKryo0i8HAx+FSBkACq+c9R60AQEOkodMgn7y9jVa+VptSsVjIULmQkjPAqzLLHbRO9xIAAMj1rndM1MT3zM7sZACo9NtAHSyAMM7fkPcdqcmWAVmztH51HDymRlge+aVWyQCpx3oAFCj5MnB6U2SIzW0keRuAyD71IrKwLE7WU4qAXtvASHYls8KgzQBeiUtbROVyQoyDUvlRwRPNOpEfULWfBdTiCR4ogkIOfNmOB+VY97rNze3aWukh7u7Y4DKvCn/ZH9aANXUtdj0Z4rptr3yHdBbH5hGezP7+grS+Hlul7fXfjTxjK0yWxBt4n/AOW0nbj+6Kzh4DGiqL/xhc7XZd4t0O5i3ox7Guc8V+J5NTdYbYeTbRjYiLwABQBP8QPFNxr+qzTSTPIznBJPQdgK4+iigAooooAKKKKAP0N/Z0/5Ir4W/wCuD/8Ao16KP2dP+SK+Fv8Arg//AKNeigDK/ar/AOSJ61/10g/9GrXwPX3x+1X/AMkT1n/rpB/6NWvgegAooooAKKKKAClBwcikooA6Pw74r1DRpg0E7qR0Kmu7fxRpniWOKPXIIJmC7TKow/PU+5ryGlVipypIPtQB6jP4K0O7cvpGrNCQudsvHPsaoSeE/EWntvsb5JR1GyXJNcVb6pdQY2yEgdjWlaeJrqJgSTx3BoA2rm48VW+Y7pGkzyd3NZM2m61qH794SVJ2gDoaup4wZhiYOxHQnmrH/CZ5J42g/wB0YoALfWr7S7ZLe50dGVVxu29RTI/FaxziRNLDAdUYZFTjxrmPbIqOM/xLml/4TODva25Pr5YoAhbxZqM+UsdOSMseipzU0dh4m1bC3Mn2OFucudoxVG68YOzkwxKjE9VXFZl74lv7ondIfTk0AdlDpHhnQ1EuoTvqN2M5BOEzVHxD8QLm5tRZ2ZENsgwscQ2r+lcHNPLMcyuzfU1FQBNc3Mty+6ZyxqGiigAooooAKKKKACiiigArc8O+I73RbmOW2ldShyCpwRWHRQB7nb+JvDvjuyMHiyyiF4wCrfwjbKn19a5zW/hjq+niW68M3qapZLyDCcOB7rXmcUrwsGjYqfaul0Pxjf6acLNIB6o2KAGJqU9m+zUbaVJF4Jxg596tT67EsKG1nwzHBDLyoretfFen6hAY9Thim7lnHzZpkuj+FNSbdFLPZu3pyooAh0Xwzd64s0ou4Xymfmbrn0q3F8N7yy/0mK6gMiDOwnr7VmSeGJbfH9kaxv7YVtuKVtN8WRSbEvBIMdRMMUAVb9dX0K4VZ4l2ZJC5yCKP+EmLRKxMSNnnI5FXDoGv3jJ9r1K3BY4G+TOKafBK5BuNWtQvO4jrmgDPl1i0fP2qZpB1wvGapLrr5ZbS2+ZjwcZNdGnhvw3aKftN9JOw5+XgUq+I9I0VT/ZVlEsvTe43HH+NAFvQvBmseIIPt3iK7/svSE5LScFvZVrUk8SaF4Jt3h8LwpJdnIN9IuXxjoB2rz/WvFuoallXmcoexPH5Vzruztl2JPvQBra9r99rVzJLdzu5c5OT1Pqax6KKACiiigAooooAKKKKAP0N/Z0/5Ir4W/64P/6Neij9nT/kivhb/rg//o16KAO31/RdO8QaZLp2tWcV5YykF4ZRlWIOR+ork/8AhT/w/wD+hU03/vg/40UUAH/Cn/h//wBCppv/AHwf8aP+FP8Aw/8A+hU03/vg/wCNFFAB/wAKf+H/AP0Kmm/98H/Gj/hT/wAP/wDoVNN/74P+NFFAB/wp/wCH/wD0Kmm/98H/ABo/4U/8P/8AoVNN/wC+D/jRRQAf8Kf+H/8A0Kmm/wDfB/xo/wCFP/D/AP6FTTf++D/jRRQAf8Kf+H//AEKmm/8AfB/xo/4U/wDD/wD6FTTf++D/AI0UUAH/AAp/4f8A/Qqab/3wf8aP+FP/AA//AOhU03/vg/40UUAH/Cn/AIf/APQqab/3wf8AGj/hT/w//wChU03/AL4P+NFFAB/wp/4f/wDQqab/AN8H/Gj/AIU/8P8A/oVNN/74P+NFFAB/wp/4f/8AQqab/wB8H/Gj/hT/AMP/APoVNN/74P8AjRRQAf8ACn/h/wD9Cppv/fB/xo/4U/8AD/8A6FTTf++D/jRRQAf8Kf8Ah/8A9Cppv/fB/wAaP+FP/D//AKFTTf8Avg/40UUAH/Cn/h//ANCppv8A3wf8aP8AhT/w/wD+hU03/vg/40UUAH/Cn/h//wBCppv/AHwf8aP+FP8Aw/8A+hU03/vg/wCNFFAB/wAKf+H/AP0Kmm/98H/Gj/hT/wAP/wDoVNN/74P+NFFAB/wp/wCH/wD0Kmm/98H/ABo/4U/8P/8AoVNN/wC+D/jRRQAf8Kf+H4/5lTTf++D/AI1Inwl8Bp93wxp4/wCAn/GiigCRfhb4IX7vhuwH0U/40/8A4Vj4L/6F2x/I/wCNFFAB/wAKw8F4x/wjtjj/AHT/AI0w/CzwO3Xw3YH/AICf8aKKAI2+E3gRvveGNPP/AAE/41H/AMKf+H//AEKmm/8AfB/xoooAP+FP/D//AKFTTf8Avg/40f8ACn/h/wD9Cppv/fB/xoooAP8AhT/w/wD+hU03/vg/40f8Kf8Ah/8A9Cppv/fB/wAaKKAD/hT/AMP/APoVNN/74P8AjR/wp/4f/wDQqab/AN8H/GiigA/4U/8AD/8A6FTTf++D/jR/wp/4f/8AQqab/wB8H/GiigA/4U/8P/8AoVNN/wC+D/jR/wAKf+H/AP0Kmm/98H/GiigDr9G0uy0XTINO0q2jtbKAFYoYxhUBJPH4k0UUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted (A) and axial fluid-attenuated inversion recovery (FLAIR) (B) are shown. Virtually, all hemispheric white matter appeared homogeneously hyperintense on T2-weighted and hypointense on T1-weighted (not shown) with atrophy of the corpus callosum. On FLAIR, large part of the white matter has a signal identical to CSF, surrounded by a rim of hyperintensity demonstrating the cavitated breakdown of the white matter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Denier C, Orgibet A, Roffi F. Adult-Onset vanishing white matter leukoencephalopathy presenting as psychosis. Neurology 2007; 68:1538. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18996=[""].join("\n");
var outline_f18_35_18996=null;
var title_f18_35_18997="Lanreotide: Patient drug information";
var content_f18_35_18997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lanreotide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     see \"Lanreotide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5357701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somatuline&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5046220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Somatuline&reg; Autogel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause gallstones. If you have high blood sugar (diabetes), closely watch your blood sugar. If you are taking cyclosporine, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acromegaly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat too much growth hormone release.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lanreotide, somatostatin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A slower, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698106",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallstones may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to give closely if you or a family member is giving the shot at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         If drug is given at home:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         If this drug is given by your doctor:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in pouch until ready for use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take each dose out of the refrigerator just before using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11979 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18997=[""].join("\n");
var outline_f18_35_18997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357701\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5046220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018793\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018795\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018794\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018799\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018800\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018802\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018797\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018798\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018803\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018804\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=related_link\">",
"      Lanreotide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_35_18998="Pulmonary capillaritis DAH II";
var content_f18_35_18998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary capillaritis in diffuse alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in pulmonary capillaritis showing marked broadening of the alveolar septa caused by edema and necrosis. There is a striking infiltration of neutrophils in the alveolar septa (arrows), with many of those cells undergoing fragmentation and appearing pyknotic. The alveolar spaces are packed with red blood cells (diffuse alveolar hemorrhage) as well as some neutrophils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18998=[""].join("\n");
var outline_f18_35_18998=null;
var title_f18_35_18999="Pityriasis rosea";
var content_f18_35_18999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pityriasis rosea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/18999/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/35/18999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pityriasis rosea (PR) is an acute, self-limited, exanthematous skin disease characterized by the appearance of slightly inflammatory, oval, papulosquamous lesions on the trunk and proximal areas of the extremities. The diagnosis and management of this disorder are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A viral etiology for pityriasis rosea (PR) has been hypothesized based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PR is sometimes preceded by a prodrome.",
"     </li>",
"     <li>",
"      It occasionally occurs in small case clusters.",
"     </li>",
"     <li>",
"      It has not been shown to be associated with bacterial or fungal organisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This supposition is reinforced by the finding of viral-like particles in PR biopsy specimens examined with the electron microscope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/1\">",
"     1",
"    </a>",
"    ]. A significant literature supports the hypothesis that PR is a manifestation of human herpesvirus 7 (HHV-7) reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, others have failed to detect HHV-7 DNA sequences and antigens in a significant number of PR cases, arguing against a causative role for this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/4\">",
"     4",
"    </a>",
"    ]. Some studies have also implicated HHV-6 in the pathogenesis of PR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. More recently, possible associations with HHV-8 and 2009-2010 pandemic H1N1 influenza A virus have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More study is needed before this issue can be definitively resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;PR is largely a disease of older children and young adults. It is slightly more common in women than men. A prodrome of headache, malaise, and pharyngitis may occur in a small number of cases, but except for itching, the condition is usually asymptomatic.",
"   </p>",
"   <p>",
"    In 50 to 90 percent of cases, the eruption begins with a \"herald\" or \"mother\" patch, a single round or oval, sharply delimited, pink or salmon-colored lesion on the chest, neck, or back (",
"    <a class=\"graphic graphic_picture graphicRef87126 graphicRef69881 \" href=\"UTD.htm?19/32/19977\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/10\">",
"     10",
"    </a>",
"    ]. The herald patch is usually 2 to 5 cm in diameter. The lesion soon becomes scaly and begins to clear centrally, leaving the free edge of the cigarette paper-like scale directed inwards toward the center. This clinical finding is often described as a &ldquo;collarette&rdquo; of scale.",
"   </p>",
"   <p>",
"    A few days or one to two weeks later, oval lesions similar in appearance to the herald patch, but smaller, appear in crops on the trunk and proximal areas of the extremities (",
"    <a class=\"graphic graphic_picture graphicRef53701 graphicRef87124 graphicRef71058 graphicRef87126 \" href=\"UTD.htm?40/19/41274\">",
"     picture 1A, 1C-E",
"    </a>",
"    ). The long axes of these oval lesions tend to be oriented along the lines of cleavage of the skin. This characteristic arrangement is most evident on the back where it is emphasized by the oblique direction of the cleavage lines in that location (",
"    <a class=\"graphic graphic_picture graphicRef58283 graphicRef87126 \" href=\"UTD.htm?40/4/41032\">",
"     picture 1A, 1F",
"    </a>",
"    ). This morphologic pattern has been referred to as a &ldquo;fir tree&rdquo; or &ldquo;Christmas tree&rdquo; distribution.",
"   </p>",
"   <p>",
"    The eruption spreads centrifugally or from the top down over the course of a few days. Erythema gradually subsides, desquamation is completed, and the eruption fades, leaving little residual changes, except occasional mild post-inflammatory changes in light-skinned individuals. Most cases are clear in four to six weeks; occasionally the disease will persist for several months. PR generally has only mild effects on quality of life, at least in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The erythema may be difficult to see in people with dark skin, and post-inflammatory pigmentation may be prominent, persisting for several months or longer (",
"    <a class=\"graphic graphic_picture graphicRef69881 graphicRef53701 graphicRef71058 graphicRef58283 \" href=\"UTD.htm?42/31/43514\">",
"     picture 1B-C, 1E-F",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In children, the distribution of the lesions is often atypical, involving the scalp and face; it may be completely \"inverse,\" affecting the face and distal extremities, while sparing the trunk, or may be concentrated in the pubic, inguinal, and axillary regions (",
"    <a class=\"graphic graphic_picture graphicRef64728 \" href=\"UTD.htm?21/44/22214\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/12\">",
"     12",
"    </a>",
"    ]. The lesions themselves also are sometimes atypical in children; they may be folliculo-papular, vesicular, pustular, urticarial, or purpuric.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a herald patch by history or on examination, the characteristic morphology and distribution of the lesions, and the absence of symptoms other than pruritus combine to make PR an easy diagnosis in most instances. However, the herald patch can resemble tinea corporis so closely that KOH examination of scales for dermatophyte hyphae may be necessary to distinguish these conditions.",
"   </p>",
"   <p>",
"    There are typically no laboratory abnormalities with PR. Skin biopsy is rarely necessary, but when performed shows focal parakeratosis with or without acanthosis, spongiosis, a perivascular infiltrate of lymphocytes and histiocytes, and occasionally extravasation of red cells. The biopsy picture is characteristic, but not pathognomonic.",
"   </p>",
"   <p>",
"    In doubtful cases, signs, symptoms, and laboratory abnormalities relevant to the conditions listed in the differential diagnosis list will assist in proper identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of other disorders should be considered in patients who present with lesions that are suspicious for PR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/13\">",
"     13",
"    </a>",
"    ]. When the diagnosis is in question, a skin biopsy can be performed. A potassium hydroxide preparation is useful for ruling out fungal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Secondary syphilis",
"      </strong>",
"      &minus; The papulosquamous eruption of secondary syphilis can closely resemble PR; however, unlike the latter, secondary syphilis often presents with red-brown macules on the palms and soles (",
"      <a class=\"graphic graphic_picture graphicRef65500 \" href=\"UTD.htm?6/6/6242\">",
"       picture 3",
"      </a>",
"      ). Patients with secondary syphilis also may recall the appearance of a chancre and will lack a history of a herald patch. In patients in whom secondary syphilis is suspected, appropriate serologic testing should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H13#H13\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Secondary syphilis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"       \"Diagnostic testing for syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Guttate psoriasis",
"      </strong>",
"      &minus; Guttate psoriasis is a variant of psoriasis that most frequently affects children and young adults. Small, erythematous, scaly plaques are distributed primarily on the trunk (",
"      <a class=\"graphic graphic_picture graphicRef55141 \" href=\"UTD.htm?24/9/24725\">",
"       picture 4",
"      </a>",
"      ). The scale tends to be coarser than the scale associated with PR, and a herald patch does not proceed the eruption. Guttate psoriasis frequently is associated with a preceding streptococcal infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Guttate psoriasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tinea corporis",
"      </strong>",
"      &minus; The herald patch of PR may be mistaken for tinea corporis, which may also present with an annular plaque with peripheral scale (",
"      <a class=\"graphic graphic_picture graphicRef66102 \" href=\"UTD.htm?7/37/7765\">",
"       picture 5",
"      </a>",
"      ). A KOH preparation from a lesion of tinea corporis will reveal fungal hyphae. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tinea versicolor",
"      </strong>",
"      &minus; Tinea versicolor presents with hypopigmented or hyperpigmented macules that are most commonly located on the neck and trunk (",
"      <a class=\"graphic graphic_picture graphicRef59533 graphicRef73839 \" href=\"UTD.htm?27/63/28664\">",
"       picture 6A-B",
"      </a>",
"      ). Unlike PR, erythema is absent or minimal. The scale in tinea versicolor is fine, and lesions lack the peripheral rim of scale that is often seen in PR. A KOH preparation easily confirms a diagnosis of tinea versicolor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=see_link\">",
"       \"Tinea versicolor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nummular eczema",
"      </strong>",
"      &minus; Nummular eczema presents with intensely pruritic, coin-shaped plaques that may range in size from 2 to 10 cm (",
"      <a class=\"graphic graphic_picture graphicRef58067 graphicRef66792 \" href=\"UTD.htm?33/55/34679\">",
"       picture 7A-B",
"      </a>",
"      ). Involvement of the extremities is more common in nummular eczema than in PR. Serous exudate may be visible in acute lesions of nummular eczema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of dermatitis\", section on 'Nummular dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides chronica",
"      </strong>",
"      &minus; Pityriasis lichenoides chronica (PLC) is an uncommon condition that is characterized by recurrent crops of erythematous to brown scaly papules on the trunk and proximal extremities. Lesions may be asymptomatic or pruritic, and spontaneously regress over the course of weeks to months. PLC most commonly occurs in children and young adults. The disorder may persist for years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other disorders that should be considered in the differential diagnosis of PR include Lyme disease, human immunodeficiency virus (HIV) seroconversion illness, and drug eruptions. Testing for HIV should be performed in patients with risk factors for or symptoms suggestive of HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic gold injections also can cause eruptions that mimic PR closely; these eruptions do not represent allergic reactions, but are dose-related and can be managed safely by reduction in dose size and the frequency of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/14\">",
"     14",
"    </a>",
"    ]. Other medications and procedures more recently suspected of producing PR-like reactions are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/15\">",
"     15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/16\">",
"     16",
"    </a>",
"    ], bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/17\">",
"     17",
"    </a>",
"    ], interferon alpha 2A [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/18\">",
"     18",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/19\">",
"     19",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/20\">",
"     20",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/21\">",
"     21",
"    </a>",
"    ], and bacillus Calmette-Guerin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of PR need no treatment other than reassurance and proper patient education. Nevertheless, a number of therapies have been evaluated, some of which may provide clinical benefit in patients who require therapy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Patient/parent education'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5635428\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience has shown that topical corticosteroids in the medium potency range are helpful in the control of itching (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). They can be applied to the pruritic areas two or three times daily. Topical antipruritic lotions that contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    or menthol and oral antihistamines may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5635421\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placebo controlled trials have examined the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A blinded, controlled trial that alternately assigned 90 patients to treatment or placebo found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (250 mg four times daily for 14 days) was effective in reducing both the duration and the severity of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/23\">",
"       23",
"      </a>",
"      ]. In this report, a complete response at six weeks of follow-up was noted in 73 percent of patients in the treatment group compared with none in the placebo group.",
"     </li>",
"     <li>",
"      A systematic review identified a small (n = 40) unpublished randomized trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (250 mg every six hours for fourteen days), that the authors of the systematic review felt to be a good quality trial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/24\">",
"       24",
"      </a>",
"      ]. Among the 34 evaluable patients, a higher percentage of those treated with erythromycin achieved complete cure of rash at two weeks (77 versus 6 percent). Patients treated with erythromycin also had greater improvements in itching.",
"     </li>",
"     <li>",
"      In contrast to the above results, a trial of 184 patients with PR published after the above systematic review found no benefit with two weeks of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (200 mg four times daily in adults; 20 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily in four divided doses in children) started within seven days of the appearance of secondary lesions of PR [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/25\">",
"       25",
"      </a>",
"      ]. The trial was not randomized, evaluators were not blinded, and the placebo was an emollient cream rather than a pill. No patient in either arm of the trial achieved complete clearance of lesions at two weeks, and there were also no differences in complete clearance between the arms at weeks four, six, or eight. Despite the methodologic issues with this trial, it is difficult to reconcile these results with the beneficial outcomes discussed above. The authors argue that earlier trials did not adequately identify a group of patients with a clear diagnosis of early PR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If real, a positive effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    could stem more from antiinflammatory and immune modulating effects than from antimicrobial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast to the results with erythromycin, a blinded randomized trial in 49 children found no statistically significant benefit to five days of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/27\">",
"     27",
"    </a>",
"    ]. At four weeks, there were similar percentages of complete (60 versus 42 percent) and partial (28 versus 29 percent) responses with azithromycin and placebo.",
"   </p>",
"   <p>",
"    It is uncertain why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    would be of benefit when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is not. This, and the conflicting trials of erythromycin, suggests the need for additional trials of macrolide antibiotics. Given common gastrointestinal side effects and uncertain benefit we would suggest not treating patients with PR with erythromycin until additional data become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5635414\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed link between PR and human herpesvirus led to trials of antiviral therapy in patients with this disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial without a placebo-control arm in which the evaluators were unaware of treatment assignment, 64 patients with PR received either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg five times per day for one week or no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/28\">",
"       28",
"      </a>",
"      ]. Treatment with acyclovir significantly accelerated improvement in erythema; after two weeks, the percentage of patients with a reduction in erythema was 79 percent in the acyclovir group versus 27 percent in the group that was not treated. By the fourth week, a reduction in erythema was seen in 93 versus 61 percent of patients, respectively. Scale also resolved more quickly in the acyclovir group, but the difference between the groups was no longer statistically significant at the four week time-point.",
"     </li>",
"     <li>",
"      In a nonrandomized single-blind trial, high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (800 mg five times daily) was beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients treated with acyclovir had more rapid resolution of lesions (mean time to clearance 19 versus 38 days), and fewer new lesions after one week of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    The results of these studies suggest that there may be some benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy for patients with PR. However, in vitro studies demonstrating that acyclovir has poor antiviral activity against HHV-6 and HHV-7 raise additional questions about the etiology of PR and the reasons for the efficacy of acyclovir in PR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5635441\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) light may have benefit in PR. Phototherapy may be considered for patients who have severe, extensive disease, and who cannot expose themselves to noontime natural sunlight.",
"   </p>",
"   <p>",
"    UVB phototherapy decreases disease severity during periods of treatment, although it may have less effect on pruritus and overall disease outcome than previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In an intraindividual comparison study of extensive PR (n = 17) in which broadband UVB was used to treat one-half of the body for 10 treatments over two weeks, and an extremely low dose of UVA was given contralaterally as a control, UVB significantly decreased disease severity during the treatment period. However, the difference in effect was no longer present two weeks after the completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast to a prior report [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/33\">",
"     33",
"    </a>",
"    ], UVB had no effect on pruritus in this study.",
"   </p>",
"   <p>",
"    UVA1 phototherapy also may have some benefit for the treatment of PR. In an uncontrolled study of patients with extensive PR, UVA1 was associated with improvements in disease severity, and 12 out of 15 patients noted improvement in pruritus (mean number of treatments = 6.5&plusmn;1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worsening of PR following narrowband UVB phototherapy has been reported in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/35\">",
"     35",
"    </a>",
"    ]; however, it is unclear whether the exacerbation of disease was secondary to phototherapy or the natural course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies are necessary to explore the efficacy of phototherapy for PR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised that the rash may persist for two to three months; no follow-up is necessary as long as it resolves within this time. New lesions may occur during this period but should disappear spontaneously.",
"   </p>",
"   <p>",
"    An analysis of a case series of 38 women who developed PR during pregnancy suggested that PR may increase the risk for spontaneous abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/37\">",
"     37",
"    </a>",
"    ]. Spontaneous abortions occurred in five of eight women (62 percent) who developed PR prior to 15 weeks gestation. Further studies are necessary to clarify the impact of PR on pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT/PARENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents of children with PR typically want information about etiology (not really known), infectivity (thought to be very low), relapse (unusual), and complications or dangers (rare) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/18999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/60/17345?source=see_link\">",
"       \"Patient information: Pityriasis rosea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pityriasis rosea is an acute, self-limited, exanthematous skin disease felt most likely to be due to a viral etiology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eruption commonly begins with a \"herald\" or \"mother\" patch, a single round or oval, rather sharply delimited pink or salmon-colored lesion on the chest, neck, or back, 2 to 5 cm in diameter. A few days or a week or two later oval lesions similar in appearance to the herald patch, but smaller, appear in crops on the trunk and proximal areas of the extremities (",
"      <a class=\"graphic graphic_picture graphicRef87124 graphicRef87126 \" href=\"UTD.htm?7/13/7384\">",
"       picture 1A, 1D",
"      </a>",
"      ). The long axes of these oval lesions tend to be oriented along the lines of cleavage of the skin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A prodrome of headache, malaise, and pharyngitis may occur in a small number of cases, but except for itching, the condition is usually asymptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pityriasis rosea is typically made based on the history of a herald patch and the clinical appearance of the rash. Laboratory testing may sometimes be needed to exclude other conditions such as secondary syphilis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients do not require therapy. For patients with mild itching who desire therapy, we suggest treatment with medium potency topical corticosteroids (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5635428\">",
"       'Pruritus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more severe itching or who desire rapid resolution of the rash for cosmetic reasons, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg five times daily for one week) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest not treating such patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5635414\">",
"       'Antiviral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5635421\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phototherapy is an additional treatment option for patients with extensive disease. (See",
"      <a class=\"local\" href=\"#H5635441\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/1\">",
"      el-Shiemy S, Nassar A, Mokhtar M, Mabrouk D. Light and electron microscopic studies of pityriasis rosea. Int J Dermatol 1987; 26:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/2\">",
"      Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology 1997; 195:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/3\">",
"      Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009; 61:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/4\">",
"      Kempf W, Adams V, Kleinhans M, et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol 1999; 135:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/5\">",
"      Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol 2002; 119:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/6\">",
"      Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005; 124:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/7\">",
"      Mubki TF, Bin Dayel SA, Kadry R. A case of Pityriasis rosea concurrent with the novel influenza A (H1N1) infection. Pediatr Dermatol 2011; 28:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/8\">",
"      Kwon NH, Kim JE, Cho BK, Park HJ. A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea? J Eur Acad Dermatol Venereol 2011; 25:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/9\">",
"      Prantsidis A, Rigopoulos D, Papatheodorou G, et al. Detection of human herpesvirus 8 in the skin of patients with pityriasis rosea. Acta Derm Venereol 2009; 89:604.",
"     </a>",
"    </li>",
"    <li>",
"     Blauvelt, A. Pityriasis rosea. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolf, K, Goldsmith, LA, Katz, SI, et al. (Eds), McGraw Hill, 2008. p.362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/11\">",
"      Chuh AA. Quality of life in children with pityriasis rosea: a prospective case control study. Pediatr Dermatol 2003; 20:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/12\">",
"      Trager JD. What's your diagnosis? Scaly pubic plaques in a 2-year-old girl--or an \"inverse\" rash. J Pediatr Adolesc Gynecol 2007; 20:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/13\">",
"      Browning JC. An update on pityriasis rosea and other similar childhood exanthems. Curr Opin Pediatr 2009; 21:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/14\">",
"      Wilkinson SM, Smith AG, Davis MJ, et al. Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold. Ann Rheum Dis 1992; 51:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/15\">",
"      Buckley C. Pityriasis rosea-like eruption in a patient receiving omeprazole. Br J Dermatol 1996; 135:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/16\">",
"      Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol 1998; 138:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/17\">",
"      Spelman LJ, Robertson IM, Strutton GM, Weedon D. Pityriasis rosea-like eruption after bone marrow transplantation. J Am Acad Dermatol 1994; 31:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/18\">",
"      Durusoy C, Alpsoy E, Yilmaz E. Pityriasis rosea in a patient with Beh&ccedil;et's disease treated with interferon alpha 2A. J Dermatol 1999; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/19\">",
"      Yosipovitch G, Kuperman O, Livni E, et al. [Pityriasis rosea-like eruption after anti-inflammatory and antipyretic medication]. Harefuah 1993; 124:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/20\">",
"      Ghersetich I, Rindi L, Teofoli P, et al. [Pityriasis rosea-like skin eruptions caused by captopril]. G Ital Dermatol Venereol 1990; 125:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/21\">",
"      Helfman RJ, Brickman M, Fahey J. Isotretinoin dermatitis simulating acute pityriasis rosea. Cutis 1984; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/22\">",
"      Honl BA, Keeling JH, Lewis CW, Thompson IM. A pityriasis rosea-like eruption secondary to bacillus Calmette-Gu&eacute;rin therapy for bladder cancer. Cutis 1996; 57:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/23\">",
"      Sharma PK, Yadav TP, Gautam RK, et al. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000; 42:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/24\">",
"      Chuh AA, Dofitas BL, Comisel GG, et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev 2007; :CD005068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/25\">",
"      Rasi A, Tajziehchi L, Savabi-Nasab S. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol 2008; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/26\">",
"      Chuh AA, Chan HH. Prospective case-control study of chlamydia, legionella and mycoplasma infections in patients with pityriasis rosea. Eur J Dermatol 2002; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/27\">",
"      Amer A, Fischer H. Azithromycin does not cure pityriasis rosea. Pediatrics 2006; 117:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/28\">",
"      Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients. J Eur Acad Dermatol Venereol 2011; 25:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/29\">",
"      Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol 2006; 54:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/30\">",
"      Zhang Y, Schols D, De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res 1999; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/31\">",
"      De Clercq E, Naesens L, De Bolle L, et al. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/32\">",
"      Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol 1995; 33:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/33\">",
"      Arndt KA, Paul BS, Stern RS, Parrish JA. Treatment of pityriasis rosea with UV radiation. Arch Dermatol 1983; 119:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/34\">",
"      Lim SH, Kim SM, Oh BH, et al. Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea. Ann Dermatol 2009; 21:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/35\">",
"      Castanedo-Cazares JP, Lepe V, Moncada B. Should we still use phototherapy for Pityriasis rosea? Photodermatol Photoimmunol Photomed 2003; 19:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/36\">",
"      Chuh A. Narrow band UVB phototherapy and oral acyclovir for pityriasis rosea. Photodermatol Photoimmunol Photomed 2004; 20:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/18999/abstract/37\">",
"      Drago F, Broccolo F, Zaccaria E, et al. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol 2008; 58:S78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5665 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-48EC6668F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_18999=[""].join("\n");
var outline_f18_35_18999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5635428\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5635421\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5635414\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5635441\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT/PARENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5665|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/61/35793\" title=\"picture 1A\">",
"      Pityriasis rosea with herald patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/42/679\" title=\"picture 1B\">",
"      Herald patch dark skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/6/13414\" title=\"picture 1C\">",
"      Pityriasis rosea dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/18/8484\" title=\"picture 1D\">",
"      Pityriasis rosea on abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/34/21030\" title=\"picture 1E\">",
"      Pityriasis rosea drk skin 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/15/43253\" title=\"picture 1F\">",
"      Pityriasis rosea drk skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/44/22214\" title=\"picture 2\">",
"      Inverse pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/6/6242\" title=\"picture 3\">",
"      Palmar rash secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/9/24725\" title=\"picture 4\">",
"      Guttate psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/37/7765\" title=\"picture 5\">",
"      Tinea corporis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/16/10496\" title=\"picture 6A\">",
"      Tinea versicolor arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/9/20630\" title=\"picture 6B\">",
"      Tinea versicolor shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/8/11394\" title=\"picture 7A\">",
"      Nummular eczema legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/46/38626\" title=\"picture 7B\">",
"      Nummular eczema legs 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/60/17345?source=related_link\">",
"      Patient information: Pityriasis rosea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=related_link\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_35_19000="Guidelines for adolescent preventive services";
var content_f18_35_19000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guidelines for adolescent preventive services",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Arthur Elster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19000/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/35/19000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The health status and health behaviors of adolescents have been monitored closely for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although improvement has been noted in certain indicators, compared with other age groups, adolescent health has failed to respond to the range of interventions developed for schools, communities, and the health system.",
"   </p>",
"   <p>",
"    Unintentional injuries such as automobile crashes, intentional injuries such as homicide and suicide, and reproductive health issues such as unintended pregnancy and sexually transmitted infections remain the leading causes of adolescent morbidity and mortality. Alcohol and drug use contribute to many of these injuries and deaths. Obesity has become a major cause of adolescent morbidity and is a contributor to a dramatic increase in the number of youth with type 2 diabetes mellitus. The common denominator in this list is that most adolescent morbidity and mortality is related to personal behavior and, as such, is preventable.",
"   </p>",
"   <p>",
"    The preventable nature of all of these conditions provides a clear mandate to pediatric health care providers. The challenge is to integrate preventive services into routine medical care. Practitioners can use clinic visits for routine examinations, such as preparticipation athletic evaluations and chronic disease management, to provide a range of preventive services. These clinical encounters offer an opportunity for early identification of risk behavior and disease, updating immunizations, and offering health guidance. Clinical preventive services are an adjunct to preventive interventions provided through schools and in the community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTIVE SERVICE RECOMMENDATIONS FOR ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of preventive services is to reduce serious morbidity and premature mortality. Preventive services typically fall into four categories: screening, counseling to reduce risk, providing immunizations, and giving general health guidance. In addition, a recommendation for how frequently routine visits should occur usually is included. Various organizations have developed or revised guidelines that are designed to enable practitioners to identify and address specific health problems and behaviors that cause the greatest burden of suffering among adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States Preventive Services Task Force (USPSTF) &mdash; Guide to Clinical Preventive Services [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      American Medical Association (AMA) &mdash; Guidelines for Adolescent Preventive Services (GAPS) 1994 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      American Academy of Family Physicians (AAFP) &mdash; Age Charts for Periodic Health Examinations (",
"      <a class=\"external\" href=\"file://www.aafp.org/\">",
"       www.aafp.org",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maternal and Child Health Bureau (MCHB), US Public Health Services, and American Academy of Pediatrics (AAP) &mdash; Bright Futures: Guidelines for Health Care Supervision of Infants, Children, and Adolescents (",
"      <a class=\"external\" href=\"file://www.brightfutures.org/\">",
"       www.brightfutures.org",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      American Academy of Pediatrics (AAP) &mdash; Recommendations for Pediatric Preventive Health Care 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advisory Committee on Immunization Practices (ACIP) &mdash; Update of adolescent immunization schedules 2012. These recommendations include vaccines for preventing pertussis, human papillomavirus, influenza, and meningococcal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The organizations use different methods to arrive at their guidelines. The USPSTF guidelines, for example, are based upon the proven ability of screening procedures and interventions to improve clinical outcomes. Because data from preventive service studies using adolescent subjects in clinical settings are sparse, the AMA and Bright Futures guidelines also incorporate expert opinion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An analysis of the recommendations reveals the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General agreement is that primary care clinicians should provide the basic set of immunizations identified by the Advisory Committee on Immunizations Practices of the Centers for Disease Control and Prevention (",
"      <a class=\"graphic graphic_figure graphicRef58209 \" href=\"UTD.htm?26/56/27523\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"       \"Standard immunizations for children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data provide strong support that clinical services should include screening and counseling to prevent injuries from violence and accidents, reduce risk for future cardiovascular disease (eg, smoking cessation, management of obesity, early treatment of hypertension and hyperlipidemia), reduce involvement in health-risk behaviors (eg, alcohol and drug use, unsafe sexual practices), and promote dental health.",
"     </li>",
"     <li>",
"      Less agreement exists for teaching self-breast and self-testicular examinations, providing routine health guidance to parents, offering routine hearing and vision testing, and conducting routine testing for hematocrit and urinalysis.",
"     </li>",
"     <li>",
"      Disagreement exists regarding the recommended periodicity for routine health evaluations. Although the AMA, Bright Futures, and AAP recommend annual preventive service visits for adolescents, the AAFP and USPSTF recommend that these visits occur every one to three years as necessary. The National Commission on Quality Assurance includes in its recommended set of performance measures for managed care organizations (Health Employer Data and Information Set) that adolescents between 13 and 18 years of age should be seen annually for a routine health visit [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPREHENSIVE GUIDELINES FOR ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Society for Adolescent Medicine focuses on the similarities between the guidelines and calls for the widespread acceptance and implementation of clinical preventive services for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/16\">",
"     16",
"    </a>",
"    ]. The AMA's GAPS paradigm provides a framework for the content and delivery of comprehensive preventive services for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/5\">",
"     5",
"    </a>",
"    ]. The recommendations target screening, anticipatory guidance, and immunizations.",
"   </p>",
"   <p>",
"    New, inexpensive technologies, such as personal digital assistants (PDA) may enhance clinician screening and counseling and improve adolescents' perceptions that their visit was confidential and that they were listened to carefully [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/17\">",
"     17",
"    </a>",
"    ]. Social networking, including cell phones, may also provide new opportunities to reach adolescents with health messages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents should be screened for the following conditions during clinical preventive services visits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation of hypertension in children and adolescents\", section on 'Definition'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Obesity and eating disorders (",
"      <a class=\"graphic graphic_table graphicRef64900 \" href=\"UTD.htm?37/9/38043\">",
"       table 1",
"      </a>",
"      )(",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"       calculator 3",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"       calculator 4",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical evaluation of the obese child and adolescent\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperlipidemia, if indicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link&amp;anchor=H1256953#H1256953\">",
"       \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\", section on 'Identifying children at risk for CVD'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tuberculosis, if at risk (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link&amp;anchor=H3#H3\">",
"       \"Latent tuberculosis infection in children\", section on 'Whom to test'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Physical, sexual, and emotional abuse",
"     </li>",
"     <li>",
"      Learning or school problems (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"       \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44329?source=see_link&amp;anchor=H629395108#H629395108\">",
"       \"Specific learning disabilities in children: Role of the primary care provider\", section on 'Early identification'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Substance use (both tobacco and alcohol) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37081?source=see_link&amp;anchor=H15124835#H15124835\">",
"       \"Prevention of smoking initiation in children and adolescents\", section on 'Smoking prevention in the primary care office'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Behaviors or emotions that indicate recurrent or severe depression or risk of suicide (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H17#H17\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation and management of suicidal behavior in children and adolescents\", section on 'Identification of suicide risk'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sexual behavior that may result in unintended pregnancy and sexually transmitted diseases, including HIV infection",
"     </li>",
"     <li>",
"      Sexually transmitted diseases, if sexually active (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H16#H16\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Screening and diagnostic testing'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HIV infection; 2006 CDC recommendations call for all adolescents seen in health care settings to be tested for HIV infection unless they specifically \"opt out\" [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link&amp;anchor=H12#H12\">",
"       \"Serologic screening for HIV infection\", section on 'Opt-out testing'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical cancer (as indicated) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H22#H22\">",
"       \"Screening for cervical cancer: Rationale and recommendations\", section on 'Initial screening'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anticipatory guidance for adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through anticipatory guidance, providers can help teens have a better understanding of their physical growth, psychosocial and psychosexual development, and the importance of becoming actively involved in decisions regarding their health care. In addition, adolescents should receive counseling regarding healthy habits and risk reduction in the following areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy dietary habits, including ways to achieve a healthy diet and safe weight management (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H12#H12\">",
"       \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Dietary guidelines'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduction of injuries through use of use of bicycle and motorcycle helmets and car seatbelts",
"     </li>",
"     <li>",
"      Regular exercise",
"     </li>",
"     <li>",
"      Responsible sexual behaviors, including abstinence (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=see_link&amp;anchor=H11#H11\">",
"       \"Adolescent sexuality\", section on 'Health issues and outcomes related to sexuality'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Avoidance of tobacco, alcohol, other abusable substances, and anabolic steroids (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37081?source=see_link&amp;anchor=H15124835#H15124835\">",
"       \"Prevention of smoking initiation in children and adolescents\", section on 'Smoking prevention in the primary care office'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Avoiding online behaviors that can have negative consequences, such as &ldquo;sexting&rdquo; and sharing of personal information and pictures with strangers; resources are available through the",
"      <a class=\"external\" href=\"file://www.healthychildren.org/English/family-life/Media/Pages/default.aspx\">",
"       American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      Strategies to deal with bullying; resources are available through",
"      <a class=\"external\" href=\"file://www.brightfutures.org/mentalhealth/pdf/families/mc/bullying.pdf\">",
"       Bright Futures",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anticipatory guidance for parents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health guidance for parents includes advice to assist them in making appropriate parental decisions and in adapting their parenting practices to meet the changing needs of their adolescent children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/13\">",
"     13",
"    </a>",
"    ]. Parents should receive health guidance at least once during their child's early, middle, and late adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parental involvement and attitudes affect adolescent behavior and health outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, cross-sectional analysis of interview data from more than 12,000 7th- through 12th-grade students found that parent-family connectedness (eg, feelings of warmth, love, and caring from the parents) was protective against every health-risk behavior measure (emotional distress, suicidality, violence, cigarette use, alcohol use, and marijuana use) except history of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/21\">",
"     21",
"    </a>",
"    ]. In another prospective study of 10,000 adolescents in the Longitudinal Study of Adolescent Health, adolescent perception of maternal attitudes toward the adolescent's engaging in sexual intercourse and adolescent satisfaction with the maternal relationship were predictive of the occurrence of the onset of sexual intercourse in the ensuing 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents should also be counseled to monitor their teen&rsquo;s use of online social media. Specific attention should be directed at helping parents understand the hazards associated with sharing personal information with strangers.",
"   </p>",
"   <p>",
"    Lastly, parents should be counseled to take seriously any comments or indications of bullying of their teen. If bullying is suspected, parents should discuss with school personnel the nature of the problem and interventions that will be taken. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents should have their immunizations reviewed and updated as necessary (",
"    <a class=\"graphic graphic_figure graphicRef58209 \" href=\"UTD.htm?26/56/27523\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .) Special attention should be given to those students who are matriculating to college and to those who are incarcerated or in detention facilities. By age 11 to 12 years, they should have received:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Two doses of measles, mumps, and rubella vaccine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=see_link\">",
"       \"Prevention and treatment of measles\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      if they have not had varicella infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"       \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A booster dose of tetanus if &ge;5 years have elapsed since their last dose; ideally, this booster should include the acellular pertussis vaccine.",
"     </li>",
"     <li>",
"      Meningococcal vaccine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43574?source=see_link\">",
"       Human papillomavirus vaccine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Annual influenza vaccine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pneumococcal vaccine if they are at high risk for infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STRATEGY FOR PROVISION OF ADOLESCENT PREVENTIVE SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medical education prepares practitioners to identify and manage biomedical disease but may not prepare them to manage preventable disorders related to personal behavior, especially in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/24\">",
"     24",
"    </a>",
"    ]. When seeing adolescents for routine health evaluation, practitioners tend to focus on diseases or conditions with which they are familiar, rather than on health-risk behaviors and problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to guidelines, therefore, practitioners need a strategy to help them integrate preventive services into routine medical care. The scheme presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef58331 \" href=\"UTD.htm?38/37/39518\">",
"     algorithm 1",
"    </a>",
"    ) can help providers screen for a large number of potential health risks, identify those that need further assessment, and focus on those that are of immediate concern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Step 1: Gather information and identify problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of this step is to identify indicators of all or a subset of the specific health risks and problems listed above. Data that are easy to obtain and have a high sensitivity for the issues of greatest concern are collected. Height, weight, and blood pressure are measured; questionnaires to assess health risks, habits, and behaviors can be completed in the waiting area. The use of questionnaires can save time and improve identification of problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The AMA developed a series of questionnaires to promote the use of adolescent preventive services in primary care. The questionnaires are available through the",
"    <a class=\"external\" href=\"file://www.ama-assn.org/ama/pub/physician-resources/public-health/promoting-healthy-lifestyles/adolescent-health/guidelines-adolescent-preventive-services.page\">",
"     AMA Web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The data that are gathered are used to guide the clinical interview and for further assessment. If no areas of concern are elicited, the practitioner can offer support and reinforcement for healthy behaviors. If, however, the indications are that the teen has a problem, such as being overweight or engaging in a health-risk behavior, then the practitioner goes to Step 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Step 2: Further assess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of this step is to determine, for each potential problem identified in Step 1, whether the teen is at high, moderate, or low risk for adverse consequences. The problems identified by the screening information are further assessed with a complete history and physical examination. If the problem presents an imminent and serious risk, then referral for specialty evaluation and management is appropriate. To illustrate the assignment of risk category, consider three 16-year-old girls who have a blood pressure of",
"    <span class=\"nowrap\">",
"     85/60,",
"    </span>",
"    a pulse rate of 60, a weight of 85 pounds, and a weight for height ratio that is below the 55th percentile:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first girl discloses during the interview that she views her ideal weight as 70 pounds, is a gymnast who exercises vigorously on a daily basis, skips meals frequently, uses laxatives daily, and is amenorrheic. She has an eating disorder and is at high risk for metabolic collapse. Immediate referral for further medical and psychiatric evaluation is warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The second girl reports a 10-pound weight loss over the past year, participates on the school gymnastic team, is a picky eater but does not skip meals, and is amenorrheic. She maintains a diet to control her weight because it helps her perform her routines. The physical examination is normal. This girl is at moderate risk for an eating disorder and should have her weight and metabolic status monitored closely during follow-up visits. If the clinical situation is different at the time of follow-up, the risk category can be amended.",
"     </li>",
"     <li>",
"      The third girl has always been thin, views her body weight as appropriate, exercises only during physical education classes at school, and is having regular menses. This girl is at low risk for an eating disorder and can be provided with information on healthy diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Step 3: Identify and prioritize problems together",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the practitioner has determined the risk category for each of the problems, he or she should have a discussion with the adolescent to acknowledge the problems and prioritize the problem list. The existence of a therapeutic relationship between the practitioner and the adolescent will facilitate this discussion. Adolescents tend to respond to an approach that enlists their cooperation and involvement in the decision-making process. The practitioner can foster a therapeutic alliance by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assuring the adolescent the information shared with the practitioner will remain confidential",
"     </li>",
"     <li>",
"      Listening to and valuing the adolescent's perspective",
"     </li>",
"     <li>",
"      Not responding to information regarding personal behaviors in a derogatory or punitive manner",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The practitioner and the adolescent must come to an agreement regarding the type and severity of each problem. Although the practitioner might believe that smoking, monthly use of alcohol, and skipping breakfast are the top issues of concern, the adolescent may rank these behaviors in a different order or may not even view them as problems. Without the teenager's acceptance of the problem list and its prioritization, chances of compliance with the management plan are nil. Unless the behavior is life-threatening in the immediate future, the practitioner and the adolescent must negotiate what they will work on together. The negotiation process provides the occasion to determine whether the adolescent is ready to change his or her behavior and to identify opportunities for and barriers to change. This information is necessary to proceed to the development of a management plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Step 4: Solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developing a management plan for the set of problems involves five steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negotiate the intervention &mdash; Discuss management options with the teen and determine, together, the best course of action. If the adolescent views the ultimate outcome to be too difficult, then negotiating more immediate, attainable objectives is reasonable. As an example, losing 2 pounds per month for six months may be more acceptable to a teen than losing 12 pounds as the long-term goal.",
"     </li>",
"     <li>",
"      Promote the teen's confidence that the management plan can work &mdash; Motivation to work on a behavioral change plan is key to success.",
"     </li>",
"     <li>",
"      Discuss strategies with the teen to overcome barriers to the management plan &mdash; Have the teenager identify a list of the barriers that he or she believes will interfere with the strategy for changing the behavior. Help plan ways to overcome the barriers.",
"     </li>",
"     <li>",
"      Develop a contract or verbal agreement with the teen regarding joint expectations.",
"     </li>",
"     <li>",
"      Follow up with the actions identified &mdash; The patient can make contact through electronic mail, telephone calls to office staff, and postcards prior to future office visits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INTEGRATING PREVENTIVE SERVICES INTO ROUTINE MEDICAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most health systems for pediatric care have well-established procedures for health maintenance visits, they are less likely to be set up to provide comprehensive preventive services for adolescents. Establishing systematic changes facilitates the ability of practitioners to deliver preventive services [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. National programs and materials can be modified to meet local needs and directions, as the local clinic must take ownership of the preventive services that are delivered. Objectives should be clear and protocols well delineated before broad changes are instituted. The integration process requires time and the complicity of each staff member. Experience with the GAPS program and information from the clinical literature on services for adult patients provide a set of steps for successful integration of comprehensive adolescent preventive services into routine medical care (",
"    <a class=\"graphic graphic_table graphicRef68463 \" href=\"UTD.htm?27/35/28220\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the GAPS recommendations to improve preventive health care service to adolescents was analyzed before and after implementation of the GAPS program in five community and migrant health centers (CMHCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/31\">",
"     31",
"    </a>",
"    ]. The percentage of adolescents who reported having received preventive screening or counseling increased after implementation in 19 of 31 content areas including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical or sexual abuse (22 versus 10 percent)",
"     </li>",
"     <li>",
"      Sexual orientation (27 versus 13 percent)",
"     </li>",
"     <li>",
"      Fighting (21 versus 6 percent)",
"     </li>",
"     <li>",
"      Weapons (22 versus 5 percent)",
"     </li>",
"     <li>",
"      Depression (34 versus 16 percent)",
"     </li>",
"     <li>",
"      Suicide (22 versus 7 percent)",
"     </li>",
"     <li>",
"      Eating disorders (29 versus 11 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an additional study, researchers found that with appropriate skill-based training, clinicians can successfully implement preventive services in routine outpatient visits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19000/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, following an educational intervention, the proportion of adolescents screened by their primary care providers for seat belt use, helmet use, tobacco use, alcohol use, and sexual behavior increased from 38 to 56 percent, 27 to 45 percent, 64 to 76 percent, 59 to 76 percent, and 61 to 75 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most adolescent morbidity and mortality is related to personal behavior and, as such, is preventable. Clinicians have an important role in early identification of risk (screening), counseling to reduce risk and provide general health guidance (anticipatory guidance), and provision of immunizations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Preventive service recommendations for adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that adolescent patients be screened for hypertension; obesity and eating disorders; hyperlipidemia (if indicated); tuberculosis (if at risk); physical, sexual, and emotional abuse; learning or school problems; substance use; depression and suicide; sexual behavior that may result in unintended pregnancy and sexually transmitted diseases; sexually transmitted diseases, including human immunodeficiency virus infection; and cervical cancer (as indicated). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that adolescents receive counseling about healthy eating habits, reduction of injuries, regular exercise, responsible sexual behaviors, avoidance of sharing personal information and pictures on the Internet, and avoidance of tobacco, alcohol, and other abusable substances. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anticipatory guidance for adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parental involvement and attitudes affect adolescent behavior and health outcomes. We suggest that parents receive anticipatory guidance at least once during their child's early, middle, and late adolescence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Anticipatory guidance for parents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that adolescents have their immunizations reviewed and updated as necessary (",
"      <a class=\"graphic graphic_figure graphicRef58209 \" href=\"UTD.htm?26/56/27523\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A strategy for integrating preventive services into routine medical care is provided in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef58331 \" href=\"UTD.htm?38/37/39518\">",
"       algorithm 1",
"      </a>",
"      ). Such a strategy can help providers screen for a range of potential health risks, identify those that need further assessment, and focus on those that are of immediate concern. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Strategy for provision of adolescent preventive services'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ozer, EM, Park J, Paul T, et al. America's Adolescents: Are They Healthy. 2003 Edition Revised and Updated. National Adolescent Health Information Center. Department of Pediatrics and Institute for Health Policy Studies, University of California School of Medicine, San Francisco, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/2\">",
"      Shanklin S, Brener ND, Kann L, et al. Youth risk behavior surveillance--selected Steps communities, United States, 2007. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/3\">",
"      Brener ND, Kann L, Garcia D, et al. Youth risk behavior surveillance--selected steps communities, 2005. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     Guide to Clinical Preventive Services, 2010-2011. Recommendations of the U.S. Preventive Services Task Force file://www.ahrq.gov/clinic/pocketgd.htm (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     Elster, AB, Kuznets, NJ. AMA Guidelines for Adolescent Preventive Services (GAPS): Recommendations and Rationale. Williams &amp; Wilkins, Baltimore 1994. www.ama-assn.org/ama/pub/physician-resources/public-health/promoting-healthy-lifestyles/adolescent-health/guidelines-adolescent-preventive-services.page (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Clinical Preventive Services. www.aafp.org/online/en/home/clinical/exam.html (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Age charts for periodic health examinations. Kansas City 1994.",
"    </li>",
"    <li>",
"     Hagen JF, Shaw JS, Duncan PM. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd, American Academy of Pediatrics, Elk Grove Village, IL 2008.",
"    </li>",
"    <li>",
"     Bright Futures www.brightfutures.aap.org/web (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Recommendations for preventive pediatric health care (periodicity schedule). file://practice.aap.org/content.aspx?aid=1599 (Accessed on February 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/11\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/12\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/13\">",
"      Elster AB. Comparison of recommendations for adolescent clinical preventive services developed by national organizations. Arch Pediatr Adolesc Med 1998; 152:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/14\">",
"      Richmond TK, Freed GL, Clark SJ, et al. Guidelines for adolescent well care: is there consensus? Curr Opin Pediatr 2006; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Quality Assurance. Health Plan Employer Data and Information Set (HEDIS) 3.0. Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/16\">",
"      Rosen DS, Elster A, Hedberg V, Paperny D. Clinical preventive services for adolescents: position paper of the Society for Adolescent Medicine. J Adolesc Health 1997; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/17\">",
"      Olson AL, Gaffney CA, Hedberg VA, Gladstone GR. Use of inexpensive technology to enhance adolescent health screening and counseling. Arch Pediatr Adolesc Med 2009; 163:172.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman J. When the cellphone teaches sex education. The New York Times. May 3, 2009. www.nytimes.com/2009/05/03/fashion/03sexed.html?_r=2&amp;ref (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/19\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/20\">",
"      D'Angelo LJ, Samples C, Rogers AS, et al. HIV infection and AIDS in adolescents: an update of the position of the Society for Adolescent Medicine. J Adolesc Health 2006; 38:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/21\">",
"      Resnick MD, Bearman PS, Blum RW, et al. Protecting adolescents from harm. Findings from the National Longitudinal Study on Adolescent Health. JAMA 1997; 278:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/22\">",
"      Dittus PJ, Jaccard J. Adolescents' perceptions of maternal disapproval of sex: relationship to sexual outcomes. J Adolesc Health 2000; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/23\">",
"      DiClemente RJ, Wingood GM, Crosby R, et al. Parental monitoring: association with adolescents' risk behaviors. Pediatrics 2001; 107:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/24\">",
"      Preventive medicine in general internal medicine residency training. Preventive Health Care Committee, Society for Research and Education in Primary Care Internal Medicine. Ann Intern Med 1985; 102:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/25\">",
"      Blum RW, Beuhring T, Wunderlich M, Resnick MD. Don't ask, they won't tell: the quality of adolescent health screening in five practice settings. Am J Public Health 1996; 86:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/26\">",
"      Goodwin MA, Flocke SA, Borawski EA, et al. Direct observation of health-habit counseling of adolescents. Arch Pediatr Adolesc Med 1999; 153:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/27\">",
"      Frankenfield DL, Keyl PM, Gielen A, et al. Adolescent patients--healthy or hurting? Missed opportunities to screen for suicide risk in the primary care setting. Arch Pediatr Adolesc Med 2000; 154:162.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for Adolescent Preventive Services: Clinical Evaluation and Management Handbook. American Medical Association, Chicago, IL 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/29\">",
"      Schubiner H, Tzelepis A, Wright K, Podany E. The clinical utility of the Safe Times Questionnaire. J Adolesc Health 1994; 15:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/30\">",
"      Schubiner H, Robin A. Screening adolescents for depression and parent-teenager conflict in an ambulatory medical setting: a preliminary investigation. Pediatrics 1990; 85:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/31\">",
"      Klein JD, Allan MJ, Elster AB, et al. Improving adolescent preventive care in community health centers. Pediatrics 2001; 107:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/32\">",
"      Lustig JL, Ozer EM, Adams SH, et al. Improving the delivery of adolescent clinical preventive services through skills-based training. Pediatrics 2001; 107:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/33\">",
"      Ozer EM, Adams SH, Lustig JL, et al. Increasing the screening and counseling of adolescents for risky health behaviors: a primary care intervention. Pediatrics 2005; 115:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/34\">",
"      Poses RM. One size does not fit all: questions to answer before intervening to change physician behavior. Jt Comm J Qual Improv 1999; 25:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/35\">",
"      Hulscher ME, Wensing M, Grol RP, et al. Interventions to improve the delivery of preventive services in primary care. Am J Public Health 1999; 89:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/36\">",
"      Goodson P, Gottlieb NH, Smith MM. Put prevention into practice. Evaluation of program initiation in nine Texas clinical sites. Am J Prev Med 1999; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/37\">",
"      Elster AB, Levenberg P. Integrating comprehensive adolescent preventive services into routine medicine care. Rationale and approaches. Pediatr Clin North Am 1997; 44:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19000/abstract/38\">",
"      Dietrich AJ, Woodruff CB, Carney PA. Changing office routines to enhance preventive care. The preventive GAPS approach. Arch Fam Med 1994; 3:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 108 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19000=[""].join("\n");
var outline_f18_35_19000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTIVE SERVICE RECOMMENDATIONS FOR ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPREHENSIVE GUIDELINES FOR ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anticipatory guidance for adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anticipatory guidance for parents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STRATEGY FOR PROVISION OF ADOLESCENT PREVENTIVE SERVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Step 1: Gather information and identify problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Step 2: Further assess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Step 3: Identify and prioritize problems together",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Step 4: Solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INTEGRATING PREVENTIVE SERVICES INTO ROUTINE MEDICAL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/108|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/37/39518\" title=\"algorithm 1\">",
"      Approach to prevention in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/108|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27523\" title=\"figure 1\">",
"      Childhood immunization schedule 7 to 18 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/9/38043\" title=\"table 1\">",
"      Screen eating disorders obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/35/28220\" title=\"table 2\">",
"      Integration GAPS routine care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 3\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 4\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37081?source=related_link\">",
"      Prevention of smoking initiation in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44329?source=related_link\">",
"      Specific learning disabilities in children: Role of the primary care provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_35_19001="Operative management of achalasia: Laparoscopic and open Heller myotomy";
var content_f18_35_19001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operative management of achalasia: Laparoscopic and open Heller myotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Brant K Oelschlager, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Rebecca P Petersen, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Jeffrey Marks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19001/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/35/19001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H37208847\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heller described a surgical approach for the treatment of achalasia in 1913 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The Heller myotomy with a fundoplication is the optimal surgical treatment of achalasia, with effective symptom control in 90 to 97 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The muscle fibers of the lower esophageal sphincter are incised without disrupting the mucosal lining of the esophagus and can be performed as a laparoscopic or open procedure. With the advancement of laparoscopic surgery, the open technique is rarely used.",
"   </p>",
"   <p>",
"    The indications for surgery, surgical technical insights, and postoperative results of the Heller myotomy will be reviewed here. The pathophysiology and etiology, clinical manifestations and diagnosis, and medical treatment of achalasia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=see_link\">",
"     \"Pneumatic dilation and botulinum toxin injection for achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208854\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key component for selecting appropriate patients for surgical management is to differentiate achalasia from other motility disorders and from pseudoachalasia, malignancy, and mechanical obstruction. The preoperative evaluation by the surgeon includes a history of patient symptoms as well as a review of previous studies and the results of medical therapies to alleviate symptoms. As an example, patients who are older than 50 years, with symptoms less than six months duration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who have lost more than 10 pounds (4.5 kg) must be evaluated for esophageal cancer.",
"   </p>",
"   <p>",
"    Pertinent details of the preoperative assessment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      History of weight loss",
"     </li>",
"     <li>",
"      Duration of symptoms",
"     </li>",
"     <li>",
"      Physiologic studies of esophageal function",
"     </li>",
"     <li>",
"      Radiographic imaging studies",
"     </li>",
"     <li>",
"      Results of dilatations",
"     </li>",
"     <li>",
"      Botulinum toxin injections",
"     </li>",
"     <li>",
"      Biopsy results",
"     </li>",
"     <li>",
"      Previous intra-abdominal and intra-thoracic surgery",
"     </li>",
"     <li>",
"      Comorbid illnesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical therapies, which are nonspecific and have inconsistent results and side effects, have a limited role in the treatment of achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. While some controversy exists as to whether endoscopic or surgical therapy should be initiated first [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/7\">",
"     7",
"    </a>",
"    ], most specialists agree that it is no longer necessary or even preferred that patients first undergo a trial of medical therapy or dilatation.",
"   </p>",
"   <p>",
"    Laparoscopic myotomy is the first line of therapy for patients with a confirmed diagnosis of achalasia. An open approach to the Heller myotomy is rarely performed as the initial treatment. Only in a patient who has undergone multiple failed dilatations with persistent symptoms would an open approach be considered and even then one may opt to perform a myotomy via a thoracoscopic approach. Pneumatic dilatation is used in centers with significant experience with its use and for patients who prefer to avoid surgery, have undergone multiple prior abdominal operations, or who would be unable to tolerate the pneumoperitoneum required to perform the procedure laparoscopically (eg, restrictive pulmonary disease, chronic heart failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37210839\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of achalasia is based upon the clinical history,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, and esophageal manometry. This section will review the key diagnostic studies that a surgeon must review or perform to prepare a patient for the operation. A review of standard manometry, high-resolution manometry, endoscopy, and radiographic imaging in achalasia are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208861\">",
"    <span class=\"h2\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manometry is the measurement of muscular function of the esophagus and includes three zones: lower esophageal sphincter (LES), esophageal body, and upper esophageal sphincter (UES). High-resolution manometry (HRM) provides for a more accurate characterization of esophageal function compared with standard manometry (",
"    <a class=\"graphic graphic_figure graphicRef67060 \" href=\"UTD.htm?14/52/15174\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59926 \" href=\"UTD.htm?41/18/42277\">",
"     picture 1",
"    </a>",
"    ). HRM permits continuous recording of motor activity along the entire length of the esophagus and yields a more complete and detailed picture of esophageal motility. Manometry systems include a catheter with multiple pressure sensor channels, pressure transducers, and a recording device with a computer for analysis. The technique and the interpretation of the results are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'Standard manometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'High-resolution manometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link&amp;anchor=H2#H2\">",
"     \"Motility testing: When does it help?\", section on 'Esophageal manometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\", section on 'Manometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal manometry is the cornerstone of diagnosis of achalasia and is an essential test that must be performed before proceeding with an operation. The surgeon should personally review the manometric findings to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35752449\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients undergo endoscopy to establish a diagnosis well in advance of consideration for surgery. It is important that the surgeon review the results to exclude other etiologies of the symptoms. It is not necessary to routinely repeat the endoscopy before every operative procedure, but the surgeon must have a low threshold to repeat endoscopy if concomitant or alternative upper gastrointestinal disease remains a consideration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'Endoscopy'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208882\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow is the preferred initial study to define the esophageal anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53672 \" href=\"UTD.htm?23/55/24446\">",
"     image 1",
"    </a>",
"    ). This study will show the extent of esophageal dilation, shape, and gastroesophageal junction (GEJ) obstruction. Absence of obstruction at the GEJ, which is characterized by a column of barium with air-fluid levels, should make one question the diagnosis. Routine CT scans of the chest and abdomen are not necessary, but if pseudoachalasia is suspected based on the clinical history, a CT scan or endoscopic ultrasound should be performed to ensure accuracy of diagnosis.",
"   </p>",
"   <p>",
"    A sigmoid esophagus is a complication of long standing achalasia. The surgical approach to a sigmoid esophagus may be to limit the procedure to myotomy without fundoplication or an esophagectomy for patients with prior attempts at myotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3226516\">",
"    <span class=\"h1\">",
"     SURGICAL MYOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical myotomy, in which the lower esophageal sphincter (LES) is weakened by incising the muscle fibers, is the primary alternative to pneumatic dilatation for achalasia. The advantages of surgical myotomy are high initial success rates and, compared to pneumatic dilation, lower rates of symptom recurrence. The major disadvantages of surgery are the high initial cost, the protracted recovery period, and the frequent development of gastroesophageal reflux disease postoperatively.",
"   </p>",
"   <p>",
"    The primary goal of the operative treatment is to relieve the functional obstruction of the LES while preventing reflux. The surgical principles include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimal dissection of the cardia",
"     </li>",
"     <li>",
"      Adequate distal myotomy to release the pressure of the LES",
"     </li>",
"     <li>",
"      Prevention of postoperative gastroesophageal reflux",
"     </li>",
"     <li>",
"      Prevention of scarred closure of the myotomy site",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A modification of the Heller technique is the most common operative procedure used to treat achalasia. The operation can be performed using an open or a minimally invasive technique, and the esophagus can be approached through either the abdomen or thorax [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. There are advantages and disadvantages to each procedure. The outcomes of the laparoscopic approach are comparable to an open approach but with less postoperative pain and morbidity, and a shorter hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/15\">",
"     15",
"    </a>",
"    ]. The limitations of a thoracoscopic approach compared with a laparoscopic esophageal myotomy include the limited exposure of the distal LES and stomach, the technical challenges of performing a fundoplication, and a higher rate of residual or recurrent dysphagia. Outcomes for the laparoscopic and open techniques are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the treatment of achalasia\", section on 'Open surgical myotomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of achalasia\", section on 'Laparoscopic myotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3226935\">",
"    <span class=\"h2\">",
"     Laparoscopic technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a description of the key technical elements of performing a laparoscopic esophageal myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. General issues related to laparoscopic abdominal surgery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227116\">",
"    <span class=\"h3\">",
"     Patient position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are placed in a supine, split leg, or lithotomy position with padding, such as a surgical bean bag. We prefer the lithotomy position for optimal ergonomics and access to the hiatus. The patient is positioned in a steep reverse Trendelenburg position, which allows the stomach and other organs to fall away from the esophageal hiatus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227126\">",
"    <span class=\"h3\">",
"     Abdominal access and port placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal access is obtained at the left upper quadrant just inferior to the costal margin. Pneumoperitoneum is established according to standard laparoscopic techniques. Four operative ports (two for the surgeon, one for the assistant, and one for the scope) are then placed under direct visualization, and liver retraction is then achieved by any number of such devices on the market (",
"    <a class=\"graphic graphic_figure graphicRef68596 \" href=\"UTD.htm?35/14/36066\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227153\">",
"    <span class=\"h3\">",
"     Mobilization of the gastric fundus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the surgeon&rsquo;s preference, the initial dissection can begin on the right or the left side of the esophageal hiatus. The steps to mobilize the gastric fundus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dividing the left phrenogastric ligaments by dividing the short gastric arteries, starting at the inferior pole of the spleen to the exposed left crus of the diaphragm",
"     </li>",
"     <li>",
"      Incising the gastrohepatic ligament in an avascular plane",
"     </li>",
"     <li>",
"      Preserving the nerve of Latarjet and avoiding injury to an accessory or replaced hepatic artery",
"     </li>",
"     <li>",
"      Dividing the right anterior phrenoesophageal ligament and the peritoneum overlying the anterior abdominal esophagus",
"     </li>",
"     <li>",
"      Preserving the anterior vagus nerve, which lies immediately posterior to the right anterior phrenoesophageal ligament",
"     </li>",
"     <li>",
"      At this point, if a",
"      <strong>",
"       posterior",
"      </strong>",
"      partial (Toupet) fundoplication is performed, a posterior esophageal window is created. In performing this window, the posterior vagus nerve is identified and protected. If an",
"      <strong>",
"       anterior",
"      </strong>",
"      fundoplication (Dor) technique is used, a posterior esophageal window is unnecessary unless a hiatal hernia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      and a relatively short esophagus is encountered and there is a need for further mobilization to allow more intra-abdominal length in order to construct a good fundoplication. (See",
"      <a class=\"local\" href=\"#H3227471\">",
"       'Fundoplication'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H37208917\">",
"       'Addition of a fundoplication'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227250\">",
"    <span class=\"h3\">",
"     Mobilization of the mediastinal esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal portion of the mediastinal esophagus is mobilized in order to achieve sufficient length to perform a myotomy incision that divides the entire length of the LES and permits a tension free fundoplication. A Penrose drain is placed around the gastroesophageal junction to retract the esophagus laterally and inferiorly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227260\">",
"    <span class=\"h3\">",
"     Myotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical when performing the myotomy that visualization and exposure are adequate to prevent inadvertent mucosal injuries. The cardioesophageal fat pad and the anterior vagus nerve",
"    <strong>",
"     must",
"    </strong>",
"    be cleared from the esophagus and the gastroesophageal junction. A continuous myotomy is performed for 6 cm on the esophagus and 3 cm onto the stomach.",
"   </p>",
"   <p>",
"    The following principles are important when performing the myotomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A suitable and stable platform is useful. Our preference is a lighted bougie dilator (50 Fr), which illuminates the esophagus and stretches the muscle fibers around the gastroesophageal junction, facilitating their division. An endoscope may be used instead of the lighted bougie dilator. The anterior surface of the esophagus is completely exposed and slight tension is created by retracting caudally with a Babcock retractor or similar instrument.",
"     </li>",
"     <li>",
"      The incision may be started on either the stomach or the esophagus. We prefer starting on the stomach; while this is a more difficult submucosal plane to identify, we find it easier to proceed in a cephalad than caudal direction.",
"     </li>",
"     <li>",
"      The use of electrocautery should be",
"      <strong>",
"       avoided",
"      </strong>",
"      unless critical when creating the myotomy. If bleeding is encountered, it should be controlled with pressure and patience since thermal injury can lead to an unrecognized perforation of the esophagus.",
"     </li>",
"     <li>",
"      The myotomy is performed by individually dividing the esophageal and gastric muscle fibers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The longitudinal muscles are divided first, which exposes the underlying circular muscles.",
"     </li>",
"     <li>",
"      Division of the circular layer reveals a bulging mucosal plane that should appear smooth and white (",
"      <a class=\"graphic graphic_picture graphicRef50030 \" href=\"UTD.htm?5/60/6082\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The most critical and challenging factor is to create a 3 cm myotomy caudal to the gastroesophageal junction, where the tissue plane becomes less readily identifiable. An intervening sling of muscle fibers may blur the dissection, and the stomach mucosa is thinner and more prone to perforation (",
"      <a class=\"graphic graphic_figure graphicRef69389 \" href=\"UTD.htm?34/16/35087\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The esophageal myotomy should be approximately 6 cm in length.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic inspection of the mucosa and the myotomy is performed prior to proceeding to the next steps to identify and repair any mucosal perforations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227471\">",
"    <span class=\"h3\">",
"     Fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a fundoplication procedure is performed, it is typically a partial (eg, Toupet or Dor) and not a circumferential (Nissen) wrap (see",
"    <a class=\"local\" href=\"#H37208917\">",
"     'Addition of a fundoplication'",
"    </a>",
"    below). A Toupet fundoplication is a 270 degree posterior wrap of the fundus around the esophagus, while the Dor fundoplication is a 180 degree anterior wrap.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a Toupet (posterior) fundoplication is being performed, a retroesophageal window is established along the lines of dissection (",
"      <a class=\"graphic graphic_figure graphicRef62809 \" href=\"UTD.htm?39/0/39939\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72012 \" href=\"UTD.htm?39/49/40722\">",
"       picture 3",
"      </a>",
"      ). The following is a brief description of the technique:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The fundus is mobilized by dividing the short gastric vessels and all fundal attachments starting approximately at the inferior pole of the spleen, approximately 10 to 15 cm inferior to the angle of His.",
"     </li>",
"     <li>",
"      The retroesophageal window is developed by further dissection along the base of the left crus.",
"     </li>",
"     <li>",
"      Following mobilization of the mediastinal esophagus, the gastroesophageal hiatus is closed posteriorly with interrupted sutures if a large defect is present, but our preference is to leave laxity of the hiatus.",
"     </li>",
"     <li>",
"      The posterior aspect of the gastric fundus is passed through the retroesophageal window and secured to the right edge of the myotomy and right crus of the diaphragm with a coronal suture. Another interrupted suture is placed to secure the posterior fundus to the base of the right crus.",
"     </li>",
"     <li>",
"      The leading posterior edge of the fundus is secured to the right edge of the myotomy with interrupted sutures.",
"     </li>",
"     <li>",
"      Any redundancy of the fundus is removed from behind the esophagus and the proximal, anterior aspect of the fundus is secured to the left side in a similar fashion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Dor (anterior) fundoplication may be particularly useful to buttress the repair of an esophageal perforation that may occur. The greater curve of the fundus is grasped and placed anteriorly to the right side of the gastroesophageal hiatus. The following is a brief description of the technique:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An inner row of interrupted sutures are used to secure the medial aspect of the fundus to the left side of the myotomy, which begins to recreate the angle of His.",
"     </li>",
"     <li>",
"      The anterior fundus is folded over the esophagus, and a coronal suture to the right crus and right side of the esophagus is performed.",
"     </li>",
"     <li>",
"      A second row of interrupted sutures is placed to fix the leading edge to the right side of the myotomy (",
"      <a class=\"graphic graphic_picture graphicRef52028 \" href=\"UTD.htm?38/31/39408\">",
"       picture 4",
"      </a>",
"      ). A final suture from the apex of the gastroesophageal hiatus to the fundus completes the fundoplication. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227098\">",
"    <span class=\"h2\">",
"     Open technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no differences in surgical technique or principles when performing a myotomy with or without a fundoplication between a laparoscopic or open (laparotomy or thoracotomy) approach. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227463\">",
"    <span class=\"h2\">",
"     Intraoperative technical risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major intraoperative risks include an unrecognized perforation of the esophageal or gastric mucosa, division or injury to the anterior vagus nerve, and splenic injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal or gastric perforation &mdash; The risk of an esophageal or gastric perforation during surgical myotomy ranges from 10 to 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/3,17\">",
"       3,17",
"      </a>",
"      ]. Mucosal perforations are repaired with fine 4-0 and 5-0 absorbable monofilament suture. An advantage of the anterior (Dor) fundoplication is that it will buttress the repair.",
"     </li>",
"     <li>",
"      Division of vagus nerve &mdash; Using careful dissection and attention to detail, injury to the vagus nerves is rare. The",
"      <strong>",
"       anterior",
"      </strong>",
"      vagus nerve is at risk of injury during several technical steps of the operation including the initial dissection of the esophagus, excising the gastroesophageal fat pad, performing the myotomy, and performing the fundoplication [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/18\">",
"       18",
"      </a>",
"      ]. The",
"      <strong>",
"       posterior",
"      </strong>",
"      vagus nerve is less likely to be injured. If an injury to only the anterior or posterior vagus nerve occurs, it is not repaired as postvagotomy diarrhea, bloating, early satiety,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dumping syndrome rarely occur with a unilateral vagotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/19\">",
"       19",
"      </a>",
"      ]. Nevertheless, extra care should be taken to identify and preserve both nerves.",
"     </li>",
"     <li>",
"      Splenic injury &mdash; The risk of injury to the spleen ranges from &lt; 1 to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. The higher rates are from reports when laparoscopic surgery was in the early stages of use. Management of an intraoperative splenic injury is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H12350972#H12350972\">",
"       \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Splenic injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18856620\">",
"    <span class=\"h1\">",
"     OPERATIVE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several technical variations for performing a laparoscopic or open Heller myotomy, reflecting areas of contention. These areas of controversy include length of the gastric component of the myotomy incision, addition of an antireflux procedure (fundoplication), management of a sigmoid megaesophagus, and the role of robotic surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208910\">",
"    <span class=\"h2\">",
"     Extended gastric myotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extended gastric myotomy, which is defined as a 3 cm myotomy incision onto the cardia of the stomach, is an important technical component for reducing recurrence of symptoms of achalasia. The standard esophageal myotomy includes a 1.5 to 2.0 cm extension of the incision onto the cardia of the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. A 3 cm extension of the esophageal myotomy incision onto the stomach provides long-term durable dysphagia relief due to disruption of the gastric sling, which consists of short transverse muscle fibers on the lesser curve of the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The importance of the gastric sling fibers in the lower esophageal sphincter (LES) mechanism was recognized when transitioning from the thoracoscopic to laparoscopic approach (",
"    <a class=\"graphic graphic_figure graphicRef69389 \" href=\"UTD.htm?34/16/35087\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the outcomes of performing a standard or an extended myotomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series from a prospective database found that symptoms following the laparoscopic Heller myotomy were improved with an extended gastric myotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients treated with a 3 cm extended gastric myotomy (n=58) and a Toupet fundoplication had a significantly lower LES pressure (9.5 versus 15.8 mmHg), less frequent dysphagia (1.2 versus 2.1 percent), less severe dysphagia on VAS pain score (3.2 versus 5.3), and fewer recurrences requiring dilatation (2 versus 9 patients) compared with patients treated with a standard 1.5 cm gastric myotomy and a Dor fundoplication (n=52). Patients treated with the extended gastric myotomy had similar rates of heartburn (1.3 versus 1.7 percent), regurgitation (0.3 versus 0.8 percent), chest pain (0.3 versus 0.6 percent), and proximal (1.7 versus 2.3 percent) and distal (6.0 versus 5.9 percent) esophageal acid exposure.",
"     </li>",
"     <li>",
"      A retrospective review of 113 patients undergoing a laparoscopic Heller myotomy reported good or excellent results in 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/26\">",
"       26",
"      </a>",
"      ]. Ten patients (8.7 percent) were considered surgical failures, including two who reported no relief of symptoms. The reasons for recurrence of or persistent symptoms included an incomplete myotomy, sclerosis of the myotomy, and a sigmoid megaesophagus. Patients who were symptomatic following surgery had a significantly larger esophageal diameter identified on a postoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow (25.5 versus 20 mm), and a significantly longer intact LES overall (42.5 versus 37.5 mm), longer intact length of the gastric component of the LES (32 verus 27 mm), and a higher amplitude of contraction above the LES (32 versus 18 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208917\">",
"    <span class=\"h2\">",
"     Addition of a fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for performing an anti-reflux fundoplication is to reduce the risk of symptomatic gastroesophageal reflux that may result from obliterating the LES mechanism. The indications for addition of a fundoplication vary in part with the approach to the myotomy. A fundoplication is included in most patients in whom a laparoscopic myotomy is performed.",
"   </p>",
"   <p>",
"    A randomized trial of 43 patients undergoing a myotomy for achalasia found that patients treated with the addition of an anterior (Dor) fundoplication had significantly fewer gastroesophageal reflux symptoms (10 versus 2 patients) and a lower acid exposure time to the distal esophagus compared with patients treated with a myotomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/16\">",
"     16",
"    </a>",
"    ]. There was no difference in the frequency of dysphagia.",
"   </p>",
"   <p>",
"    Both anterior (Dor) and posterior (Toupet) partial fundoplication techniques are used, and there is no consensus on which procedure is superior:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Dor procedure avoids mobilization of the stomach during the initial dissection and is technically easier to perform. In addition, it is a useful technique to buttress the repair of an inadvertent esophageal perforation.",
"     </li>",
"     <li>",
"      The Toupet fundoplication splays the edges of the myotomy, which may decrease fibrosis at the incision site and reduce recurrence of dysphagia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data from high quality trials comparing the Dor and Toupet fundoplications to reduce the risk of objective findings of gastroesophageal reflux",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. A circumferential complete fundoplication (Nissen) is usually not performed to avoid excessive constriction at the gastroesophageal junction. Our preference is to perform a Toupet partial fundoplication as we believe it reduces the risk of recurrent dysphagia by stenting open the edges of the myotomy thus preventing scarring, but primarily because it is a superior anti-reflux barrier. We perform a Dor fundoplication to provide coverage of the primary repair only when there is an esophageal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    While a fundoplication is routinely performed with a laparoscopic myotomy, there are several instances when a fundoplication is not performed. These settings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The myotomy is performed with a left video-assisted thorascopic surgery (VATS) approach without disruption of the phrenoesophageal ligament [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Late stage disease manifested by the presence of a sigmoid megaesophagus on the preoperative esophagogram. (See",
"      <a class=\"local\" href=\"#H37208924\">",
"       'Sigmoid megaesophagus'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who are morbidly obese. Although achalasia is rarely seen in obese patients, we believe that the optimal procedure for these patients is a laparoscopic Heller myotomy with a concomitant Roux-en-Y gastric bypass, which we have performed with success in a small series of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208924\">",
"    <span class=\"h2\">",
"     Sigmoid megaesophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sigmoid megaesophagus is an enlarged and atonic esophagus that results from long standing increased LES pressure. Traditionally, a standard Heller myotomy was not performed on patients with a sigmoid megaesophagus, as the degree of esophageal dilation and relief of symptoms were not thought to improve with myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/29\">",
"     29",
"    </a>",
"    ]. Hence, patients with a sigmoid esophagus were typically treated with an esophagectomy prior to the laparoscopic era [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of an esophageal myotomy with a fundoplication for patients with a sigmoid megaesophagus are illustrated in the following retrospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 113 consecutive patients with achalasia who were treated with a laparoscopic Heller myotomy and Dor fundoplication [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/29\">",
"       29",
"      </a>",
"      ]. The twelve patients with a sigmoid megaesophagus had an equivalent operating time, length of hospital stay, rate of postoperative complications, and relief of symptoms compared with patients without esophageal dilatation.",
"     </li>",
"     <li>",
"      A review of 51 patients with achalasia treated with a Heller myotomy and Dor fundoplication by laparoscopy or laparotomy found that the 14 patients with a sigmoid megaesophagus had equivalent postoperative changes in esophageal width, LES pressure, dysphagia score, and regurgitation score as the 37 patients without a megaesophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to the previous two studies, a retrospective review of 394 patients with achalasia undergoing a laparoscopic Heller myotomy found that sigmoid megaesophagus was an independent predictor for failure of a laparoscopic myotomy as the primary or secondary treatment of achalasia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/4\">",
"       4",
"      </a>",
"      ]. There were 13 patients with a megaesophagus in this study: five had a good outcome and eight patients were considered a surgical failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a Heller myotomy is performed in patients with a sigmoid megaesophagus, one should be careful if adding a concomitant partial fundoplication, which is more likely to cause angulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance in a megaesophagus. An alternative to an esophagectomy or a myotomy with a fundoplication may be a laparoscopic esophagogastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/32\">",
"     32",
"    </a>",
"    ]. However, there are no short-term or long-term studies on the efficacy of this procedure to improve symptoms and no high quality data from randomized trials to suggest the best operative approach for management of sigmoid megaesophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208931\">",
"    <span class=\"h2\">",
"     Robotic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evolving surgical modality for treatment of achalasia is robot-assisted minimally invasive surgery. Theoretical advantages for the surgeon over standard laparoscopic surgery include increased range of motion, decreased tremor, improved visibility with respect to depth perception, and improved ability to perform finer movements in a smaller, confined space [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/33\">",
"     33",
"    </a>",
"    ]. The largest prospective series included 104 patients with achalasia treated with a robot-assisted Heller myotomy with partial fundoplication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/34\">",
"     34",
"    </a>",
"    ]. There were no esophageal perforations, eight minor complications, and two conversions to an open procedure because of bleeding and computer system failure. Almost two-thirds of patients were discharged on the first postoperative day. A symptom survey was completed in 79 patients (76 percent); all had a significant improvement in postoperative symptom score compared with a preoperative score (0.5 versus 5.0), and none required a reoperation to control symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208938\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle components of postoperative care for laparoscopic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    open myotomy include advancement of diet and control of nausea. The following is a summary of the major issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While some advocate performing a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow prior to initiating a diet, we find this unnecessary if there has been good intraoperative visualization of the esophagus and stomach as well as intraoperative endoscopy. However, one should have a low threshold for obtaining a barium swallow if a patient develops symptoms and signs suggestive of an esophageal or gastric perforation (eg, chest pain, epigastric pain, fever, tachycardia, subcutaneous or mediastinal emphysema,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      otherwise unexplained leukocytosis).",
"     </li>",
"     <li>",
"      Clear liquids are typically started the night of the procedure following laparoscopic surgery, or when bowel function returns following an open procedure. If no dysphagia occurs, the diet is advanced to a soft diet the following day. If episodes of dysphagia occur, patients are maintained on a full liquid diet for a longer period of time prior to advancing the diet.",
"     </li>",
"     <li>",
"      Aggressive treatment with antiemetics is provided for patients complaining of nausea to avoid emesis, which can lead to rupture of the repair. Medications can be administered in a crushed form until the patient is tolerating a regular diet.",
"     </li>",
"     <li>",
"      Antacids or proton pump inhibitors are used only if patients experience symptoms of heartburn and regurgitation and a pH monitoring study reveals gastroesophageal reflux. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H3#H3\">",
"       \"Medical management of gastroesophageal reflux disease in adults\", section on 'Acid suppressive medications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208945\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications following laparoscopic and open myotomy with a fundoplication include perforation, recurrent dysphagia, and gastroesophageal reflux. Following laparoscopic Heller myotomy, the morbidity rate ranges between 1 and 10 percent and the mortality rate is &lt;0.1 percent in the 30 day perioperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/4,24,35-37\">",
"     4,24,35-37",
"    </a>",
"    ]. Open myotomy may be associated with higher 30 day mortality rates (0 to 5.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/38\">",
"     38",
"    </a>",
"    ], more postoperative pain, and a longer hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208954\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common early postoperative complication is gastric or esophageal perforation, which occurs in 1 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/4,24,35-37\">",
"     4,24,35-37",
"    </a>",
"    ]. Late perforations usually result from either direct mucosal injury that is not recognized during surgery, or inadvertent thermal injury. Perforations usually result in diffuse peritonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinitis and may be life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a perforation is suspected, a water-soluble contrast radiograph should be obtained. Management of a late perforation requires diversion and a gastrostomy tube or an esophagectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208961\">",
"    <span class=\"h2\">",
"     Recurrent dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent dysphagia is a late complication of a Heller myotomy and fundoplication. It occurs in approximately 3 to 10 percent of patients undergoing a Heller myotomy, with the onset of symptoms 6 months or later after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/4,24,26,36,41\">",
"     4,24,26,36,41",
"    </a>",
"    ]. The",
"    <strong>",
"     most common",
"    </strong>",
"    cause is a suboptimal incision of the myotomy, defined as less than 3 cm below the gastroesophageal junction. This is more common in patients that were managed with a thoracoscopic approach to myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/25\">",
"     25",
"    </a>",
"    ]. In some cases, the incision was suboptimal, even with the laparoscopic approach; as a result, a repeat procedure may be warranted to extend the incision further into the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential reasons for recurrent dysphagia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Herniated fundoplication",
"     </li>",
"     <li>",
"      Peri-hiatal scarring",
"     </li>",
"     <li>",
"      Peptic stricture",
"     </li>",
"     <li>",
"      Obstructing tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the patient with recurrent dysphagia is to identify the cause and to rule out significant pathology, such as a malignancy, stricture, or hernia. The diagnostic evaluation typically begins with upper endoscopy or, if endoscopy is not available, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow. Manometry may be performed if achalasia is a possible cause of the dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208968\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of gastroesophageal reflux (GER) developing in patients undergoing myotomy with a partial fundoplication (Dor or Toupet) ranges from 2 to 26 percent in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/16,24,42-44\">",
"     16,24,42-44",
"    </a>",
"    ]. The rate of GER for patients undergoing myotomy alone is much higher. This was demonstrated in a randomized trial of 43 patients with achalasia in which patients undergoing a Heller myotomy with a Dor fundoplication had a significantly lower rate of pathologic GER at 6 months after surgery compared with patients undergoing a Heller myotomy without a fundoplication (9 versus 48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who develop GER should have pH monitoring performed three to six months after myotomy and repeated with any change in symptoms that could suggest GER, especially heartburn and regurgitation. Patients with abnormal esophageal acid exposure are treated medically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208975\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax, bleeding, inadvertent vagal injury, and infection are uncommon complications, with at least one occurring in approximately 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/45\">",
"     45",
"    </a>",
"    ]. A pneumothorax can be caused from inadvertent injury to the pleura during mobilization of the mediastinal esophagus. If this occurs, the defect can be repaired with a primary suture closure if the patient develops intraoperative hypotension or hypoxia. Otherwise, neither a primary repair nor a chest tube is necessary in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37208982\">",
"    <span class=\"h1\">",
"     RISK OF ESOPHAGEAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated achalasia is associated with an increased risk of squamous cell esophageal cancer. There is a paucity of long-term data on the development of esophageal cancer following a myotomy. In a retrospective review of 226 patients surgically treated for achalasia, four (1.8 percent) developed a squamous cell carcinoma at 2, 8, 13, and 18 years after the operation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19001/abstract/44\">",
"     44",
"    </a>",
"    ]. The risk of esophageal cancer in patients with achalasia and the possible role of screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H262982107#H262982107\">",
"     \"Clinical manifestations and diagnosis of achalasia\", section on 'Risk of esophageal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1389739\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic Heller myotomy with a partial fundoplication is the optimal surgical treatment of achalasia, with effective control of symptoms in 90 to 97 percent of patients. The primary goal of the operative treatment is to relieve the functional obstruction of the lower esophageal sphincter (LES) while preventing reflux.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A laparoscopic Heller myotomy is the first line of surgical therapy for patients with a confirmed diagnosis of achalasia and who are operative candidates. An open approach (laparotomy) to the Heller myotomy is rarely performed as the initial treatment, and is reserved for patients who have had multiple prior abdominal operations or who cannot tolerate a pneumoperitoneum because of cardiac or pulmonary disease. (See",
"      <a class=\"local\" href=\"#H37208854\">",
"       'Patient selection criteria'",
"      </a>",
"      above.) For those patients, or those who prefer a nonoperative approach, pneumatic dilatation is performed.",
"     </li>",
"     <li>",
"      The surgeon must review the results of the manometry, endoscopy, and pathology if not personally performing the tests. (See",
"      <a class=\"local\" href=\"#H37210839\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is critical when performing the myotomy that visualization and exposure are adequate to prevent inadvertent mucosal injuries. The cardioesophageal fat pad and the anterior vagus nerve",
"      <strong>",
"       must",
"      </strong>",
"      be cleared from the esophagus and the gastroesophageal junction. A continuous myotomy is performed for 6 cm on the esophagus and 3 cm onto the stomach. (See",
"      <a class=\"local\" href=\"#H3226516\">",
"       'Surgical myotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18856620\">",
"       'Operative considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a partial fundoplication when performing a laparoscopic myotomy for achalasia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3227471\">",
"       'Fundoplication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37208917\">",
"       'Addition of a fundoplication'",
"      </a>",
"      above.) Our preference is to perform a Toupet partial fundoplication (270 degree posterior wrap of the fundus around the esophagus) as we believe it reduces the risk of recurrent dysphagia by stenting open the edges of the myotomy thus preventing scarring, but primarily because it is a superior anti-reflux barrier. We perform a Dor fundoplication (180 degree anterior wrap) to provide coverage of the primary repair only when there is an esophageal perforation.",
"     </li>",
"     <li>",
"      The major intraoperative risks include an unrecognized perforation of the esophageal or gastric mucosa, division or injury to the anterior vagus nerve and splenic injury. (See",
"      <a class=\"local\" href=\"#H3227463\">",
"       'Intraoperative technical risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a Heller myotomy is performed in patients with a sigmoid megaesophagus, one should be careful if adding a concomitant partial fundoplication, as this is more likely to cause angulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resistance to a very abnormal esophagus. (See",
"      <a class=\"local\" href=\"#H37208924\">",
"       'Sigmoid megaesophagus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complications following laparoscopic and open myotomy with a fundoplication include esophageal or gastric perforation (1 to 7 percent), recurrent dysphagia (3 to 10 percent), and gastroesophageal reflux (2 to 26 percent). (See",
"      <a class=\"local\" href=\"#H37208945\">",
"       'Postoperative complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/1\">",
"      Heller E. Extra mucous cardioplasty in chronic cardiospasm with dilatation of the esophagus (Extramukose Cardiaplastik mit dilatation des oesophagus). Mitt Grenzgels Med Chir 1913; 27:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/2\">",
"      Payne WS. Heller's contribution to the surgical treatment of achalasia of the esophagus. 1914. Ann Thorac Surg 1989; 48:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/3\">",
"      Litle VR. Laparoscopic Heller myotomy for achalasia: a review of the controversies. Ann Thorac Surg 2008; 85:S743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/4\">",
"      Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single centre experience. Ann Surg 2008; 248:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/5\">",
"      Traube M, Dubovik S, Lange RC, McCallum RW. The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1989; 84:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/6\">",
"      Abir F, Modlin I, Kidd M, Bell R. Surgical treatment of achalasia: current status and controversies. Dig Surg 2004; 21:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/7\">",
"      Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg 2009; 249:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/8\">",
"      Ellis FH Jr, Gibb SP, Crozier RE. Esophagomyotomy for achalasia of the esophagus. Ann Surg 1980; 192:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/9\">",
"      Pai GP, Ellison RG, Rubin JW, Moore HV. Two decades of experience with modified Heller's myotomy for achalasia. Ann Thorac Surg 1984; 38:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/10\">",
"      Hunter JG, Trus TL, Branum GD, Waring JP. Laparoscopic Heller myotomy and fundoplication for achalasia. Ann Surg 1997; 225:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/11\">",
"      Vogt D, Curet M, Pitcher D, et al. Successful treatment of esophageal achalasia with laparoscopic Heller myotomy and Toupet fundoplication. Am J Surg 1997; 174:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/12\">",
"      Ancona E, Anselmino M, Zaninotto G, et al. Esophageal achalasia: laparoscopic versus conventional open Heller-Dor operation. Am J Surg 1995; 170:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/13\">",
"      Holzman MD, Sharp KW, Ladipo JK, et al. Laparoscopic surgical treatment of achalasia. Am J Surg 1997; 173:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/14\">",
"      Arreola-Risa C, Sinanan M, Pellegrini CA. Thoracoscopic Heller's myotomy. Treatment of achalasia by the videoendoscopic approach. Chest Surg Clin N Am 1995; 5:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/15\">",
"      Pellegrini C, Wetter LA, Patti M, et al. Thoracoscopic esophagomyotomy. Initial experience with a new approach for the treatment of achalasia. Ann Surg 1992; 216:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/16\">",
"      Richards WO, Torquati A, Holzman MD, et al. Heller myotomy versus Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. Ann Surg 2004; 240:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/17\">",
"      Omura N, Kashiwagi H, Ishibashi Y, et al. Laparoscopic Heller myotomy and Dor fundoplication for the treatment of achalasia. Assessment in relation to morphologic type. Surg Endosc 2006; 20:210.",
"     </a>",
"    </li>",
"    <li>",
"     Wohlers A, Evans SRT. Section III: Gastrointestinal surgery. Chapter 18: Laparoscopic esophagomyotomy with Dor fundoplication. In: Surgical pitfalls: Prevention and management, Evans SRT.  (Ed), Saunders Elsevier, 2009. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/19\">",
"      Oelschlager BK, Yamamoto K, Woltman T, Pellegrini C. Vagotomy during hiatal hernia repair: a benign esophageal lengthening procedure. J Gastrointest Surg 2008; 12:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/20\">",
"      Cacchione RN, Tran DN, Rhoden DH. Laparoscopic Heller myotomy for achalasia. Am J Surg 2005; 190:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/21\">",
"      Peracchia A, Rosati R, Bona S, et al. Laparoscopic treatment of functional diseases of the esophagus. Int Surg 1995; 80:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/22\">",
"      Bonavina L, Nosadini A, Bardini R, et al. Primary treatment of esophageal achalasia. Long-term results of myotomy and Dor fundoplication. Arch Surg 1992; 127:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/23\">",
"      Oelschlager BK, Chang L, Pellegrini CA. Improved outcome after extended gastric myotomy for achalasia. Arch Surg 2003; 138:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/24\">",
"      Wright AS, Williams CW, Pellegrini CA, Oelschlager BK. Long-term outcomes confirm the superior efficacy of extended Heller myotomy with Toupet fundoplication for achalasia. Surg Endosc 2007; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/25\">",
"      Patti MG, Molena D, Fisichella PM, et al. Laparoscopic Heller myotomy and Dor fundoplication for achalasia: analysis of successes and failures. Arch Surg 2001; 136:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/26\">",
"      Zaninotto G, Costantini M, Portale G, et al. Etiology, diagnosis, and treatment of failures after laparoscopic Heller myotomy for achalasia. Ann Surg 2002; 235:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/27\">",
"      Tatum RP, Pellegrini CA. How I do it: laparoscopic Heller myotomy with Toupet fundoplication for achalasia. J Gastrointest Surg 2009; 13:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/28\">",
"      Kaufman JA, Pellegrini CA, Oelschlager BK. Laparoscopic Heller myotomy and Roux-en-Y gastric bypass: a novel operation for the obese patient with achalasia. J Laparoendosc Adv Surg Tech A 2005; 15:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/29\">",
"      Sweet MP, Nipomnick I, Gasper WJ, et al. The outcome of laparoscopic Heller myotomy for achalasia is not influenced by the degree of esophageal dilatation. J Gastrointest Surg 2008; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/30\">",
"      Patti MG, Feo CV, Diener U, et al. Laparoscopic Heller myotomy relieves dysphagia in achalasia when the esophagus is dilated. Surg Endosc 1999; 13:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/31\">",
"      Mineo TC, Pompeo E. Long-term outcome of Heller myotomy in achalasic sigmoid esophagus. J Thorac Cardiovasc Surg 2004; 128:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/32\">",
"      Ablassmaier B, Jacobi CA, Stoesslein R, et al. Laparoscopic esophagogastrostomy: an alternative minimally invasive treatment for achalasia stage III. Surg Endosc 2002; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/33\">",
"      Lanfranco AR, Castellanos AE, Desai JP, Meyers WC. Robotic surgery: a current perspective. Ann Surg 2004; 239:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/34\">",
"      Melvin WS, Dundon JM, Talamini M, Horgan S. Computer-enhanced robotic telesurgery minimizes esophageal perforation during Heller myotomy. Surgery 2005; 138:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/35\">",
"      Rosemurgy AS, Morton CA, Rosas M, et al. A single institution's experience with more than 500 laparoscopic Heller myotomies for achalasia. J Am Coll Surg 2010; 210:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/36\">",
"      Schuchert MJ, Luketich JD, Landreneau RJ, et al. Minimally-invasive esophagomyotomy in 200 consecutive patients: factors influencing postoperative outcomes. Ann Thorac Surg 2008; 85:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/37\">",
"      Torquati A, Richards WO, Holzman MD, Sharp KW. Laparoscopic myotomy for achalasia: predictors of successful outcome after 200 cases. Ann Surg 2006; 243:587.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts JR, Vela MF, Richter JE.. Part 1: Gastrointestinal disorders. Charpter 4: Esophageal motility disorders: Achalasia and spastic motor disorders. In: Evidenced-based gastroenterology adn hepatology, McDonald JWD, Burroughs AK, Fegan BG, Finnerty MB..  (Eds), Wiley-Blackwell, Hoboken 2010. p.78.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/39\">",
"      Velanovich V. Comparison of symptomatic and quality of life outcomes of laparoscopic versus open antireflux surgery. Surgery 1999; 126:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/40\">",
"      Vaziri K, Soper NJ. Laparoscopic Heller myotomy: technical aspects and operative pitfalls. J Gastrointest Surg 2008; 12:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/41\">",
"      Petersen RP, Pellegrini CA. Revisional surgery after Heller myotomy for esophageal achalasia. Surg Laparosc Endosc Percutan Tech 2010; 20:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/42\">",
"      Donahue PE, Horgan S, Liu KJ, Madura JA. Floppy Dor fundoplication after esophagocardiomyotomy for achalasia. Surgery 2002; 132:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/43\">",
"      Luketich JD, Fernando HC, Christie NA, et al. Outcomes after minimally invasive esophagomyotomy. Ann Thorac Surg 2001; 72:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/44\">",
"      Zaninotto G, Rizzetto C, Zambon P, et al. Long-term outcome and risk of oesophageal cancer after surgery for achalasia. Br J Surg 2008; 95:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19001/abstract/45\">",
"      Ludemann R, Krysztopik R, Jamieson GG, Watson DI. Pneumothorax during laparoscopy. Surg Endosc 2003; 17:1985.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15060 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19001=[""].join("\n");
var outline_f18_35_19001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1389739\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37208847\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37208854\">",
"      PATIENT SELECTION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37210839\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208861\">",
"      Manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35752449\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208882\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3226516\">",
"      SURGICAL MYOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3226935\">",
"      Laparoscopic technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227116\">",
"      - Patient position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227126\">",
"      - Abdominal access and port placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227153\">",
"      - Mobilization of the gastric fundus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227250\">",
"      - Mobilization of the mediastinal esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227260\">",
"      - Myotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227471\">",
"      - Fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3227098\">",
"      Open technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3227463\">",
"      Intraoperative technical risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18856620\">",
"      OPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208910\">",
"      Extended gastric myotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208917\">",
"      Addition of a fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208924\">",
"      Sigmoid megaesophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208931\">",
"      Robotic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37208938\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37208945\">",
"      POSTOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208954\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208961\">",
"      Recurrent dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208968\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37208975\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37208982\">",
"      RISK OF ESOPHAGEAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1389739\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15060|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/55/24446\" title=\"diagnostic image 1\">",
"      Achalasia barium swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15060|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15174\" title=\"figure 1\">",
"      High-resolution manometry achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/14/36066\" title=\"figure 2\">",
"      Port placement laparoscopic Heller myotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/16/35087\" title=\"figure 3\">",
"      Gastric component of the LES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/0/39939\" title=\"figure 4\">",
"      Heller myotomy with Toupet fundoplication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15060|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/18/42277\" title=\"picture 1\">",
"      High-resolution manometry - Vigorous achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/60/6082\" title=\"picture 2\">",
"      Heller myotomy performed laparoscopically",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/49/40722\" title=\"picture 3\">",
"      Laparoscopic Heller myotomy with Toupet fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/31/39408\" title=\"picture 4\">",
"      Heller myotomy and fundoplication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_35_19002="Treatment of pulmonary tuberculosis in the HIV-infected patient";
var content_f18_35_19002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pulmonary tuberculosis in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19002/contributors\">",
"     Timothy R Sterling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19002/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/35/19002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/35/19002/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/35/19002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of tuberculosis in the HIV-infected patient is complex and must address the patient's requirement for antiretroviral therapy (ART), potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address issues surrounding the care of the HIV-infected patient with tuberculosis (TB) with special attention to drug interactions between the rifamycins and the various classes of HIV medications. The clinical manifestations of TB disease in HIV-infected patients, monitoring on anti-tuberculous medications, and the treatment of latent M. tuberculosis infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of multidrug-resistant tuberculosis in HIV-infected patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician taking care of the HIV-infected patient with TB should be expert in HIV clinical management and treatment. The selection of ART regimens and the various antiretroviral drug classes for the treatment of HIV are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14774?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of tuberculosis (TB) in the HIV-infected patient involves three basic components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of an appropriate multidrug chemotherapeutic regimen. While the initial TB regimen is empiric, therapy needs to be subsequently tailored to the drug resistance profile of the isolate, when available [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of TB drugs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patient counseling regarding the need for antiretroviral therapy (ART), since TB is an AIDS-defining illness",
"     </li>",
"     <li>",
"      Close monitoring for treatment response and the immune reconstitution inflammatory syndrome (IRIS); the latter particularly in the immunosuppressed host (eg, CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initiation or revision of ART must be made with close attention to potential drug interactions with TB medications. The timing of ART relative to TB therapy in the HIV treatment-naive patient is discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Timing of ART in the treatment-naive patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Directly observed therapy (DOT) facilitates adherence and helps to prevent the development of drug resistance. Details regarding DOT, monitoring for sputum conversion, drug side effects, and clinical response to treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHOICE OF TB DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for selecting anti-TB treatment regimens in HIV-infected adults follow the same general approach as for adults without HIV infection, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/4\">",
"     4",
"    </a>",
"    ]. However, highly intermittent dosing of these antituberculous medications is not recommended for HIV-infected patients, particularly those with &lt;100 CD4+",
"    <span class=\"nowrap\">",
"     lymphocytes/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Highly intermittent therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pending drug resistance testing results, the initial treatment for TB should include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH), a rifamycin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    for two months followed by isoniazid and a rifamycin for an additional four months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/5\">",
"     5",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58653 \" href=\"UTD.htm?38/52/39756\">",
"     table 1",
"    </a>",
"    ). Combination therapy promotes rapid killing of the tubercle bacilli, prevents the emergence of drug resistance, and decreases the period of contagion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial two-month induction phase can be administered as either seven days per week (ie, 56 doses) or five days per week (ie, 40 doses) or three times weekly (ie, 24 doses) by directly observed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All HIV-infected patients taking INH should also take pyridoxine supplementation to decrease the risk of peripheral neuropathy, which is also associated with certain antiretroviral medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ). Stavudine is no longer recommended as a first-line therapy in the United States and Europe, but is often still used in resource-limited settings where TB is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rifamycin is considered a key component of TB treatment; regimens that do not include a rifamycin are less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    are considered comparable in terms of activity against M. tuberculosis. In HIV-infected patients, the choice of agent will be governed by HIV drug interactions and cost considerations. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Rifampin-based TB regimens with ART'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Rifabutin-based regimens and ART'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Suspected drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial empiric therapy for patients in areas with a known high prevalence of MDR-TB (or for patients who contract TB after contact with a patient with known MDR-TB) should include the standard four-drug treatment regimen plus two additional drugs to assure that at least four active drugs effective against the most prevalent drug-resistant strains are included in the regimen. One possible approach is to use a fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) plus an injectable agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extensively drug-resistant tuberculosis (XDR TB) is caused by an isolate of M. tuberculosis, which is resistant to at least",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , fluoroquinolones, and either aminoglycosides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    , or both. XDR TB is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various guideline statements can be accessed for further information regarding combination TB regimens. The American Thoracic Society (ATS), Centers for Disease Control (CDC), and Infectious Disease Society of America (IDSA) statement on the treatment of TB, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     www.thoracic.org/statements/",
"    </a>",
"    . Guidelines on the treatment of TB in HIV-infected patients were published by the CDC and the full document can be accessed at the following website:",
"    <a class=\"external\" href=\"file://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm\">",
"     file://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm",
"    </a>",
"    . The WHO also has 2010 guidelines for the treatment of TB (4th edition).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHOICE OF ANTIRETROVIRAL THERAPY (ART)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician taking care of the HIV-infected patient with TB should be expert in HIV clinical management and treatment. Antiretroviral therapy (ART) regimens are described as having a \"backbone\" and a \"base\". The backbone typically consists of two nucleoside analogs. The base has traditionally included either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (ISTI). Choice of agents will depend on multiple factors including patient comorbidities, drug resistance, and cost.",
"   </p>",
"   <p>",
"    The selection of ART regimens and the various antiretroviral drug classes for the treatment of HIV are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFICACY OF TB TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for susceptible TB appears to be as effective in the HIV-infected patient as it is in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy for susceptible TB appears to be similarly effective in HIV-infected patients and the general population. This was illustrated by an observational study of 280 patients with tuberculosis (94 percent of whom received directly observed therapy), which found that patients whose HIV status was positive, negative, and unknown had relapse rates of 6.0, 5.5, and 3.0 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/10\">",
"     10",
"    </a>",
"    ]. Effective TB therapy also leads to reduction in T cell activation markers and stabilization of CD4+ T cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of treatment for the HIV-infected patient with active TB is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFICACY OF HIV TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for HIV infection appears to be as effective in the",
"    <span class=\"nowrap\">",
"     HIV/TB",
"    </span>",
"    coinfected patient as it is in patients with HIV alone when attention is paid to potential drug-drug interactions.",
"   </p>",
"   <p>",
"    An observational study was performed to evaluate the antiviral efficacy of ART in HIV-infected patients coinfected with TB (n = 111) compared with HIV-infected patients without concomitant TB, who were matched for sex, ethnicity, and baseline CD4 cell count (within a range of 50 cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/12\">",
"     12",
"    </a>",
"    ]. Viral suppression was achieved at six months in similar proportions of",
"    <span class=\"nowrap\">",
"     HIV/TB-coinfected",
"    </span>",
"    patients and patients with HIV alone (87 versus 88 percent). Similar improvements in CD4 cell counts were also noted between",
"    <span class=\"nowrap\">",
"     HIV/TB-coinfected",
"    </span>",
"    patients and HIV-infected controls (97 versus 89",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    Most patients in this study were taking a non-nucleoside reverse transcriptase inhibitor (NNRTI) along with two nucleoside analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HIGHLY INTERMITTENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly intermittent therapy (eg, once or twice-weekly administration of therapy) is sometimes considered for the treatment of TB infection in HIV-seronegative patients. However, among HIV-infected patients with advanced immunosuppression, intermittent TB therapy has been identified as a risk factor for relapse and acquired rifamycin resistance, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 71 HIV-seropositive patients who had been treated with four-drug TB therapy for two months, once-weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       rifapentine",
"      </a>",
"      was compared with twice-weekly isoniazid and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      in the continuation phase of directly observed therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/13\">",
"       13",
"      </a>",
"      ]. Eight of 61 patients who completed therapy relapsed; four of the five patients in the once-weekly group had monoresistance when they relapsed, compared with none of the three patients in the twice-weekly group. Patients who relapsed had lower baseline CD4 cell counts (median 16 versus",
"      <span class=\"nowrap\">",
"       144/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      in nonrelapsers) and were more likely to have extrapulmonary involvement at baseline (75 versus 18 percent).",
"     </li>",
"     <li>",
"      A CDC-sponsored single arm trial utilized twice-weekly therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      &nbsp;",
"      <strong>",
"       after",
"      </strong>",
"      the first two months of TB treatment (ie, in the four-month continuation phase). Of 169 patients enrolled, 9 (5.3 percent) had treatment failure or relapse, of whom 8 (89 percent) had acquired rifamycin resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/17\">",
"       17",
"      </a>",
"      ]. All patients with acquired rifamycin resistance had CD4 counts &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of these observations, we agree with the CDC recommendation that HIV-infected patients with TB who have CD4 cell counts below",
"    <span class=\"nowrap\">",
"     100/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    should not be treated with highly intermittent regimens (eg, once- or twice-weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/5,16,18\">",
"     5,16,18",
"    </a>",
"    ]. These patients should receive daily therapy during the induction phase, and daily or three doses weekly during the continuation phase. Twice-weekly TB therapy during the continuation phase may be considered in HIV-infected patients with higher CD4 cell counts (&gt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/16\">",
"     16",
"    </a>",
"    ]. Suggested dosing schedules are found above (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Choice of TB drugs'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    More detailed discussions on the mechanisms, risk factors, and the prevention of drug-resistant TB are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful review for drug interactions is essential when considering antituberculous therapy in patients taking ART (",
"    <a class=\"graphic graphic_table graphicRef57197 \" href=\"UTD.htm?42/35/43581\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rifamycins induce hepatic CYP3A4 enzymes that can accelerate metabolism of protease inhibitors (PIs) and some non-nucleoside reverse transcriptase inhibitors (NNRTIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is a much more potent inducer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    . Conversely, serum concentrations of rifabutin may be decreased by the concomitant administration of certain antiretroviral drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a retrospective chart review of 367 HIV-infected patients diagnosed with TB, prescription of a rifamycin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) and a medication known to interact with this agent occurred in 73 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/22\">",
"     22",
"    </a>",
"    ]. Such interactions can interfere with efficacy of therapy for either HIV or TB infections.",
"   </p>",
"   <p>",
"    Despite the complexity of managing these drug interactions, rifamycins are integral to the success of TB therapy and should not be substituted with other antituberculosis medications based on concerns regarding drug interactions alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The following sections address selection of antiretroviral medications with either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    - or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    -based TB regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RIFAMPIN-BASED TB REGIMENS WITH ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few antiretroviral medications within a limited number of drug classes can be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -based TB treatment due to significant drug interactions that negatively affect HIV treatment efficacy. The most common HIV treatment regimen to be given concomitantly with rifampin-based TB medications is the non-nucleoside reverse transcriptase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , with two nucleoside analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug interaction information related to specific ART drug classes and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -based TB therapy is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinically significant interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and nucleoside analogs, which form the \"backbone\" of many combination ART regimens. Thus, nucleoside analogs can be used within ART regimens along with a third antiretroviral agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two commonly used non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . In the HIV-infected patient with concomitant TB infection, efavirenz-based ART is preferred to nevirapine-based ART because the reduction of nevirapine concentrations with concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is greater than with efavirenz [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is metabolized by the cytochrome P450 isoenzyme CYP3A4 with some metabolism by CYP2B6, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is metabolized almost exclusively by CYP2B6 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    induces the expression of CYP2B6 by approximately ninefold and CYP3A4 by 55-fold; thus, a greater reduction in drug concentrations would be expected with nevirapine than with efavirenz, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Efavirenz",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    -based TB treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART is the preferred treatment approach for HIV-associated TB, although the appropriate dose of efavirenz is somewhat controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective analyses of a therapeutic drug monitoring database found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    concentrations were significantly lower in patients taking concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/25\">",
"     25",
"    </a>",
"    ]. Rifampin lowers efavirenz exposure by approximately 20 percent.",
"   </p>",
"   <p>",
"    However, a subsequent prospective pharmacokinetic study among a Thai study population with a mean weight of 53 kg did not confirm that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    has a significant impact on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    drug levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/26\">",
"     26",
"    </a>",
"    ]. Rifampin recipients (n = 142) with concurrent HIV and TB coinfection were randomly assigned to receive ART that included either efavirenz (600 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    (400 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/26\">",
"     26",
"    </a>",
"    ]. Serum drug concentrations were inadequate in a smaller percentage of the efavirenz recipients compared with nevirapine recipients (3 versus 21 percent, respectively); thus, as noted above, efavirenz-based ART is preferred to nevirapine-based ART because the reduction of nevirapine concentrations with concomitant rifampin is greater than with efavirenz.",
"   </p>",
"   <p>",
"    We prefer to start with the standard dose of 600",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    in patients weighing &gt;60 kg we increase the dose to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    after two weeks if the initial dose was well tolerated. In January 2012, the FDA recommended that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    dose be increased to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in persons weighing &gt;50 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians also need to be aware that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    levels are generally higher in patients from Southern Africa, West Africa, and India due to varying pharmacogenetics of efavirenz among different ethnic and racial groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/25,28,29\">",
"     25,28,29",
"    </a>",
"    ]. Higher serum drug concentrations of efavirenz are associated with increased rates of side effects, such as dizziness.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    must be avoided in the first trimester of pregnancy or in women who may become pregnant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"     \"Tuberculosis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nevirapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As demonstrated in multiple studies from South Africa, Spain, and Thailand, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    leads to significant decreases in serum nevirapine concentrations up to 55 percent, which negatively affect virologic suppression rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/26,30-34\">",
"     26,30-34",
"    </a>",
"    ]. The negative impact of these drug interactions is particularly relevant to the HIV treatment-naive patient initiating ART. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Choice of NNRTI and virologic outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, several clinical trials of HIV therapy in treatment-naive patients have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is associated with generally higher rates of hepatotoxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/35\">",
"     35",
"    </a>",
"    ]. Since TB agents can also cause drug-induced liver injury, this issue needs to be considered as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial comparing standard dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    (eg, 200 mg twice daily) with a higher dose (eg, 300 mg twice daily) led to increased rates of nevirapine hypersensitivity among those randomly assigned to the higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, higher doses of nevirapine are not recommended for use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Choice of NNRTI and virologic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although monitoring of drug concentrations is not usually performed, the potential negative impact of drug interactions on HIV control can be inferred through viral load monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/23,37\">",
"     23,37",
"    </a>",
"    ]. Studies of HIV-infected patients with TB have demonstrated that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -based ART is associated with lower rates of viral suppression compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/23,37\">",
"     23,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the timing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    initiation relative to TB therapy is another important consideration. This principle was well illustrated in a prospective study of more than 2000 treatment-naive patients in South Africa who began a NNRTI-based ART regimen with or without concurrent antitubercular therapy containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/23\">",
"     23",
"    </a>",
"    ]. The main outcome measures included virologic failure, time to death, and time to treatment-limiting toxicity. The following outcomes were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in time to death or time to drug toxicity between patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      - or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      -based ART.",
"     </li>",
"     <li>",
"      Patients starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      after initiating TB therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      were at a twofold higher risk of having detectable viremia at six months than those without TB. In contrast, patients already on nevirapine who developed incident TB were not at risk of developing virologic failure when antitubercular medications were added onto their ART regimen.",
"     </li>",
"     <li>",
"      There were no differences in virologic outcomes between patients starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      with or without concomitant antitubercular medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One explanation as to why patients already on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    at the time of tuberculosis diagnosis had better viral suppression than those who initiated nevirapine while on anti-TB therapy may be related to the manner in which nevirapine is given at treatment initiation. A two-week lead-in phase of once-daily dosing of nevirapine followed by twice-daily dosing had been recommended to allow for the autoinduction of the cytochrome p450 enzyme system by nevirapine. However, in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , the p450 system is already induced and this may lead to subtherapeutic levels of nevirapine during this initial period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART is the preferred NNRTI-containing regimen when dosing with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -based TB regimen.",
"   </p>",
"   <p>",
"    Virologically suppressed patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -containing ART who develop TB may continue the same ART regimen. However, initiation of nevirapine-containing ART should be avoided in patients who are already taking TB medications due to the risk of virologic failure. The two-week lead-in phase of once-daily dosing of nevirapine is no longer recommended because it may increase the risk of virologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the patient with drug resistance or intolerance to NNRTIs, treatment options are very limited. If only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -based TB therapy is available, the only option is to use a triple nucleoside analog combination for HIV infection, although an HIV treatment regimen composed of three nucleoside analogues is less effective than regimens using at least two classes of drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    should not be administered during pregnancy during the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"     \"Tuberculosis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and protease inhibitor-based therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended by the CDC. Rifampin induces both CYP3A4 and the transmembrane efflux pump P-glycoprotein; protease inhibitors (PIs) are substrates of both systems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/24\">",
"     24",
"    </a>",
"    ]. In HIV-infected patients initiating ART, PIs are usually dosed with the pharmacokinetic enhancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , which boosts serum drug levels. However, even boosted PIs cannot be given with rifampin, since PI levels are reduced by as much as 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    , rather than rifampin, is recommended when protease inhibitors are used for HIV therapy. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rifabutin-based regimens and ART'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some studies have evaluated dose increments of a particular PI (eg, lopinavir, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ) to see if serum concentrations can be maintained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . However, this approach has been associated with significant adverse events, such as gastrointestinal intolerance and hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    could potentially be given with standard-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (eg, 600 mg twice daily), this dose of ritonavir is generally not used for the treatment of HIV due to poor tolerability (eg, nausea, diarrhea).",
"   </p>",
"   <p>",
"    There are no data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    -based ART and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , although significant drug-drug interactions would be expected, precluding the use of this PI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Integrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    should be avoided with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . Rifampin decreases serum levels of raltegravir by 40 to 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/42\">",
"     42",
"    </a>",
"    ]. In a dosing study of raltegravir with rifampin in healthy volunteers, doubling the dose of raltegravir to 800 mg a day with rifampin led to improved overall raltegravir drug exposure (eg, improved area under curve concentrations), but trough levels were still low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/43\">",
"     43",
"    </a>",
"    ]. Since there is no correlation between raltegravir trough concentrations and rates of viral suppression, the clinical significance of this interaction is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/42\">",
"     42",
"    </a>",
"    ]. Raltegravir trough concentrations were reduced by 53 percent even with an increased dose to 800 mg bid. If this raltegravir dose is used, caution is warranted and viral load monitoring is required [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     CCR5 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    decreases serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    by 78 percent. An increased dose of maraviroc is recommended in the package insert when the two drugs are used together; however, there is no published experience regarding efficacy or toxicity of this combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no interactions between fusion inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ; enfuvirtide is usually used in HIV treatment salvage regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RIFABUTIN-BASED REGIMENS AND ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are limited data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in the treatment of TB when used in combination therapy. The drug-drug interactions between rifabutin and antiretroviral medications are generally more manageable. However, rifabutin has limited distribution in resource-limited settings, where TB is endemic, due to its expense.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    is a substrate for CYP3A4. Thus, its serum concentration is affected by the degree to which CYP3A4 is inhibited or induced by the specific PI, NNRTI, or other drug that is coadministered (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     \"Rifabutin: Drug information\"",
"    </a>",
"    .) The standard dose of rifabutin is 300 mg daily; however, when dosed with ART, rifabutin often requires dose adjustments depending on the coadministered drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no significant drug interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and nucleoside analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no significant drug interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    can reduce serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    . Therefore, if efavirenz is administered, the dose of rifabutin should be increased from the standard dose of 300 mg to 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , PIs can be dosed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    without significantly compromising the serum drug concentrations of the coadministered PI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the standard dose of rifabutin (300 mg daily) should be decreased according to the CDC recommendations for each individual PI (",
"    <a class=\"graphic graphic_table graphicRef82486 \" href=\"UTD.htm?10/44/10957\">",
"     table 4",
"    </a>",
"    ). When administered with PIs that are pharmacologically boosted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , rifabutin should be decreased to 150 mg three times per week or 150 mg every other day. The combination of ritonavir-boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    plus rifabutin, which has only been evaluated in HIV-seronegative healthy volunteers, also requires dose reduction of rifabutin to 150 mg daily or 300 mg three times a week [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/44,48\">",
"     44,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some researchers recommend monitoring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    concentrations in HIV-infected patients taking specific PIs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/49\">",
"     49",
"    </a>",
"    ]. For example, in a small study of patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    with rifabutin, investigators found subtherapeutic levels of rifabutin (dosed at 150 mg three times weekly) in 9 of 10 subjects, leading to their recommendation that rifabutin concentrations be monitored when this particular combination is used.",
"   </p>",
"   <p>",
"    There are no published data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Integrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published data on the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     CCR5 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published data on the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fusion inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no drug interactions between the fusion inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ; however, enfuvirtide is usually used as part of treatment salvage regimens in patients with multidrug-resistant HIV infection. It also requires twice-daily injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    can be used with nucleoside analogs, PIs and NNRTIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . However, the dose of rifabutin must be adjusted depending on the coadministered drug. Rifabutin is more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and is generally less available in resource-limited settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     INTERACTIONS WITH ART AND SECOND-LINE TB DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient cannot tolerate a rifamycin (eg, severe rash), then second-line TB medications may need to be considered.",
"   </p>",
"   <p>",
"    Antiretroviral medications, including NNRTIs and PIs, do not have clinically significant drug interactions with other first- and second-line anti-TB drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     IMMUNE RECONSTITUTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"immune reconstitution inflammatory syndrome\" (IRIS) describes a paradoxical worsening of a preexisting infectious process following ART-associated immune recovery. This inflammatory reaction is usually self-limited, although significant morbidity and mortality may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Functional restoration of CD4+ T cells can lead to a wide spectrum of clinical manifestations depending on the underlying infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations in the HIV-infected patient with TB can include new or expanding lymph nodes, enlarging intracranial tuberculomas, persistent pyrexia, worsening pulmonary infiltrates, and new serositis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of IRIS appears to depend on the baseline CD4 cell count and the timing of ART initiation relative to TB medications (ie, less than eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/5,51,52\">",
"     5,51,52",
"    </a>",
"    ]. In a randomized trial of 642 patients with HIV and TB in South Africa, IRIS was assessed in patients randomized to initiate ART within four weeks of TB treatment initiation, within four weeks of completing the intensive phase of TB treatment, or within four weeks after completion of TB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/52\">",
"     52",
"    </a>",
"    ]. The incidence of IRIS in these groups was 19.5, 7.5, and 8.1 per 100 person-years, respectively. Among those with CD4 counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    the incidence of IRIS was 45.5, 9.7, and 19.7 per 100 person-years, respectively.",
"   </p>",
"   <p>",
"    The observed morbidity related to IRIS led to concerns about optimum management of HIV-infected patients with TB and whether interventions for both therapies should overlap. However, a delay in ART initiation until after TB therapy is completed is associated with increased overall morbidity and mortality, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     TIMING OF ART IN THE TREATMENT-NAIVE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of TB disease is an indication for prompt initiation of antituberculous medications and for HIV testing. If the patient is found to be HIV-seropositive, initiation of ART is warranted, regardless of CD4 count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7753015\">",
"    <span class=\"h2\">",
"     Clinical trials evaluating timing of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the timing of ART relative to TB therapy was controversial. Some advocated initiation of ART during TB therapy (ie, &ldquo;integrated ART&rdquo;), while others advocated the initiation of ART after TB therapy had been completed (ie, &ldquo;sequential ART&rdquo;). However, a controlled trial in South Africa (SAPiT) demonstrated the superiority of integrated ART compared with sequential ART in reducing morbidity and mortality among 642 sputum smear-positive TB patients in South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/53\">",
"     53",
"    </a>",
"    ]. Integrated ART was initiated at less than 4 weeks or within 8 to 12 weeks after initiation of TB therapy while sequential ART was administered after completion of TB treatment (ie, at six months). There was a significant reduction in the rate of death among the 429 patients in the combined integrated therapy groups (5.4 deaths per 100 person-years, or 25 deaths), as compared with the 213 patients in the sequential therapy group (12.1 per 100 person-years, or 27 deaths). The trial was stopped early since all-cause mortality was 56 percent lower in the two integrated treatment arms compared with the sequential treatment arm (HR 0.44, 95% CI 0.25-0.79). Thus, integrated ART is recommended for all HIV-infected patients who are diagnosed with TB infection.",
"   </p>",
"   <p>",
"    Subsequent trials and additional analyses of the SAPiT trial have evaluated the optimal timing of integrated ART relative to anti-TB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SAPiT trial of patients with CD4 count &lt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      the risk of AIDS or death did not differ between the two integrated therapy arms [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/55\">",
"       55",
"      </a>",
"      ]. However, among those with a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      the risk of AIDS or death was lower among those who initiated ART within four weeks of anti-TB therapy compared with 8 to 12 weeks. Among the patients with a CD4 count &ge;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      rates of IRIS were 16 percent in the 4-week group and 7 percent in the 8- to 12-week group.",
"     </li>",
"     <li>",
"      A controlled trial in Cambodia (CAMELIA) assessed whether initiation of ART within two weeks of anti-TB therapy may offer greater survival benefit than starting ART after eight weeks among 661 HIV-infected patients with a CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (median CD4 = 25",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/56\">",
"       56",
"      </a>",
"      ]. Mortality was significantly lower among patients assigned to the &ldquo;early ART&rdquo; arm compared with the &ldquo;late ART&rdquo; arm (18 versus 27 percent), although rates of IRIS were two times higher.",
"     </li>",
"     <li>",
"      In the ACTG 5221 trial (STRIDE), 809 patients with confirmed or suspected tuberculosis and CD4 counts &lt;250 were randomly assigned to &ldquo;immediate&rdquo; ART (ie, less than 2 weeks) versus &ldquo;early&rdquo; ART (ie, 8 to 12 weeks) after the initiation of TB therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/57\">",
"       57",
"      </a>",
"      ]. Immediate ART reduced the risk of AIDS and mortality among patients with a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      although IRIS occurred more commonly among patients assigned to this arm than to &ldquo;early&rdquo; ART (11 percent versus 5 percent). No difference in AIDS or mortality rates were seen among those patients with a CD4 count &gt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of HIV viral suppression did not differ by ART strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], although there were more changes in antiretroviral medications among patients in the early ART arm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/55\">",
"     55",
"    </a>",
"    ]. As noted above, the risk of IRIS and drug toxicity was higher among patients who initiated ART at earlier time points than later within the course of TB treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/53,55-57\">",
"     53,55-57",
"    </a>",
"    ]. Although steroids were required for the management of complications in some patients, there were no deaths related specifically to IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of ART in the HIV-infected patient with TB meningitis may differ from the patient with pulmonary TB. Clinicians should be aware that in one clinical trial of 253 HIV-infected patients with TB meningitis, &ldquo;immediate&rdquo; ART (ie, on study entry) did not reduce mortality compared to &ldquo;later&rdquo; ART (ie, after two months) and was associated with an increased risk of severe adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Suggestions for clinical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) recommends ART in all HIV-infected patients with active TB, irrespective of CD4 cell count. The expert panel from the Department of Health and Human Services (DHHS) recommends &ldquo;integrated ART&rdquo; (eg, within 2 to 12 weeks after initiating anti-TB therapy) rather than &ldquo;sequential ART&rdquo; for",
"    <span class=\"nowrap\">",
"     HIV/TB",
"    </span>",
"    coinfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal timing of integrated HIV and TB therapy is influenced by the patient&rsquo;s immune status. For patients with pulmonary TB and CD4 cell counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    &ldquo;early ART&rdquo; (ie, within two weeks after starting anti-TB therapy) decreases the combined risk of an AIDS-defining illness and death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with CD4 cell counts &gt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in the setting of severe HIV disease (including low Karnofsky score, low body mass index, low hemoglobin, low albumin, organ system dysfunction, or extent of disease), ART should be initiated within two to four weeks of starting treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/44,56\">",
"     44,56",
"    </a>",
"    ]. For patients with CD4 cell counts &gt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    in the absence of severe disease, early ART is not associated with a decreased risk of AIDS or death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]; later initiation of ART (eg, 8 to 12 weeks) is associated with a lower risk of IRIS regardless of baseline CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/35/19002/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides immunologic status, the exact timing of ART may also depend on other clinical considerations. For example, later initiation of ART (eg, 8 to 12 weeks) may be preferred based on the patient's tolerance of TB medications and ability to swallow multiple pills. In contrast, early initiation of ART (eg, within 2 to 4 weeks) may be considered in a patient with malnutrition or wasting, regardless of CD4 cell count. Initiating ART and TB medications simultaneously is not recommended.",
"   </p>",
"   <p>",
"    Patients who develop symptoms related to IRIS may require initiation of an anti-inflammatory agent (eg, nonsteroidal agents or steroids) for symptomatic relief. Management of IRIS is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When TB therapy is initiated, drug resistance testing for HIV should be performed in preparation for ART selection. The choice of antiretroviral medications will depend on patient comorbidities, HIV drug resistance patterns, and cost considerations, particularly in resource-limited settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     INTRODUCTION OF TB THERAPY IN HIV PATIENTS ALREADY ON ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination TB therapy should be initiated as soon as possible in the patient who is already on ART. If the patient has attained viral suppression and tolerates his current ART regimen, it is preferable to administer a rifamycin that will not lead to significant drug interactions that could interfere with HIV suppression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient taking PI-containing ART, the preferred choice would be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"     </li>",
"     <li>",
"      In the patient taking NNRTI-containing ART,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      is preferred due to fewer drug interactions. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      is more cost-effective in areas where resources are limited.",
"     </li>",
"     <li>",
"      In the patient taking ISTI-containing ART, it is preferable to change the ART regimen since there are significant interactions between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and ISTIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      ) and there are no data on the use of concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recommendations for selecting anti-TB treatment regimens in HIV-infected adults follow the same general approach as for adults without HIV infection. For suspected drug-susceptible tuberculosis, a combination regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , a rifamycin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      is considered first-line therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of TB drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rifamycin is considered a key component of TB treatment; regimens that do not include a rifamycin are less effective. Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      are considered comparable in terms of activity against M. tuberculosis. In HIV-infected patients, the choice of agent will be governed by HIV drug interaction and cost considerations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of TB drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy (ART) regimens are described as having a \"backbone\" and a \"base\". The backbone typically consists of two nucleoside analogs. The base has traditionally included either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (ISTI). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Careful review for drug interactions is essential when initiating antituberculous therapy in patients taking ART. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      has clinically significant drug interactions with most antiretroviral medications. For HIV-infected patients who are receiving a rifampin-based anti-tuberculous regimen, we suggest an ART regimen consisting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      plus two nucleoside analogs rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      plus two nucleoside analogs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A notable exception is that women who are in the first trimester of pregnancy should NOT receive efavirenz therapy. In geographical locations where efavirenz is unavailable, or in a situation where its cost is prohibitive, nevirapine is an alternative. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rifampin-based TB regimens with ART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HIV-infected patients who are receiving a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      -based anti-tuberculous regimen, we suggest a pair of nucleoside analogs plus either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The standard dose of rifabutin will need adjustment (eg, higher or lower) depending on the coadministered agent. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Rifabutin-based regimens and ART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with TB are at risk for the \"immune reconstitution inflammatory syndrome\" (IRIS) after they initiate antiretroviral therapy. This syndrome describes a paradoxical worsening of a preexisting infectious process following ART-associated immune recovery. IRIS is usually self-limited, although significant morbidity and mortality may occur. The risk of IRIS is higher at lower CD4 counts and with earlier initiation of ART, but such risk is balanced by improved overall outcomes. The optimal timing of integrated HIV and TB therapy depends on the level of immunosuppression as measured by CD4 count. Among patients with &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      &ldquo;early ART&rdquo; (ie, after two weeks after anti-TB therapy) is associated with a decreased risk of AIDS-related illness or death compared with &ldquo;later ART&rdquo; (ie, after 8 to 12 weeks of anti-TB therapy).",
"     </li>",
"     <li>",
"      We recommend that all HIV-infected patients diagnosed with active TB be treated with antiretroviral therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In the HIV-infected patient with a CD4 cell count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      we recommend that ART be initiated within two weeks after starting anti-TB therapy rather than later time points (eg, 8 to 12 weeks) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In the HIV-infected patient with a CD4 cell count &ge;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and severe clinical disease, we suggest initiation of ART within two to four weeks (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). In the HIV-infected patient with a CD4 cell count &ge;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      in the absence of severe clinical disease, we suggest initiation of ART within 8 to 12 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Timing of ART in the treatment-naive patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TB therapy should be initiated as soon as possible in the patient who is already taking ART. If the patient has attained viral suppression and tolerates his current ART regimen, it is preferable to administer a rifamycin that will not lead to significant drug interactions that could interfere with HIV suppression. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Introduction of TB therapy in HIV patients already on ART'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/1\">",
"      Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/2\">",
"      Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010; 50:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/3\">",
"      Onyebujoh PC, Ribeiro I, Whalen CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis 2007; 196 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/4\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/5\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/6\">",
"      Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/tb/publications/guidelines/HIV_AIDS.htm (Accessed on August 31, 2011).",
"    </li>",
"    <li>",
"     CDC. Managing Drug Interactiosn in the treatment of HIV related tuberculosis 2007 file://www.cdc.gov/tb/TB_HIV_Drugs/default.htm (Accessed on August 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/9\">",
"      Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/10\">",
"      Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/11\">",
"      Lancioni CL, Mahan CS, Johnson DF, et al. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ &gt;350 cells/mm3. J Infect Dis 2011; 203:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/12\">",
"      Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/13\">",
"      Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/14\">",
"      Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/15\">",
"      Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/17\">",
"      Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/18\">",
"      Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/19\">",
"      Drugs for tuberculosis. Treat Guidel Med Lett 2004; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. file://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on June 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/21\">",
"      Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/22\">",
"      Dworkin MS, Adams MR, Cohn DL, et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005; 39:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/23\">",
"      Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/24\">",
"      Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/25\">",
"      St&ouml;hr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/26\">",
"      Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Sustiva labeling update/dosing adjustment with rifampin. Jan 6. 2012. file://www.natap.org/2012/newsUpdates/010612_06.htm (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/28\">",
"      Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/29\">",
"      Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/30\">",
"      Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/31\">",
"      Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/32\">",
"      Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/33\">",
"      Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/34\">",
"      Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007; 44:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/35\">",
"      Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.",
"     </a>",
"    </li>",
"    <li>",
"     Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 12 weeks efficacy of nevirapine, 400 mg vs. 600 mg per day in HIV-infected patients with active TB receiving rifampicin: a multicenter study. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.",
"    </li>",
"    <li>",
"     Swaminathan, S, Padmapriyadarsini, C, and Venkatesan, P, et al. Once-daily nevirapine versus efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract # 35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/38\">",
"      Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51:3104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/39\">",
"      Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/40\">",
"      Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/41\">",
"      L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/42\">",
"      Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011; 66:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/43\">",
"      Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. file://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/46\">",
"      Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005; 41:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/47\">",
"      TB/HIV drug interactions. MMWR Morb Mortal Wkly Rep 2004; 53:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/48\">",
"      Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54:4440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/49\">",
"      Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/50\">",
"      Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/51\">",
"      Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/52\">",
"      Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/53\">",
"      Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/54\">",
"      Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9:e1001270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/55\">",
"      Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/56\">",
"      Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/57\">",
"      Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/35/19002/abstract/58\">",
"      T&ouml;r&ouml;k ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8013 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-F0314D4D48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19002=[""].join("\n");
var outline_f18_35_19002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHOICE OF TB DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Suspected drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHOICE OF ANTIRETROVIRAL THERAPY (ART)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFICACY OF TB TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFICACY OF HIV TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIGHLY INTERMITTENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RIFAMPIN-BASED TB REGIMENS WITH ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Efavirenz",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nevirapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Choice of NNRTI and virologic outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CCR5 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RIFABUTIN-BASED REGIMENS AND ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CCR5 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fusion inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      INTERACTIONS WITH ART AND SECOND-LINE TB DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      IMMUNE RECONSTITUTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      TIMING OF ART IN THE TREATMENT-NAIVE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7753015\">",
"      Clinical trials evaluating timing of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Suggestions for clinical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      INTRODUCTION OF TB THERAPY IN HIV PATIENTS ALREADY ON ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/52/39756\" title=\"table 1\">",
"      Drug regimens TB in HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/35/43581\" title=\"table 2\">",
"      Rifampin and HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 3\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/44/10957\" title=\"table 4\">",
"      Rifabutin and HAART",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=related_link\">",
"      Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14774?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=related_link\">",
"      Rifabutin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_35_19003="JSGE classification of endoluminal cancers";
var content_f18_35_19003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Japanese Society for Gastroenterological Endoscopy classification system of early endoluminal cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subclasses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         I: Polypoid/protuberant",
"        </strong>",
"       </td>",
"       <td>",
"        Ip: Pedunculated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ips/sp: Subpedunculated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is: Sessile",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         II: Flat",
"        </strong>",
"       </td>",
"       <td>",
"        IIa: Superficial elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIb: Flat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIc: Flat depressed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         III: Ulcerated",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         IV: Lateral spreading tumor",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1998; 1:10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19003=[""].join("\n");
var outline_f18_35_19003=null;
var title_f18_35_19004="Additional evaluation in ALTE";
var content_f18_35_19004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Additional diagnostic studies to consider in the evaluation of an apparent life-threatenng event (ALTE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated funduscopic examination",
"       </td>",
"       <td>",
"        Nonaccidental head injury (Shaken baby syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial and viral screening, including lumbar puncture",
"       </td>",
"       <td>",
"        Infection (eg, sepsis, meningitis, pertussis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroencephalogram",
"       </td>",
"       <td>",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic studies: Arterial blood gases, lactate, pyruvate, NH4, urine amino and organic acids, aminotransferases",
"       </td>",
"       <td>",
"        Metabolic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway fluoroscopy",
"       </td>",
"       <td>",
"        Anatomical abnormalities of the airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cine-esophagram and upper gastrointestinal series",
"       </td>",
"       <td>",
"        Gastroesophageal reflux and anatomical abnormalities of the gastrointestinal tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT or MRI of the head, brainstem",
"       </td>",
"       <td>",
"        Intracranial mass or hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal survey",
"       </td>",
"       <td>",
"        Child abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal pH monitoring",
"       </td>",
"       <td>",
"        Gastroesophageal reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polysomnography",
"       </td>",
"       <td>",
"        Cardiologic, respiratory, neurologic or oxygenation abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holter monitoring",
"       </td>",
"       <td>",
"        Arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiogram",
"       </td>",
"       <td>",
"        Structural or functional cardiac abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchoscopy",
"       </td>",
"       <td>",
"        Anatomic abnormalities of the airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Video surveillance",
"       </td>",
"       <td>",
"        Child abuse, Munchausen syndrome by proxy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      CT: computerized tomography; MRI: magnetic resonance imaging.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kahn A. Recommended clinical evaluation of infants with an apparent life-threatening event. Consensus document of the European Society for the Study and Prevention of Infant Death, 2003. Eur J Pediatr 2004;163:108.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19004=[""].join("\n");
var outline_f18_35_19004=null;
var title_f18_35_19005="LVH and sudden death";
var content_f18_35_19005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LVH increases the risk of sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 234px; background-image: url(data:image/gif;base64,R0lGODlhVQHqANUAAP///wAzmYCAgP8AAAAAAAAZTEBAQH8AAMDAwBAQEHBwcCAgIKCgoNDQ0PDw8FBQUDAwMLCwsGBgYJCQkODg4P/AwP+AgP9AQAAMJj8AAP/g4P/w8P9QUP+goP/Q0P9wcP8gIP8QEP+wsP8wMP+QkP9gYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABVAeoAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSeQ4MAhGTmZqZDhAEngqboqOKEwShCwQUpKytgAKnAAYECEYIArgCta6Qt7m/wMHCw8TFxrm7jhQEBAYJtLa5BgK8kALTx9na28XTkQ0CDKlLuNWP5a/UkAwID7FK6OaM8X70jcwL6vD68or2fP9aBURUScAEB0bAhTvHr89AUg8LdWpGIAFCIsyYhWoU0FewZEIqVNgAYEMFDUtMehgikmTJCh5UCvEwckhEUTcHIfgkCxoR/wYAGjBzFFBAhgNIk2ZoOGAABwAVBlhYEvXCEA4DOgjpMIBEVSEXBlSw2dBVTkETISyQgGTZAqJlAQg40LTugANMm4qUKoTEBQ4iinzdOmAE2AEaBocdK+RsJseAHEhIkArCxSLuMHGMO9duU7xFCocAIYLvhwEfsAZmOcDqkBCINTiFOgCEBQsgxJLtB/mPKWruGjqYBRTukc6eQRNpzTXs1BCGN8xm7VrIaQskBgSO6pmx3Lisevth8AmBJ6DNAFDwhG3VPM50kzO1GpZvayH3qRPxUBtEiJD5LbabPOL5ocAz+QiR3k4Z+bRIUfHZpdwQ93E3lWoWdEVEVLZZoP8VACM09QGArgnYGHgQodjPIBB6dtd8QpTA1wZYhTDihna5xhViJB7mXYEMrfggZ0clhdRScABpnJCJdDQMSGwouRkgHnFjJTKESBmlijhxWYcAGBQg5phklmnmmWgWgIGXeGi5hpv+sDmHAAUEYOedeOap5558BlCAnHY4KQyUbwIqRgMMXKYGnGjQ2eejkO75Z5achVnmmkkaGsZOCQig6BmMglpnpKRCOimLnI2K56kseUcTSiGNJZIQicFKRahY3OLNopq+4WipwEraqxxFqXonq/gNMER2JdA6W1NCZDhVFbhS0QAC2DbQRrVk/Brst3Yim85xxoab1xCyDUD/UoZaQQuAtFZwG4UCDRqw7bDblgtuqeL+Uaye4rorBFZa+Zfsbc7Fi68WFeVSXKGv6LtvpP3WkyrA5w5R2gX83ejitLcunEWCmUY88bcVO3RxngErSwRsYa0EgLvwUiuyFdhKYAC2CGi7pcknA5syQJWaielyUt1mXVOGJRstXzaz0WBG9v7sr8RB8zn0HoJ+FJpdzmZFocs1h7wlMA/zCnTWFN98byDyQsGOEBFoBvHVbJO6tR5xi9G3E7sqUPXd9WCd96puW+1v4lMw2OADb+N9+KN753HNlZhnPsyuajTgzAIGGPCAz0QoIEADlH3Kxd9feDu5sIRUqfnsmROK/8bcSSTAwAMJJLBR64yb4frrLAfPJB4OTOCwEbQs8MA1YbDuxfDEH2v88Xa4Q7URzhMggODRXz8G9dX7KT72c5xCC+dDmJIABQv8Pv350Rv+euXoE0LL+9AnRIEDCFDdFqTXBfJVD3/5E4TuHrCABAxuCKErAwFXZ7/JITCBgGAAA1CXANLZ5IHhW1v5rIdBUtArdAaQXwHpBwYDEu+CJexDAzyBgAVMwAiz2F4LWdi6Ch4OhjHcAwR6hwDwKc4hPswbEIOYBwJEYGf9I0IDHoBCFa6Oh9NLItuWyMQ7JGACBojAWozgCR0CT4QjNF8XEQGLjBCKAOQBgARYOMEBav8xa1xcYx3A+AC7YaSGRQThFdE4wjzq0Q/5kAAzILdDQpbPkId0w9SYIcgGNMABD3iAALVQR07eMWiQjCQbQpcACJCSLUYAoCpDKLk0mkuUg0jALhSAyp8wwzxWHCAWC/jJk4USlmsgAFswKcgFqEVXrCycK0kITEDQKyNlWV8gk4nEZb6ymYAAowFuyD0JQEAAvqMmQHo5sV9icw4RyMj7xMk1cu7LnOeUAzgm4J5GttKV8IznGyZgu/k58oC71CcZZmHDep7xnmnMp0DBMMUqJkQBqSBAH+2pTGsqdKFeiCglj1CJZyzyoBVd5kUxygWJKuGZwmSAzkBaTYsGlKT/U3hALiEIgURRoSBc6mQWXHi/l8I0CpNxaBE26QTUNeMt+/jnC3360yfkcKNcSIUHi+AR9o3Tmmps6iaEsoBUMJKq0mAqFnhqQbFqdQkzbB43tbATCJgHjklFaCHNetYkDFGWRiRC8pb3BKHYCxYq0ulY3QmukdaVCk6EoiCfmh4opCICNIxrSPFJ18Ma4YthHGMRypOtKKRVd+So7K0IizLRWtYmDSLUNyVoWimQ9YetPS0A+OjHIUCUryy9qktlqwfGClKXSu0pb4M5yUryrGfs5Btpg2XY4S6BlKZ0Ri2laBCD+lOuj4ytZWUpBFoagTzM6GByLbdcoWn3sMIE/wAxL/sABED2q9edbELPW1eUeo95u4hifFsqUvrWVZtrJYJavhdOivKXss69g1E/QdSx+pcJr1Xig2E6ycbaYqr71W1/E4wG6J7SCKZD3QIafAXBlri8/JrwT7kLAO8WYYG9m+lOVZyECG+RxiRN73o3W8Pn/ZaTOCYXVpvL4STYtyzd+96PZxzcshY5DQA+gvvgJ2MHNxm2T6ZDA/4XwPG2CcV6C/JCfYvDJQ8SuwDNshkEF7p3EEG/Xr6DjfEoZpiutggnDF2VS1znN4O5bWpGgwNAh8N6xTlQfzZVn+PJ2OmmwcTxSjTlFn1ONhtAAqpzgOCmWNszy3eugSaDJf9nm7YhaA8BEoDvCq8s4VCPAQKmY0anCQBGZBpYwwh2dRjWB4FMMu+JCBDdob8k6T4RWddOPAWc5di7VJTa0weer67DoL3dqVq97ijwrds5ZEpjkwIyHU6nQeXtOYPS21r97J75zOobT5sNqTCAJ+hY7mJrDd1NdaIQqDhsOpjbl/iOpACse5ziCMDR0Ma1tN9d0mCriLFQXTWal8pwLlCGMkItHQoznnBu77biWmCAR82otokLF+RbUMCzCRdtUKOcC8h1A6SpZW/YvTwLC7ZM5D6d3ZuPLB8HcjRObdrvOdUcYz7Hgk/0u+DwYhi4Jndy0q3gPPdCYLqTmePBE4D/cKjzPM1TrwJ4K+JB9i3b6y3vedirME/rZh0XWS86sY5evLV7oelkl3sc/l3OgJN06CRmd9SxbPcuAN5v9e524aegyi4PAe/i3bZyFb94ud0S1kR4+9a7DuR207nyjj2mfs1uZsF/neKgd4I088psrcdd8uSlfOqZsJZvajsoI8877L8s+9krIZ3hte7h9Z4kuiPO901o+xEogC2CS/z0J0d+Eh4AAfV0Sq++DXzUBt9q6SdB3y1+IL1AZ4BUrHv70Je6948AftanUOOeVR7Ra5z4j6/fCLxTAL0CTH12IIABvRYFhiZZaQd291cEDRBROjcEwNcg46YEQLEMBHAE/1VVfxt2gBT4dKgWOhLQT0tQRPcVDbhgVR53gRg4BHuFCyt3BQwwC3s2c6PVeydIZjVWekkwCx74HZ53bieIEW7VWUMgOxH0BObxPczgfAOSfoTXgwBwZ0bQRgPoBOuBDw+YhAWIekx4WypIBPCTDyNog+h3hdHXgzT4QWa4e3JmfMzEhNfCM08nPBaYa0yoaQbAaTsnhurXg6eWandYBjFXBBSgPG/YGGp4TUxIa4rVh4cCC5XUbOAnZPbXg4kVbNdGbmeQQ4KUGW5RY4WYVUw4GZQBV0UwhOPDVDuxWPo2FEjAd+/kd5GESRWRS2eXYWNwit9VETnEiTLIhEbWDP96RnxXYItGEAHhYGFP2InHFmgbx3FCUIa0GAYNYApuhRDpQQF14wlVyIqF5YprVGFgiIZdwFi1sCDMAAFVKBfIyI16tAC7MEcJQUM2BIwyl468CAC01l2CdFfTBI7EtosHOAvyll6bBWyzyGTc5268CIsSpTqYJUacZ5BK2H31CA+pJY9gRTvbYAD02IMDZwm4RQS0hXhjVSRGUpImeZIoaZIZsJEnuD5RqFd/yI8QFiEuUpM2eZPJwZIYGEBtCIS2VI7aZzYlRpM4WZRGeRc6eYICADkUEEaXBXQCmVtTgBxHWZU3eQBJiYGgJUeCxGKs93zUQpRWOZafkZUHuHT/gvQ9OdNeg6gwYyWWZGmVWOmP9wcB5hgBt9eMxSWVrgWXcXmUcxmJJ9iA61QEHvkLK2h6YfmXfxmYJsiEFFBdMuc2VMmYcmmW95eCC3FEt+KXlnmVmMkkBTF/QxCIp8MHzvholOmZn1mTjimHCcQePCFFjniOccBZMamab9mal0mXQpJOkJMZRKCJBIBUeeCEk7mbvAmYobkigCUXIaiXmKCKeaCFm8lynbmczOmbznlfzzkE5OFA1IkHqdkoq6mdRvmaC5dAphAK+1cExEge39gGPZmb5qmc6Ama3NkPblFDqmCP9mKNkPWIdvB/RGCgnDmVrJmf6ulyGCQOxVkc/+T4CbbpKz+YM/P5jFFQmfnpIg2qdkq5lwnalx2qn4J5f+C0cYQ2ohu6oOj5oQaIFpZAmgfqeNWgXwXZLedZoq7ZnEJEEdV3iw6iZnDCoTxalvuZB8AJAMLJhR7lgbKDkcaQg6NQpC6qnTCKhXDjndHZjG3mgWCSJmI6pmhyNASyo0cqIT5qOVzKDxPwPjioi0m6CVaapjk5p3fQni12jxA0Nf2kjdvonGhqp0iJp3bQn6mwCunRhp5wEKvYiZ5oDnVKqEh6on8AoQsgoQ8Up4+KVZF6o4Nqp1k6huEBqcm4OPhJqKOah6XqqadqMakqqmsqCYBaWoIaq2m6qksoEP+mqo5ol52UWqiWCgdRKqXCoJGu6qudN5TBKqyPOSckmZLSOq1GspLJeqvMGqy6KpH+dqW8ua3cCqq4eqTg+nmB4q2tWa7meqbjyqPqCnByhq6f+a7wyhuhmquzuijyapn02nfYGi/7yq/5+mgB25i9KgmjSWKTSqn9Gqjnqq0HGwmyGaT0164l2rC2+rAMG7GPsKRNuor3Sq4D2ygFG5cYm7Hn0KYieA3YMDsGEK3UGrMpmQGWQqY2K6YY0LLGaqwvK7M+i5I0e7NCmyY5qzlUmiQqe5E7u7RM27RO+7RQG7VGuwd6+p4T6WqI+p9X62qYmphb+7VgG7ZiO7ZkW7b/Znu2aJu2aru25oAtF3EtSKhH14IQAOQe2MK29niPEqiscEAv1EAekNNWeIsPexqCLbhN6nEJgsO3YpBO9qJICQCdoUCHEuAzlvBECiAZdSgE7ZBCCBEOYIRps1ecThSK1EAvCuAO/ERJz+C1K1IRAFBKBOA50DBEAjBEq0BQqSCebwGc9AI55ZgKDzl1zcA7nXJflIELzbAT1JBOjBsGxJFsbzqBQhEK6XRDswAAzNsTTOo9AjAO6eEAxrh4zZBOsUYNxekw27u9JWQK46AWJrW+95W925u9s/ALAKogGVpxC+IAzxkc/6cL98W+GCQUJtVG3EQZ7TC73Fu/E2gKR+0VAWzRWONbeBb2nJLxDJ0iv88bBs9wQwbsM2mVqXqpvfM7gXIRUcBbNRWMty78wjAcwzI8wzRcwzZ8wzicwzq8wzy8RkEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence of sudden death is related to the presence and extent of left ventricular hypertrophy (LVH). In both men and women, the presence of left ventricular hypertropy (LVH), defined as &gt;143 g/m in men and &gt;102 g/m in women, increases the incidence of sudden death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Haider, AW, Larson, MG, Benjamin, EJ, et al. J Am Coll Cardiol 1998; 32:1454.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19005=[""].join("\n");
var outline_f18_35_19005=null;
var title_f18_35_19006="Rx pneumatosis intestinalis";
var content_f18_35_19006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for managing patients with pneumatosis intestinalis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 485px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19006=[""].join("\n");
var outline_f18_35_19006=null;
var title_f18_35_19007="Follow up pancreatogram";
var content_f18_35_19007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Residual pancreatic duct stricture following balloon dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up pancreatogram after balloon dilation of a pancreatic duct stricture shows an asymptomatic short stricture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_35_19007=[""].join("\n");
var outline_f18_35_19007=null;
              